

B105

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 August 2001 (09.08.2001)

PCT

(10) International Publication Number
WO 01/57085 A2

(51) International Patent Classification⁷: C07K 14/705, 16/28, C12N 5/10, C12Q 1/68, A61K 38/17, A01K 67/027, G01N 33/53

(74) Agents: HAMLET-COX, Diana et al.; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(21) International Application Number: PCT/US01/03455

(22) International Filing Date: 1 February 2001 (01.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/180,093 2 February 2000 (02.02.2000) US
60/182,045 11 February 2000 (11.02.2000) US

(71) Applicant (for all designated States except US): INCYTE GENOMICS, INC. [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). AU-YOUNG, Janice [US/US]; 233 Golden Eagle Lane, Brisbane, CA 94005 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US).


(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/57085 A2

(54) Title: G-PROTEIN COUPLED RECEPTORS

(57) Abstract: The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

G-PROTEIN COUPLED RECEPTORS**TECHNICAL FIELD**

This invention relates to nucleic acid and amino acid sequences of G-protein coupled receptors 5 and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of G-protein coupled receptors.

10 BACKGROUND OF THE INVENTION

Signal transduction is the general process by which cells respond to extracellular signals. Signal transduction across the plasma membrane begins with the binding of a signal molecule, e.g., a hormone, neurotransmitter, or growth factor, to a cell membrane receptor. The receptor, thus activated, triggers an intracellular biochemical cascade that ends with the activation of an intracellular target 15 molecule, such as a transcription factor. This process of signal transduction regulates all types of cell functions including cell proliferation, differentiation, and gene transcription. The G-protein coupled receptors (GPCRs), encoded by one of the largest families of genes yet identified, play a central role in the transduction of extracellular signals across the plasma membrane. GPCRs have a proven history of being successful therapeutic targets.

20 GPCRs are integral membrane proteins characterized by the presence of seven hydrophobic transmembrane domains which together form a bundle of antiparallel alpha (α) helices. GPCRs range in size from under 400 to over 1000 amino acids (Strosberg, A.D. (1991) *Eur. J. Biochem.* 196:1-10; Coughlin, S.R. (1994) *Curr. Opin. Cell Biol.* 6:191-197). The amino-terminus of a GPCR is extracellular, is of variable length, and is often glycosylated. The carboxy-terminus is cytoplasmic and 25 generally phosphorylated. Extracellular loops alternate with intracellular loops and link the transmembrane domains. Cysteine disulfide bridges linking the second and third extracellular loops may interact with agonists and antagonists. The most conserved domains of GPCRs are the transmembrane domains and the first two cytoplasmic loops. The transmembrane domains account, in part, for structural and functional features of the receptor. In most cases, the bundle of α helices forms 30 a ligand-binding pocket. The extracellular N-terminal segment, or one or more of the three extracellular loops, may also participate in ligand binding. Ligand binding activates the receptor by inducing a conformational change in intracellular portions of the receptor. In turn, the large, third intracellular loop of the activated receptor interacts with a heterotrimeric guanine nucleotide binding (G) protein complex which mediates further intracellular signaling activities, including the activation of second

messengers such as cyclic AMP (cAMP), phospholipase C, and inositol triphosphate, and the interaction of the activated GPCR with ion channel proteins. (See, e.g., Watson, S. and S. Arkinstall (1994) The G-protein Linked Receptor Facts Book, Academic Press, San Diego CA, pp. 2-6; Bolander, F.F. (1994) Molecular Endocrinology, Academic Press, San Diego CA, pp. 162-176; 5 Baldwin, J.M. (1994) *Curr. Opin. Cell Biol.* 6:180-190.)

10 GPCRs include receptors for sensory signal mediators (e.g., light and olfactory stimulatory molecules); adenosine, γ -aminobutyric acid (GABA), hepatocyte growth factor, melanocortins, neuropeptide Y, opioid peptides, opsins, somatostatin, tachykinins, vasoactive intestinal polypeptide family, and vasopressin; biogenic amines (e.g., dopamine, epinephrine and norepinephrine, histamine, 15 glutamate (metabotropic effect), acetylcholine (muscarinic effect), and serotonin); chemokines; lipid mediators of inflammation (e.g., prostaglandins and prostanoids, platelet activating factor, and leukotrienes); and peptide hormones (e.g., bombesin, bradykinin, calcitonin, C5a anaphylatoxin, endothelin, follicle-stimulating hormone (FSH), gonadotropin-releasing hormone (GnRH), neurokinin, and thyrotropin-releasing hormone (TRH), and oxytocin). GPCRs which act as receptors for stimuli 15 that have yet to be identified are known as orphan receptors.

20 The diversity of the GPCR family is further increased by alternative splicing. Many GPCR genes contain introns, and there are currently over 30 such receptors for which splice variants have been identified. The largest number of variations are at the protein C-terminus. N-terminal and cytoplasmic loop variants are also frequent, while variants in the extracellular loops or transmembrane domains are 20 less common. Some receptors have more than one site at which variance can occur. The splicing variants appear to be functionally distinct, based upon observed differences in distribution, signaling, coupling, regulation, and ligand binding profiles (Kilpatrick, G.J. et al. (1999) *Trends Pharmacol. Sci.* 20:294-301).

25 GPCRs can be divided into three major subfamilies: the rhodopsin-like, secretin-like, and metabotropic glutamate receptor subfamilies. Members of these GPCR subfamilies share similar 30 functions and the characteristic seven transmembrane structure, but have divergent amino acid sequences. The largest family consists of the rhodopsin-like GPCRs, which transmit diverse extracellular signals including hormones, neurotransmitters, and light. Rhodopsin is a photosensitive GPCR found in animal retinas. In vertebrates, rhodopsin molecules are embedded in membranous stacks found in photoreceptor (rod) cells. Each rhodopsin molecule responds to a photon of light by triggering a decrease in cGMP levels which leads to the closure of plasma membrane sodium channels. In this manner, a visual signal is converted to a neural impulse. Other rhodopsin-like GPCRs are 35 directly involved in responding to neurotransmitters. These GPCRs include the receptors for adrenaline (adrenergic receptors), acetylcholine (muscarinic receptors), adenosine, galanin, and glutamate (N-

methyl-D-aspartate/NMDA receptors). (Reviewed in Watson, S. and S. Arkinstall (1994) The G-Protein Linked Receptor Facts Book, Academic Press, San Diego CA, pp. 7-9, 19-22, 32-35, 130-131, 214-216, 221-222; Habert-Ortoli, E. et al. (1994) Proc. Natl. Acad. Sci. USA 91:9780-9783.)

The galanin receptors mediate the activity of the neuroendocrine peptide galanin, which 5 inhibits secretion of insulin, acetylcholine, serotonin and noradrenaline, and stimulates prolactin and growth hormone release. Galanin receptors are involved in feeding disorders, pain, depression, and Alzheimer's disease (Kask, K. et al. (1997) Life Sci. 60:1523-1533). Other nervous system rhodopsin-like GPCRs include a growing family of receptors for lysophosphatidic acid and other 10 lysophospholipids, which appear to have roles in development and neuropathology (Chun, J. et al. (1999) Cell Biochem. Biophys. 30:213-242).

The largest subfamily of GPCRs, the olfactory receptors, are also members of the rhodopsin-like GPCR family. These receptors function by transducing odorant signals. Numerous distinct 15 olfactory receptors are required to distinguish different odors. Each olfactory sensory neuron expresses only one type of olfactory receptor, and distinct spatial zones of neurons expressing distinct receptors are found in nasal passages. For example, the RA1c receptor which was isolated from a rat brain library, has been shown to be limited in expression to very distinct regions of the brain and a defined 20 zone of the olfactory epithelium (Raming, K. et al. (1998) Receptors Channels 6:141-151). However, the expression of olfactory-like receptors is not confined to olfactory tissues. For example, three rat genes encoding olfactory-like receptors having typical GPCR characteristics showed expression patterns not only in taste and olfactory tissue, but also in male reproductive tissue (Thomas, M.B. et al. (1996) Gene 178:1-5).

Members of the secretin-like GPCR subfamily have as their ligands peptide hormones such as secretin, calcitonin, glucagon, growth hormone-releasing hormone, parathyroid hormone, and 25 vasoactive intestinal peptide. For example, the secretin receptor responds to secretin, a peptide hormone that stimulates the secretion of enzymes and ions in the pancreas and small intestine (Watson, supra, pp. 278-283). Secretin receptors are about 450 amino acids in length and are found in the plasma membrane of gastrointestinal cells. Binding of secretin to its receptor stimulates the production of cAMP.

Examples of secretin-like GPCRs implicated in inflammation and the immune response 30 include the EGF module-containing, mucin-like hormone receptor (Emr1) and CD97 receptor proteins. These GPCRs are members of the recently characterized EGF-TM7 receptors subfamily. These seven transmembrane hormone receptors exist as heterodimers in vivo and contain between three and seven potential calcium-binding EGF-like motifs. CD97 is predominantly expressed in leukocytes and is markedly upregulated on activated B and T cells (McKnight, A.J. and S. Gordon

(1998) *J. Leukoc. Biol.* 63:271-280).

The third GPCR subfamily is the metabotropic glutamate receptor family. Glutamate is the major excitatory neurotransmitter in the central nervous system. The metabotropic glutamate receptors modulate the activity of intracellular effectors, and are involved in long-term potentiation (Watson, 5 supra, p.130). The Ca^{2+} -sensing receptor, which senses changes in the extracellular concentration of calcium ions, has a large extracellular domain including clusters of acidic amino acids which may be involved in calcium binding. The metabotropic glutamate receptor family also includes pheromone receptors, the GABA_B receptors, and the taste receptors.

Other subfamilies of GPCRs include two groups of chemoreceptor genes found in the 10 nematodes *Caenorhabditis elegans* and *Caenorhabditis briggsae*, which are distantly related to the mammalian olfactory receptor genes. The yeast pheromone receptors STE2 and STE3, involved in the response to mating factors on the cell membrane, have their own seven-transmembrane signature, as do the cAMP receptors from the slime mold *Dictyostelium discoideum*, which are thought to regulate the aggregation of individual cells and control the expression of numerous developmentally-regulated genes.

15 GPCR mutations, which may cause loss of function or constitutive activation, have been associated with numerous human diseases (Coughlin, supra). For instance, retinitis pigmentosa may arise from mutations in the rhodopsin gene. Furthermore, somatic activating mutations in the thyrotropin receptor have been reported to cause hyperfunctioning thyroid adenomas, suggesting that certain GPCRs susceptible to constitutive activation may behave as protooncogenes (Parma, J. et al. 20 (1993) *Nature* 365:649-651). GPCR receptors for the following ligands also contain mutations associated with human disease: luteinizing hormone (precocious puberty); vasopressin V₂ (X-linked nephrogenic diabetes); glucagon (diabetes and hypertension); calcium (hyperparathyroidism, hypocalcuria, hypercalcemia); parathyroid hormone (short limbed dwarfism); β_3 -adrenoceptor (obesity, non-insulin-dependent diabetes mellitus); growth hormone releasing hormone (dwarfism); and 25 adrenocorticotropin (glucocorticoid deficiency) (Wilson, S. et al. (1998) *Br. J. Pharmacol.* 125:1387-1392; Stadel, J.M. et al. (1997) *Trends Pharmacol. Sci.* 18:430-437). GPCRs are also involved in depression, schizophrenia, sleeplessness, hypertension, anxiety, stress, renal failure, and several cardiovascular disorders (Horn, F. and G. Vriend (1998) *J. Mol. Med.* 76:464-468).

In addition, within the past 20 years several hundred new drugs have been recognized that are 30 directed towards activating or inhibiting GPCRs. The therapeutic targets of these drugs span a wide range of diseases and disorders, including cardiovascular, gastrointestinal, and central nervous system disorders as well as cancer, osteoporosis and endometriosis (Wilson, supra; Stadel, supra). For example, the dopamine agonist L-dopa is used to treat Parkinson's disease, while a dopamine antagonist is used to treat schizophrenia and the early stages of Huntington's disease. Agonists and antagonists of

adrenoceptors have been used for the treatment of asthma, high blood pressure, other cardiovascular disorders, and anxiety; muscarinic agonists are used in the treatment of glaucoma and tachycardia; serotonin 5HT1D antagonists are used against migraine; and histamine H1 antagonists are used against allergic and anaphylactic reactions, hay fever, itching, and motion sickness (Horn, supra).

5 Recent research suggests potential future therapeutic uses for GPCRs in the treatment of metabolic disorders including diabetes, obesity, and osteoporosis. For example, mutant V2 vasopressin receptors causing nephrogenic diabetes could be functionally rescued *in vitro* by co-expression of a C-terminal V2 receptor peptide spanning the region containing the mutations. This result suggests a possible novel strategy for disease treatment (Schöneberg, T. et al. (1996) EMBO J. 15:1283-1291).

10 Mutations in melanocortin-4 receptor (MC4R) are implicated in human weight regulation and obesity. As with the vasopressin V2 receptor mutants, these MC4R mutants are defective in trafficking to the plasma membrane (Ho, G. and R.G. MacKenzie (1999) J. Biol. Chem. 274:35816-35822), and thus might be treated with a similar strategy. The type 1 receptor for parathyroid hormone (PTH) is a GPCR that mediates the PTH-dependent regulation of calcium homeostasis in the bloodstream. Study

15 of PTH/receptor interactions may enable the development of novel PTH receptor ligands for the treatment of osteoporosis (Mannstadt, M. et al. (1999) Am. J. Physiol. 277:F665-F675).

The chemokine receptor group of GPCRs have potential therapeutic utility in inflammation and infectious disease. (For review, see Locati, M. and P.M. Murphy (1999) Annu. Rev. Med. 50:425-440.) Chemokines are small polypeptides that act as intracellular signals in the regulation of leukocyte 20 trafficking, hematopoiesis, and angiogenesis. Targeted disruption of various chemokine receptors in mice indicates that these receptors play roles in pathologic inflammation and in autoimmune disorders such as multiple sclerosis. Chemokine receptors are also exploited by infectious agents, including herpesviruses and the human immunodeficiency virus (HIV-1) to facilitate infection. A truncated version of chemokine receptor CCR5, which acts as a coreceptor for infection of T-cells by HIV-1, 25 results in resistance to AIDS, suggesting that CCR5 antagonists could be useful in preventing the development of AIDS.

The discovery of new G-protein coupled receptors and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cell proliferative, neurological, cardiovascular, gastrointestinal, 30 autoimmune/inflammatory, and metabolic disorders, and viral infections, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of G-protein coupled receptors.

SUMMARY OF THE INVENTION

The invention features purified polypeptides, G-protein coupled receptors, referred to collectively as "GCREC" and individually as "GCREC-1," "GCREC-2," "GCREC-3," "GCREC-4," "GCREC-5," "GCREC-6," "GCREC-7," "GCREC-8," "GCREC-9," "GCREC-10," "GCREC-11," "GCREC-12," "GCREC-13," "GCREC-14," "GCREC-15," "GCREC-16," "GCREC-17," "GCREC-18," "GCREC-19," "GCREC-20," and "GCREC-21." In one aspect, the invention provides an isolated polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-21.

The invention further provides an isolated polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-21. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:22-42.

Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

The invention also provides a method for producing a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, b) a naturally occurring amino acid sequence having at least 90%

sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21. The method comprises a) culturing a cell under conditions suitable for 5 expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

Additionally, the invention provides an isolated antibody which specifically binds to a 10 polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21.

15 The invention further provides an isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:22-42, b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:22-42, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) 20 an RNA equivalent of a)-d). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of 25 SEQ ID NO:22-42, b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:22-42, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising 30 at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:22-42, b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:22-42, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

The invention further provides a composition comprising an effective amount of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-21. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment the composition.

The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment the composition.

Additionally, the invention provides a method for screening a compound for effectiveness as

an antagonist of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional GCREC, comprising administering to a patient in need of such treatment the composition.

The invention further provides a method of screening for a compound that specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

The invention further provides a method of screening for a compound that modulates the activity of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the

activity of the polypeptide.

The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO:22-42, the method comprising a) 5 exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.

The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 10 contiguous nucleotides of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of i) a polynucleotide sequence selected from the group consisting of SEQ ID NO:22-42, ii) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:22-42, iii) a polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), 15 and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence selected from the group consisting of i) a polynucleotide sequence selected from the group consisting of SEQ ID NO:22-42, ii) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a 20 polynucleotide sequence selected from the group consisting of SEQ ID NO:22-42, iii) a polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the 25 amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

BRIEF DESCRIPTION OF THE TABLES

30 Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the present invention.

Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog for polypeptides of the invention. The probability score for the match between each polypeptide and its GenBank homolog is also shown.

35 Table 3 shows structural features of polypeptide sequences of the invention, including predicted

motifs and domains, along with the methods, algorithms, and searchable databases used for analysis of the polypeptides.

Table 4 lists the cDNA and genomic DNA fragments which were used to assemble polynucleotide sequences of the invention, along with selected fragments of the polynucleotide 5 sequences.

Table 5 shows the representative cDNA library for polynucleotides of the invention.

Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.

Table 7 shows the tools, programs, and algorithms used to analyze the polynucleotides and 10 polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these 15 may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a 20 reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although 25 any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is 30 not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

"GCREC" refers to the amino acid sequences of substantially purified GCREC obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which intensifies or mimics the biological activity of GCREC. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of GCREC either by directly interacting with GCREC or by acting on components of the biological pathway in which GCREC participates.

- 5 An "allelic variant" is an alternative form of the gene encoding GCREC. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides.
- 10 Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding GCREC include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as GCREC or a polypeptide with at least one functional characteristic of GCREC. Included within this definition are

- 15 polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding GCREC, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding GCREC. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent GCREC.
- 20 Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of GCREC is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity
- 25 values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where "amino acid sequence" is recited to refer to a sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known

in the art.

The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of GCREC. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of GCREC either by

5 directly interacting with GCREC or by acting on components of the biological pathway in which GCREC participates.

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')₂, and Fv fragments, which are capable of binding an epitopic determinant.

Antibodies that bind GCREC polypeptides can be prepared using intact polypeptides or using

10 fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize

15 the animal.

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the

20 protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition capable of base-pairing with the "sense" (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as

25 phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring

30 nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or "immunogenic"

refers to the capability of the natural, recombinant, or synthetic GCREC, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

“Complementary” describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement, 3'-TCA-5'.

A “composition comprising a given polynucleotide sequence” and a “composition comprising a given amino acid sequence” refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution.

10 Compositions comprising polynucleotide sequences encoding GCREC or fragments of GCREC may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

15 “Consensus sequence” refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI) or Phrap

20 (University of Washington, Seattle WA). Some sequences have been both extended and assembled to produce the consensus sequence.

“Conservative amino acid substitutions” are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

	Original Residue	Conservative Substitution
30	Ala	Gly, Ser
	Arg	His, Lys
	Asn	Asp, Gln, His
	Asp	Asn, Glu
	Cys	Ala, Ser
	Gln	Asn, Glu, His
35	Glu	Asp, Gln, His
	Gly	Ala
	His	Asn, Arg, Gln, Glu
	Ile	Leu, Val

5	Leu	Ile, Val
	Lys	Arg, Gln, Glu
	Met	Leu, Ile
	Phe	His, Met, Leu, Trp, Tyr
	Ser	Cys, Thr
	Thr	Ser, Val
	Trp	Phe, Tyr
	Tyr	His, Phe, Trp
10	Val	Ile, Leu, Thr

15 Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation,

16 (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

17 A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

18 The term "derivative" refers to a chemically modified polynucleotide or polypeptide. Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one 20 biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

21 A "detectable label" refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

22 A "fragment" is a unique portion of GCREC or the polynucleotide encoding GCREC which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 23 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported 24 by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

25 A fragment of SEQ ID NO:22-42 comprises a region of unique polynucleotide sequence that

specifically identifies SEQ ID NO:22-42, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:22-42 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:22-42 from related polynucleotide sequences. The precise length of a fragment of SEQ 5 ID NO:22-42 and the region of SEQ ID NO:22-42 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-21 is encoded by a fragment of SEQ ID NO:22-42. A fragment of SEQ ID NO:1-21 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-21. For example, a fragment of SEQ ID NO:1-21 is useful as an immunogenic peptide 10 for the development of antibodies that specifically recognize SEQ ID NO:1-21. The precise length of a fragment of SEQ ID NO:1-21 and the region of SEQ ID NO:1-21 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A "full length" polynucleotide sequence is one containing at least a translation initiation codon 15 (e.g., methionine) followed by an open reading frame and a translation termination codon. A "full length" polynucleotide sequence encodes a "full length" polypeptide sequence.

"Homology" refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

The terms "percent identity" and "% identity," as applied to polynucleotide sequences, refer to 20 the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default 25 parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: 30 Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequences.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search

Tool (BLAST) (Altschul, S.F. et al. (1990) *J. Mol. Biol.* 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at <http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other

5 polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to
10 compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Reward for match: 1

Penalty for mismatch: -2

15 *Open Gap: 5 and Extension Gap: 2 penalties*

Gap x drop-off: 50

Expect: 10

Word Size: 11

Filter: on

20 Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences
25 shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

30 Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions,

explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment

5 program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

10 Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) with blastp set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Open Gap: 11 and Extension Gap: 1 penalties

15 *Gap x drop-off: 50*

Expect: 10

Word Size: 3

Filter: on

Percent identity may be measured over the length of an entire defined polypeptide sequence, for 20 example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to 25 describe a length over which percentage identity may be measured.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for chromosome replication, segregation and maintenance.

30 The term "humanized antibody" refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity.

Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the "washing" step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 µg/ml sheared, denatured salmon sperm DNA.

10 Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_m and conditions 15 for nucleic acid hybridization are well known and can be found in Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. 20 Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, 25 such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid 30 sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C_0 or R_0 analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of 5 various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

An "immunogenic fragment" is a polypeptide or oligopeptide fragment of GCREC which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of 10 GCREC which is useful in any of the antibody production methods disclosed herein or known in the art.

The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

15 The term "modulate" refers to a change in the activity of GCREC. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of GCREC.

20 The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the 25 antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

25 "Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

30 "Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Post-translational modification" of an GCREC may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by

cell type depending on the enzymatic milieu of GCREC.

"Probe" refers to nucleic acid sequences encoding GCREC, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical 5 labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. "Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

10 Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the 15 specification, including the tables, figures, and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel, F.M. et al. (1987) Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al. (1990) PCR 20 Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such 25 purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU 30 primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for

microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that 5 hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary 10 polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the 15 artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, *supra*. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell. 20 Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions (UTRs). 25 Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.

"Reporter molecules" are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and 30 other moieties known in the art.

An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The term "sample" is used in its broadest sense. A sample suspected of containing GCREC, nucleic acids encoding GCREC, or fragments thereof may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

5 The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope 10 A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

15 The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

20 "Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

A "transcript image" refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

25 "Transformation" describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed cells" 30 includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic

acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in 5 vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention 10 into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) 15 set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides 20 due to alternative splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given 25 species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the 30 polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% or greater sequence identity over a certain defined length of one of the polypeptides.

THE INVENTION

The invention is based on the discovery of new human G-protein coupled receptors (GCREC), the polynucleotides encoding GCREC, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative, neurological, cardiovascular, gastrointestinal, 5 autoimmune/inflammatory, and metabolic disorders, and viral infections.

Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project ID). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte 10 polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide sequence is denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown.

Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2 show the 15 polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3 shows the GenBank identification number (Genbank ID NO:) of the nearest GenBank homolog. Column 4 shows the probability score for the match between each polypeptide and its GenBank homolog. Column 5 shows the annotation of the GenBank homolog along with relevant citations where 20 applicable, all of which are expressly incorporated by reference herein.

Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence identification number (SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention. Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential 25 phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the MOTIFS program of the GCG sequence analysis software package (Genetics Computer Group, Madison WI). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.

As shown in Table 4, the full length polynucleotide sequences of the present invention were 30 assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Columns 1 and 2 list the polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and the corresponding Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) for each polynucleotide of the invention.

Column 3 shows the length of each polynucleotide sequence in basepairs. Column 4 lists fragments of the polynucleotide sequences which are useful, for example, in hybridization or amplification technologies that identify SEQ ID NO:22-42 or that distinguish between SEQ ID NO:22-42 and related polynucleotide sequences. Column 5 shows identification numbers corresponding to cDNA sequences, coding sequences (exons) predicted from genomic DNA, and/or sequence assemblages comprised of both cDNA and genomic DNA. These sequences were used to assemble the full length polynucleotide sequences of the invention. Columns 6 and 7 of Table 4 show the nucleotide start (5') and stop (3') positions of the cDNA and genomic sequences in column 5 relative to their respective full length sequences.

10 The identification numbers in Column 5 of Table 4 may refer specifically, for example, to Incyte cDNAs along with their corresponding cDNA libraries. For example, 5080262H1 is the identification number of an Incyte cDNA sequence, and LNODNOT11 is the cDNA library from which it is derived. Incyte cDNAs for which cDNA libraries are not indicated were derived from pooled cDNA libraries (e.g., SBSA02572V1). Alternatively, the identification numbers in column 5 may refer

15 to GenBank cDNAs or ESTs (e.g., g4589483_CD) which contributed to the assembly of the full length polynucleotide sequences. Alternatively, the identification numbers in column 5 may refer to coding regions predicted by Genscan analysis of genomic DNA. For example, GNN.g5902227_030.edit is the identification number of a Genscan-predicted coding sequence, with g5902227 being the GenBank identification number of the sequence to which Genscan was applied. The Genscan-predicted coding

20 sequences may have been edited prior to assembly. (See Example IV.) Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon stitching" algorithm. (See Example V.) Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon-stretching" algorithm. (See Example V.) In some cases, Incyte cDNA coverage redundant

25 with the sequence coverage shown in column 5 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.

Table 5 shows the representative cDNA libraries for those full length polynucleotide sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to

30 assemble and confirm the above polynucleotide sequences. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.

The invention also encompasses GCREC variants. A preferred GCREC variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the GCREC amino acid sequence, and which contains at least one functional or

structural characteristic of GCREC.

The invention also encompasses polynucleotides which encode GCREC. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:22-42, which encodes GCREC. The polynucleotide sequences of 5 SEQ ID NO:22-42, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The invention also encompasses a variant of a polynucleotide sequence encoding GCREC. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least 10 about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding GCREC. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:22-42 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:22-42. 15 Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of GCREC.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding GCREC, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the 20 invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring GCREC, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode GCREC and its variants are generally capable of 25 hybridizing to the nucleotide sequence of the naturally occurring GCREC under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding GCREC or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which 30 particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding GCREC and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode GCREC and

GCREC derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding GCREC or any fragment thereof.

5 Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:22-42 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.* 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in
10 10 "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Applied Biosystems), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or
15 combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing
20 system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

25 The nucleic acid sequences encoding GCREC may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site-PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) *PCR Methods Applic.* 2:318-322.)
30 Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) *Nucleic Acids Res.* 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al.

(1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-3060).

- 5 Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a
- 10 GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library

- 15 does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments

- 25 which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode GCREC may be cloned in recombinant DNA molecules that direct expression of GCREC, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent

- 30 amino acid sequence may be produced and used to express GCREC.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter GCREC-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic

oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULAR BREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) *Nat. Biotechnol.* 17:793-797; Christians, F.C. et al. (1999) *Nat. Biotechnol.* 17:259-264; and Crameri, A. et al. (1996) *Nat. Biotechnol.* 14:315-319) to alter or improve the biological properties of GCREC, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

In another embodiment, sequences encoding GCREC may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) *Nucleic Acids Symp. Ser.* 7:215-223; and Horn, T. et al. (1980) *Nucleic Acids Symp. Ser.* 7:225-232.) Alternatively, GCREC itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques. (See, e.g., Creighton, T. (1984) *Proteins, Structures and Molecular Properties*, WH Freeman, New York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) *Science* 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems). Additionally, the amino acid sequence of GCREC, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) *Methods Enzymol.* 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, *supra*, pp. 28-53.)

In order to express a biologically active GCREC, the nucleotide sequences encoding GCREC or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, 5 constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding GCREC. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding GCREC. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding GCREC and its initiation codon and upstream regulatory 10 sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be 15 enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding GCREC and appropriate transcriptional and translational control elements. These methods include *in vitro* recombinant DNA techniques, synthetic techniques, 20 and *in vivo* genetic recombination. (See, e.g., Sambrook, J. et al. (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) *Current Protocols in Molecular Biology*, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences 25 encoding GCREC. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or 30 animal cell systems. (See, e.g., Sambrook, *supra*; Ausubel, *supra*; Van Heeke, G. and S.M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509; Engelhard, E.K. et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:3224-3227; Sandig, V. et al. (1996) *Hum. Gene Ther.* 7:1937-1945; Takamatsu, N. (1987) *EMBO J.* 6:307-311; *The McGraw Hill Yearbook of Science and Technology* (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) *Proc. Natl. Acad. Sci. USA* 81:3655-3659; and

Harrington, J.J. et al. (1997) *Nat. Genet.* 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) *Cancer Gen. Ther.* 5(6):350-356; Yu, M. et al. (1993) *Proc. Natl. Acad. Sci. USA* 90(13):6340-6344; Buller, R.M. et al. (1985) *Nature* 317(6040):813-815; McGregor, D.P. et al. (1994) *Mol. Immunol.* 31(3):219-226; and Verma, I.M. and N. Somia (1997) *Nature* 389:239-242.) The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding GCREC. For example, routine cloning, 10 subcloning, and propagation of polynucleotide sequences encoding GCREC can be achieved using a multifunctional *E. coli* vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSSPORT1 plasmid (Life Technologies). Ligation of sequences encoding GCREC into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for *in vitro* 15 transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509.) When large quantities of GCREC are needed, e.g. for the production of antibodies, vectors which direct high level expression of GCREC may be used. For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.

20 Yeast expression systems may be used for production of GCREC. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast *Saccharomyces cerevisiae* or *Pichia pastoris*. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, *supra*;
25 Bitter, G.A. et al. (1987) *Methods Enzymol.* 153:516-544; and Scorer, C.A. et al. (1994) *Bio/Technology* 12:181-184.)

Plant systems may also be used for expression of CCREC. Transcription of sequences encoding GCREC may be driven by viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) *EMBO J.* 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) *EMBO J.* 3:1671-1680; Broglie, R. et al. (1984) *Science* 224:838-843; and Winter, J. et al. (1991) *Results Probl. Cell Differ.* 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., *The McGraw Hill Yearbook of Science and Technology* (1992) McGraw Hill,

New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding GCREC may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain 5 infective virus which expresses GCREC in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

10 Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.)

15 For long term production of recombinant proteins in mammalian systems, stable expression of GCREC in cell lines is preferred. For example, sequences encoding GCREC can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a 20 selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

25 Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk* and *apr* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) 30 Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate luciferin may be used.

These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) *Methods Mol. Biol.* 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is 5 also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding GCREC is inserted within a marker gene sequence, transformed cells containing sequences encoding GCREC can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding GCREC under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates 10 expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding GCREC and that express GCREC may be identified by a variety of procedures known to those of skill in the art. These 15 procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of GCREC using either 20 specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on GCREC is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) *Serological Methods, a Laboratory Manual*, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) *Current Protocols in Immunology*, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) *Immunochemical Protocols*, Humana Press, Totowa NJ.)

25 A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding GCREC include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding GCREC, or any fragments thereof, may be cloned into a vector 30 for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease

of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding GCREC may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode GCREC may be designed to contain signal sequences which direct secretion of GCREC through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding GCREC may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric GCREC protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of GCREC activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the GCREC encoding sequence and the heterologous protein sequence, so that GCREC may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, *supra*, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled GCREC may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for 5 example, ³⁵S-methionine.

GCREC of the present invention or fragments thereof may be used to screen for compounds that specifically bind to GCREC. At least one and up to a plurality of test compounds may be screened for specific binding to GCREC. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

10 In one embodiment, the compound thus identified is closely related to the natural ligand of GCREC, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, e.g., Coligan, J.E. et al. (1991) Current Protocols in Immunology 1(2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which GCREC binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the 15 compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express GCREC, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing GCREC or cell membrane fractions which contain GCREC are then contacted with a test compound and binding, stimulation, or inhibition of activity of either GCREC or the 20 compound is analyzed.

An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with GCREC, either in solution or affixed to a solid support, and detecting the binding of GCREC to the compound.

25 Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

GCREC of the present invention or fragments thereof may be used to screen for compounds 30 that modulate the activity of GCREC. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for GCREC activity, wherein GCREC is combined with at least one test compound, and the activity of GCREC in the presence of a test compound is compared with the activity of GCREC in the absence of the test compound. A change in the activity of GCREC in the presence of the test compound is 35 indicative of a compound that modulates the activity of GCREC. Alternatively, a test compound is

combined with an in vitro or cell-free system comprising GCREC under conditions suitable for GCREC activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of GCREC may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

5 In another embodiment, polynucleotides encoding GCREC or their mammalian homologs may be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent Number 5,175,383 and U.S. Patent Number 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic Acids Res. 25:4323-4330).
10 Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.
15 Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.
20 Polynucleotides encoding GCREC may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. (1998) Science 282:1145-1147).
25 Polynucleotides encoding GCREC can also be used to create "knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding GCREC is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with
30 potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress GCREC, e.g., by secreting GCREC in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).

THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists

between regions of GCREC and G-protein coupled receptors. Therefore, GCREC appears to play a role in cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections. In the treatment of disorders associated with increased GCREC expression or activity, it is desirable to decrease the expression or activity of GCREC. In the

5 treatment of disorders associated with decreased GCREC expression or activity, it is desirable to increase the expression or activity of GCREC.

Therefore, in one embodiment, GCREC or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC. Examples of such disorders include, but are not limited to, a cell proliferative

10 disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia,

15 gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy,

20 retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis,

25 tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia

30 gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, posttherapeutic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a cardiovascular disorder such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease,

35 aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular

tumors, complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse,

5 rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation; a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric

10 carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome,

15 colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha₁-antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatitis,

20 hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune

25 hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel

30 syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal,

35 parasitic, protozoal, and helminthic infections, and trauma; a metabolic disorder such as diabetes,

obesity, and osteoporosis; and an infection by a viral agent classified as adenovirus, arenavirus, bunyavirus, calicivirus, coronavirus, filovirus, hepadnavirus, herpesvirus, flavivirus, orthomyxovirus, parvovirus, papovavirus, paramyxovirus, picornavirus, poxvirus, reovirus, retrovirus, rhabdovirus, and togavirus.

5 In another embodiment, a vector capable of expressing GCRC or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCRC including, but not limited to, those described above.

In a further embodiment, a composition comprising a substantially purified GCRC in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCRC including, but not limited to, those provided above.

10 In still another embodiment, an agonist which modulates the activity of GCRC may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCRC including, but not limited to, those listed above.

15 In a further embodiment, an antagonist of GCRC may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of GCRC. Examples of such disorders include, but are not limited to, those cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections, described above. In one aspect, an antibody which specifically binds GCRC may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express GCRC.

20 In an additional embodiment, a vector expressing the complement of the polynucleotide encoding GCRC may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of GCRC including, but not limited to, those described above.

25 In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

30 An antagonist of GCRC may be produced using methods which are generally known in the art. In particular, purified GCRC may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind GCRC. Antibodies to GCRC may

also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

5 For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with GCREC or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, 10 polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to GCREC have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or 15 fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of GCREC amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to GCREC may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited 20 to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42; Cote, R.J. et al. (1983) *Proc. Natl. Acad. Sci. USA* 80:2026-2030; and Cole, S.P. et al. (1984) *Mol. Cell Biol.* 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the 25 splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) *Proc. Natl. Acad. Sci. USA* 81:6851-6855; Neuberger, M.S. et al. (1984) *Nature* 312:604-608; and Takeda, S. et al. (1985) *Nature* 314:452-454.) Alternatively, techniques described for the production of single 30 chain antibodies may be adapted, using methods known in the art, to produce GCREC-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) *Proc. Natl. Acad. Sci. USA* 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in

the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for GCREC may also be generated. For example, such fragments include, but are not limited to, F(ab)₂ fragments produced by pepsin 5 digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab)₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired 10 specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between GCREC and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering GCREC epitopes is generally used, but a competitive binding assay may also be 15 employed (Pound, supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for GCREC. Affinity is expressed as an association constant, K_a , which is defined as the molar concentration of GCREC-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_a determined 20 for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple GCREC epitopes, represents the average affinity, or avidity, of the antibodies for GCREC. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular GCREC epitope, represents a true measure of affinity. High-affinity antibody preparations with K_a ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in which the GCREC- 25 antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of GCREC, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J.E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, 30 New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of GCREC-antibody

complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding GCREC, or any fragment 5 or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding GCREC. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding GCREC. 10 (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totowa NJ.)

In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered 15 intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E. et al. (1998) *J. Allergy Cli. Immunol.* 102(3):469-475; and Scanlon, K.J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) *Blood* 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) *Pharmacol. Ther.* 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other 20 systems known in the art. (See, e.g., Rossi, J.J. (1995) *Br. Med. Bull.* 51(1):217-225; Boado, R.J. et al. (1998) *J. Pharm. Sci.* 87(11):1308-1315; and Morris, M.C. et al. (1997) *Nucleic Acids Res.* 25(14):2730-2736.)

In another embodiment of the invention, polynucleotides encoding GCREC may be used for 25 somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) *Science* 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) *Science* 270:475-480; Bordignon, C. et al. (1995) *Science* 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) *Cell* 75:207-216; Crystal, R.G. et al. (1995) *Hum. Gene 30 Therapy* 6:643-666; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:667-703), thalassamias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) *Science* 270:404-410; Verma, I.M. and N. Somia (1997) *Nature* 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g.,

against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) *Nature* 335:395-396; Poeschla, E. et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the 5 case where a genetic deficiency in GCREC expression or regulation causes disease, the expression of GCREC from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

In a further embodiment of the invention, diseases or disorders caused by deficiencies in GCREC are treated by constructing mammalian expression vectors encoding GCREC and introducing 10 these vectors by mechanical means into GCREC-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) *Annu. Rev. Biochem.* 62:191-217; Ivics, Z. (1997) *Cell* 91:501-510; Boulay, J-L. and H. Récipon (1998) *Curr. Opin. Biotechnol.* 15 9:445-450).

Expression vectors that may be effective for the expression of GCREC include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). GCREC may be expressed 20 using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β -actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) *Proc. Natl. Acad. Sci. USA* 89:5547-5551; Gossen, M. et al. (1995) *Science* 268:1766-1769; Rossi, F.M.V. and H.M. Blau (1998) *Curr. Opin. Biotechnol.* 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the 25 ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and Blau, H.M. supra), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding GCREC from a normal individual.

Commercially available liposome transformation kits (e.g., the PERFECT LIPID 30 TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) *Virology* 52:456-467), or by electroporation (Neumann, E. et al. (1982) *EMBO J.* 1:841-845). The introduction of DNA to primary cells requires modification of these

standardized mammalian transfection protocols.

In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to GCREC expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding GCREC under the control of an independent promoter or the retrovirus long

5 terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus *cis*-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-1646; Adam, M.A. and A.D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Patent Number 5,910,434 to Rigg ("Method for obtaining 10 retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4⁺ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et 15 al. (1997) Blood 89:2259-2267; Bonyhadi, M.L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding GCREC to cells which have one or more genetic abnormalities with respect to the expression of GCREC. The construction and packaging of adenovirus-based vectors are well

25 known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) Annu. 30 Rev. Nutr. 19:511-544 and Verma, I.M. and N. Somia (1997) Nature 18:389:239-242, both incorporated by reference herein.

In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding GCREC to target cells which have one or more genetic abnormalities with respect to the expression of GCREC. The use of herpes simplex virus (HSV)-based vectors may be

especially valuable for introducing GCREC to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) *Exp. Eye Res.* 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent Number 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent Number 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this 5 patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) *J. Virol.* 73:519-532 and Xu, H. et al. (1994) *Dev. Biol.* 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus 10 sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary 15 skill in the art.

In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding GCREC to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on 20 the SFV genome (Garoff, H. and K.-J. Li (1998) *Curr. Opin. Biotechnol.* 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for GCREC into the alphavirus 25 genome in place of the capsid-coding region results in the production of a large number of GCREC-coding RNAs and the synthesis of high levels of GCREC in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application. 30 (Dryga, S.A. et al. (1997) *Virology* 228:74-83). The wide host range of alphaviruses will allow the introduction of GCREC into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases,

5 transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

10 Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding GCREC.

15 Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of 20 candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis.

25 Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding GCREC. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

30 RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiester linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and

wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding GCREC.

- 5 Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or
- 10 promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased GCREC expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding GCREC may be therapeutically useful, and in the treatment of disorders associated with decreased GCREC expression or activity, a compound which specifically promotes expression of the polynucleotide encoding GCREC may be therapeutically useful.
- 15 At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound
- 20 based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding GCREC is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an in vitro cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding GCREC are assayed
- 25 by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding GCREC. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide
- 30 exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a Schizosaccharomyces pombe gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clark, M.L. et al. (2000) Biochem. Biophys.
- 35 Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a

combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruice, T.W. et al. (2000) U.S. Patent No. 6,022,691).

5 Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) *Nat.*

10 *Biotechnol.* 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

An additional embodiment of the invention relates to the administration of a composition which 15 generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such compositions may consist of GCRC, antibodies to GCRC, and mimetics, agonists, antagonists, or inhibitors of GCRC.

20 The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

Compositions for pulmonary administration may be prepared in liquid or dry powder form. 25 These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J.S. et al., U.S. 30 Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising GCREC or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, GCREC or a fragment thereof may be joined to a short cationic N-5 terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et al. (1999) *Science* 285:1569-1572).

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, 10 or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example GCREC or fragments thereof, antibodies of GCREC, and agonists, antagonists or inhibitors of GCREC, which 15 ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED₅₀ (the dose therapeutically effective in 50% of the population) or LD₅₀ (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD₅₀/ED₅₀ ratio. Compositions which exhibit large 20 therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED₅₀ with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

25 The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. 30 Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1 μ g to 100,000 μ g, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art.

Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

5 In another embodiment, antibodies which specifically bind GCREC may be used for the diagnosis of disorders characterized by expression of GCREC, or in assays to monitor patients being treated with GCREC or agonists, antagonists, or inhibitors of GCREC. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics.

Diagnostic assays for GCREC include methods which utilize the antibody and a label to detect GCREC

10 10 in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring GCREC, including ELISAs, RIAs, and FACS, are known

15 15 in the art and provide a basis for diagnosing altered or abnormal levels of GCREC expression. Normal or standard values for GCREC expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibodies to GCREC under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of GCREC expressed in

20 20 subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding GCREC may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and

25 25 quantify gene expression in biopsied tissues in which expression of GCREC may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of GCREC, and to monitor regulation of GCREC levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding GCREC or closely related molecules may be used to

30 30 identify nucleic acid sequences which encode GCREC. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding GCREC, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the GCREC encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:22-42 or from genomic sequences including promoters, enhancers, and introns of the GCREC gene.

5 Means for producing specific hybridization probes for DNAs encoding GCREC include the cloning of polynucleotide sequences encoding GCREC or GCREC derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety 10 of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

15 Polynucleotide sequences encoding GCREC may be used for the diagnosis of disorders associated with expression of GCREC. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, 20 penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating 25 diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, 30 encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including

mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a cardiovascular disorder such as arteriovenous fistula, atherosclerosis,

5 hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve,

10 mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation; a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal

15 carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis,

20 Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha₁-antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein

25 obstruction and thrombosis, centrilobular necrosis, peliosis hepatitis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia,

30 asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's

35 thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis,

myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a metabolic disorder such as diabetes, obesity, and osteoporosis; and an infection by a viral agent classified as adenovirus, arenavirus, bunyavirus, calicivirus, coronavirus, filovirus, hepadnavirus, herpesvirus, flavivirus, orthomyxovirus, parvovirus, papovavirus, paramyxovirus, picornavirus, poxvirus, reovirus, retrovirus, rhabdovirus, and togavirus. The polynucleotide sequences encoding GCREC may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered GCREC expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding GCREC may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding GCREC may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding GCREC in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of GCREC, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding GCREC, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the

patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

10 Additional diagnostic uses for oligonucleotides designed from the sequences encoding GCREC may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding GCREC, or a fragment of a polynucleotide complementary to the polynucleotide encoding GCREC, and will be employed under optimized conditions for identification of a specific gene or condition.

15 Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding GCREC may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding GCREC are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSSCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed *in silico* SNP (iSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).

Methods which may also be used to quantify the expression of GCREC include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) *J. Immunol. Methods* 159:235-244; Duplaa, C. et al. (1993) *Anal. Biochem.* 212:229-236.) The speed of quantitation of multiple samples may be

5 accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray

10 can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the

15 activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

In another embodiment, GCREC, fragments of GCREC, or antibodies specific for GCREC

20 may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by

25 quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the

30 hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.

Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the

case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N.L. Anderson (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at <http://www.niehs.nih.gov/oc/news/toxchip.htm>.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and

analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, *supra*). The proteins are

5 visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein

10 spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

15 A proteomic profile may also be generated using antibodies specific for GCREC to quantify the levels of GCREC expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) *Anal. Biochem.* 270:103-111; Mendoza, L.G. et al. (1999) *Biotechniques* 27:778-788). Detection may be performed by a variety of

20 methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J. Seilhamer (1997) *Electrophoresis* 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the

individual proteins and comparing these partial sequences to the polypeptides of the present invention.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

15 Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

20 In another embodiment of the invention, nucleic acid sequences encoding GCREC may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, for example, Lander, E.S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.)

25 Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding GCREC on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is

5 valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) *Nature* 336:577-580.) The nucleotide sequence of the instant invention may

10 also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, GCREC, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a

15 solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between GCREC and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are

20 synthesized on a solid substrate. The test compounds are reacted with GCREC, or fragments thereof, and washed. Bound GCREC is then detected by methods well known in the art. Purified GCREC can also be coated directly onto plates for use in the aforementioned drug screening techniques.

Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

25 In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding GCREC specifically compete with a test compound for binding GCREC. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with GCREC.

In additional embodiments, the nucleotide sequences which encode GCREC may be used in any

30 molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are,

therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications and publications, mentioned above and below, in particular U.S. Ser. No. 60/180,093 and U.S. Ser. No. 60/182,045, are expressly incorporated by reference herein.

EXAMPLES

I. Construction of cDNA Libraries

Incyte cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA) and shown in Table 4, column 5. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), or pINCY (Incyte Genomics, Palo Alto CA), or derivatives thereof. Recombinant plasmids were transformed into competent E. coli cells

including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 α , DH10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

Plasmids obtained as described in Example I were recovered from host cells by *in vivo* excision 5 using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid 10 purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) *Anal. Biochem.* 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using

15 PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSCAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows. Sequencing reactions were processed using standard methods or high-throughput instrumentation 20 such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared 25 using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI 30 PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, *supra*, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.

The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA

sequences or translations thereof were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and hidden Markov model (HMM)-based protein family databases such as PFAM. (HMM is a probabilistic approach which analyzes consensus primary structures of gene families.

5 See, for example, Eddy, S.R. (1996) *Curr. Opin. Struct. Biol.* 6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLIMPS, and HMMER. The Incyte cDNA sequences were assembled to produce full length polynucleotide sequences. Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length.

10 Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length polypeptide sequences. Alternatively, a polypeptide of the invention may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently

15 analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and hidden Markov model (HMM)-based protein family databases such as PFAM. Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are

20 generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity

25 between two sequences).

The programs described above for the assembly and analysis of full length polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:22-42. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 4.

IV. Identification and Editing of Coding Sequences from Genomic DNA

Putative G-protein coupled receptors were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpri and gbhtg). Genscan is a general-purpose gene identification program which analyzes genomic DNA sequences from a variety of organisms (See Burge, C. and S. Karlin (1997) *J. Mol. Biol.* 268:78-94, and Burge, C. and S. Karlin (1998) *Curr. Opin. Struct. Biol.* 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codon. The output of Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode G-protein coupled receptors, the encoded polypeptides were analyzed by querying against PFAM models for G-protein coupled receptors. Potential G-protein coupled receptors were also identified by homology to Incyte cDNA sequences that had been annotated as G-protein coupled receptors. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbpri public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA coverage was available, this information was used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in Example III. Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan-predicted coding sequences.

V. Assembly of Genomic Sequence Data with cDNA Sequence Data**"Stitched" Sequences**

Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example IV. Partial cDNAs assembled as described in Example III were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but consecutive genomic sequences to

be brought together, bridged by cDNA sequence. Intervals thus identified were then "stitched" together by the stitching algorithm in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants. Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were 5 given preference over linkages which change parent type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpri public databases. Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept. Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.

10 **"Stretched" Sequences**

Partial DNA sequences were extended to full length with an algorithm based on BLAST analysis. First, partial cDNAs assembled as described in Example III were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST analysis 15 to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog. Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the 20 public human genome databases. Partial DNA sequences were therefore "stretched" or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.

VI. Chromosomal Mapping of GCREC Encoding Polynucleotides

The sequences which were used to assemble SEQ ID NO:22-42 were compared with 25 sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:22-42 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for 30 Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO:, to that map location.

Map locations are represented by ranges, or intervals, or human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-

arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation 5 hybrid markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI "GeneMap'99" World Wide Web site (<http://www.ncbi.nlm.nih.gov/genemap/>), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.

VII. Analysis of Polynucleotide Expression

10 Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel (1995) supra, ch. 4 and 16.)

15 Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar.

The basis of the search is the product score, which is defined as:

$$20 \quad \frac{\text{BLAST Score} \times \text{Percent Identity}}{5 \times \text{minimum} \{ \text{length(Seq. 1)}, \text{length(Seq. 2)} \}}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated 25 as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The 30 product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

Alternatively, polynucleotide sequences encoding GCREC are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories.

5 Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding GCREC. cDNA sequences and cDNA library/tissue information are found in the LIFESEQ

10 15 GOLD database (Incyte Genomics, Palo Alto CA).

VIII. Extension of GCREC Encoding Polynucleotides

Full length polynucleotide sequences were also produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer was synthesized to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

25 Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg²⁺, (NH₄)₂SO₄, and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2:

94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 µl PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 µl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 µl to 10 µl aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose gel to determine which reactions were successful in extending the sequence.

10 The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were 15 religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

20 The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified 25 using the same conditions as described above. Samples were diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).

30 In like manner, full length polynucleotide sequences are verified using the above procedure or are used to obtain 5' regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.

IX. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:22-42 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is

specifically described, essentially the same procedure is used with larger nucleotide fragments.

Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μ Ci of [γ - 32 P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston

5 MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10^7 counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

10 The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and

15 compared.

X. Microarrays

The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschwiler, *supra*), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned

20 technologies should be uniform and solid with a non-porous surface (Schena (1999), *supra*). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may

25 contain any appropriate number of elements. (See, e.g., Schena, M. et al. (1995) *Science* 270:467-470; Shalon, D. et al. (1996) *Genome Res.* 6:639-645; Marshall, A. and J. Hodgson (1998) *Nat. Biotechnol.* 16:27-31.)

Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be

30 selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser

desorption and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

5 **Tissue or Cell Sample Preparation**

Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)⁺ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)⁺ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/ μ l oligo-(dT) primer (21mer), 1X first strand buffer, 0.03 units/ μ l RNase inhibitor, 500 μ M dATP, 500 μ M dGTP, 500 μ M dTTP, 40 μ M 10 dCTP, 40 μ M dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)⁺ RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)⁺ RNAs are synthesized by *in vitro* transcription from non-coding yeast genomic DNA. After incubation at 37°C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and 15 incubated for 20 minutes at 85°C to stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and 20 resuspended in 14 μ l 5X SSC/0.2% SDS.

Microarray Preparation

Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are 25 amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μ g. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water 30 washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.

35 Array elements are applied to the coated glass substrate using a procedure described in US Patent No. 5,807,522, incorporated herein by reference. 1 μ l of the array element DNA, at an average

concentration of 100 ng/ μ l, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene).

Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water.

- 5 Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60°C followed by washes in 0.2% SDS and distilled water as before.

Hybridization

Hybridization reactions contain 9 μ l of sample mixture consisting of 0.2 μ g each of Cy3 and

- 10 Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65°C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm² coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μ l of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for
- 15 about 6.5 hours at 60°C. The arrays are washed for 10 min at 45°C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45°C in a second wash buffer (0.1X SSC), and dried.

Detection

Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines

- 20 at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.
- 25 In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is
- 30 typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that

- 35 location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples

from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

5 The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and
10 measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

15 A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

XI. Complementary Polynucleotides

Sequences complementary to the GCREC-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring GCREC. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with
20 smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of GCREC. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the GCREC-encoding transcript.

25 XII. Expression of GCREC

Expression and purification of GCREC is achieved using bacterial or virus-based expression systems. For expression of GCREC in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac* (*tac*) hybrid
30 promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express GCREC upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of GCREC in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus

(AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding GCREC by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to

5 infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, GCREC is synthesized as a fusion protein with, e.g., glutathione 10 S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from GCREC at 15 specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified GCREC obtained by these methods can be used directly in the assays shown in 20 Examples XVI, XVII, and XVIII, where applicable.

XIII. Functional Assays

GCREC function is assessed by expressing the sequences encoding GCREC at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice 25 include PCMV SPORT (Life Technologies) and PCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 μ g of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish 30 transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of

fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in 5 expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of GCREC on gene expression can be assessed using highly purified populations 10 of cells transfected with sequences encoding GCREC and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression 15 of mRNA encoding GCREC and other genes of interest can be analyzed by northern analysis or microarray techniques.

XIV. Production of GCREC Specific Antibodies

GCREC substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to 20 immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the GCREC amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well 25 described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using Fmoc chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the 30 oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-GCREC activity by, for example, binding the peptide or GCREC to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XV. Purification of Naturally Occurring GCREC Using Specific Antibodies

Naturally occurring or recombinant GCREC is substantially purified by immunoaffinity

chromatography using antibodies specific for GCREC. An immunoaffinity column is constructed by covalently coupling anti-GCREC antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

5 Media containing GCREC are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of GCREC (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/GCREC binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and GCREC is collected.

10 **XVI. Identification of Molecules Which Interact with GCREC**

Molecules which interact with GCREC may include agonists and antagonists, as well as molecules involved in signal transduction, such as G proteins. GCREC, or a fragment thereof, is labeled with ¹²⁵I Bolton-Hunter reagent. (See, e.g., Bolton A.E. and W.M. Hunter (1973) Biochem. J. 133:529-539.) A fragment of GCREC includes, for example, a fragment comprising one or more of the 15 three extracellular loops, the extracellular N-terminal region, or the third intracellular loop. Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled GCREC, washed, and any wells with labeled GCREC complex are assayed. Data obtained using different concentrations of GCREC are used to calculate values for the number, affinity, and association of GCREC with the candidate ligand molecules.

20 Alternatively, molecules interacting with GCREC are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) Nature 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech). GCREC may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between 25 the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Patent No. 6,057,101).

Potential GCREC agonists or antagonists may be tested for activation or inhibition of GCREC receptor activity using the assays described in sections XVII and XVIII. Candidate molecules may be selected from known GPCR agonists or antagonists, peptide libraries, or combinatorial chemical 30 libraries.

Methods for detecting interactions of GCREC with intracellular signal transduction molecules such as G proteins are based on the premise that internal segments or cytoplasmic domains from an orphan G protein-coupled seven transmembrane receptor may be exchanged with the analogous domains of a known G protein-coupled seven transmembrane receptor and used to identify the G-

proteins and downstream signaling pathways activated by the orphan receptor domains (Kobilka, B.K. et al. (1988) *Science* 240:1310-1316). In an analogous fashion, domains of the orphan receptor may be cloned as a portion of a fusion protein and used in binding assays to demonstrate interactions with specific G proteins. Studies have shown that the third intracellular loop of G protein-coupled 5 seven transmembrane receptors is important for G protein interaction and signal transduction (Conklin, B.R. et al. (1993) *Cell* 73:631-641). For example, the DNA fragment corresponding to the third intracellular loop of GCREC may be amplified by the polymerase chain reaction (PCR) and subcloned into a fusion vector such as pGEX (Pharmacia Biotech). The construct is transformed into an appropriate bacterial host, induced, and the fusion protein is purified from the cell lysate by 10 glutathione-Sepharose 4B (Pharmacia Biotech) affinity chromatography.

For *in vitro* binding assays, cell extracts containing G proteins are prepared by extraction with 50 mM Tris, pH 7.8, 1 mM EGTA, 5 mM MgCl₂, 20 mM CHAPS, 20% glycerol, 10 µg of both aprotinin and leupeptin, and 20 µl of 50 mM phenylmethylsulfonyl fluoride. The lysate is incubated on ice for 45 min with constant stirring, centrifuged at 23,000 g for 15 min at 4°C, and the 15 supernatant is collected. 750 µg of cell extract is incubated with glutathione S-transferase (GST) fusion protein beads for 2 h at 4°C. The GST beads are washed five times with phosphate-buffered saline. Bound G subunits are detected by [³²P]ADP-ribosylation with pertussis or cholera toxins. The reactions are terminated by the addition of SDS sample buffer (4.6% (w/v) SDS, 10% (v/v) β-mercaptoethanol, 20% (w/v) glycerol, 95.2 mM Tris-HCl, pH 6.8, 0.01% (w/v) bromphenol blue). 20 The [³²P]ADP-labeled proteins are separated on 10% SDS-PAGE gels, and autoradiographed. The separated proteins in these gels are transferred to nitrocellulose paper, blocked with blotto (5% nonfat dried milk, 50 mM Tris-HCl (pH 8.0), 2 mM CaCl₂, 80 mM NaCl, 0.02% NaN₃, and 0.2% Nonidet P-40) for 1 hour at room temperature, followed by incubation for 1.5 hours with Gα subtype selective 25 antibodies (1:500; Calbiochem-Novabiochem). After three washes, blots are incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin (1:2000, Cappel, Westchester PA) and visualized by the chemiluminescence-based ECL method (Amersham Corp.).

XVII. Demonstration of GCREC Activity

An assay for GCREC activity measures the expression of GCREC on the cell surface. cDNA encoding GCREC is transfected into an appropriate mammalian cell line. Cell surface proteins are 30 labeled with biotin as described (de la Fuente, M.A. et al. (1997) *Blood* 90:2398-2405). Immunoprecipitations are performed using GCREC-specific antibodies, and immunoprecipitated samples are analyzed using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting techniques. The ratio of labeled immunoprecipitant to unlabeled immunoprecipitant is proportional to the amount of GCREC expressed on the cell surface.

35 In the alternative, an assay for GCREC activity is based on a prototypical assay for

ligand/receptor-mediated modulation of cell proliferation. This assay measures the rate of DNA synthesis in Swiss mouse 3T3 cells. A plasmid containing polynucleotides encoding GCREC is added to quiescent 3T3 cultured cells using transfection methods well known in the art. The transiently transfected cells are then incubated in the presence of [³H]thymidine, a radioactive DNA precursor molecule. Varying amounts of GCREC ligand are then added to the cultured cells. Incorporation of [³H]thymidine into acid-precipitable DNA is measured over an appropriate time interval using a radioisotope counter, and the amount incorporated is directly proportional to the amount of newly synthesized DNA. A linear dose-response curve over at least a hundred-fold GCREC ligand concentration range is indicative of receptor activity. One unit of activity per milliliter is defined as the 5 concentration of GCREC producing a 50% response level, where 100% represents maximal incorporation of [³H]thymidine into acid-precipitable DNA (McKay, I. and I. Leigh, eds. (1993) Growth Factors: A Practical Approach, Oxford University Press, New York NY, p. 73.)

In a further alternative, the assay for GCREC activity is based upon the ability of GPCR family proteins to modulate G protein-activated second messenger signal transduction pathways (e.g., 10 cAMP; Gaudin, P. et al. (1998) *J. Biol. Chem.* 273:4990-4996). A plasmid encoding full length GCREC is transfected into a mammalian cell line (e.g., Chinese hamster ovary (CHO) or human embryonic kidney (HEK-293) cell lines) using methods well-known in the art. Transfected cells are grown in 12-well trays in culture medium for 48 hours, then the culture medium is discarded, and the attached cells are gently washed with PBS. The cells are then incubated in culture medium with or 15 without ligand for 30 minutes, then the medium is removed and cells lysed by treatment with 1 M perchloric acid. The cAMP levels in the lysate are measured by radioimmunoassay using methods well-known in the art. Changes in the levels of cAMP in the lysate from cells exposed to ligand compared to those without ligand are proportional to the amount of GCREC present in the transfected cells.

20 To measure changes in inositol phosphate levels, the cells are grown in 24-well plates containing 1×10^5 cells/well and incubated with inositol-free media and [³H]myoinositol, 2 μ Ci/well, for 48 hr. The culture medium is removed, and the cells washed with buffer containing 10 mM LiCl followed by addition of ligand. The reaction is stopped by addition of perchloric acid. Inositol 25 phosphates are extracted and separated on Dowex AG1-X8 (Bio-Rad) anion exchange resin, and the total labeled inositol phosphates counted by liquid scintillation. Changes in the levels of labeled inositol phosphate from cells exposed to ligand compared to those without ligand are proportional to the amount of GCREC present in the transfected cells.

XVIII. Identification of GCREC Ligands

GCREC is expressed in a eukaryotic cell line such as CHO (Chinese Hamster Ovary) or HEK

(Human Embryonic Kidney) 293 which have a good history of GPCR expression and which contain a wide range of G-proteins allowing for functional coupling of the expressed GCREC to downstream effectors. The transformed cells are assayed for activation of the expressed receptors in the presence of candidate ligands. Activity is measured by changes in intracellular second messengers, such as cyclic AMP or Ca^{2+} . These may be measured directly using standard methods well known in the art, or by the use of reporter gene assays in which a luminescent protein (e.g. firefly luciferase or green fluorescent protein) is under the transcriptional control of a promoter responsive to the stimulation of protein kinase C by the activated receptor (Milligan, G. et al. (1996) Trends Pharmacol. Sci. 17:235-237). Assay technologies are available for both of these second messenger systems to allow high throughput readout in multi-well plate format, such as the adenylyl cyclase activation FlashPlate Assay (NEN Life Sciences Products), or fluorescent Ca^{2+} indicators such as Fluo-4 AM (Molecular Probes) in combination with the FLIPR fluorimetric plate reading system (Molecular Devices). In cases where the physiologically relevant second messenger pathway is not known, GCREC may be coexpressed with the G-proteins $\text{G}_{\alpha 15/16}$ which have been demonstrated to couple to a wide range of G-proteins (Offermanns, S. and M.I. Simon (1995) J. Biol. Chem. 270:15175-15180), in order to funnel the signal transduction of the GCREC through a pathway involving phospholipase C and Ca^{2+} mobilization. Alternatively, GCREC may be expressed in engineered yeast systems which lack endogenous GPCRs, thus providing the advantage of a null background for GCREC activation screening. These yeast systems substitute a human GPCR and G_α protein for the corresponding components of the endogenous yeast pheromone receptor pathway. Downstream signaling pathways are also modified so that the normal yeast response to the signal is converted to positive growth on selective media or to reporter gene expression (Broach, J.R. and J. Thorner (1996) Nature 384 (supp.):14-16). The receptors are screened against putative ligands including known GPCR ligands and other naturally occurring bioactive molecules. Biological extracts from tissues, biological fluids and cell supernatants are also screened.

25

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

Incyte Project ID	Polypeptide SEQ ID NO:	Incyte Polypeptide ID	Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID
7472033	1	7472033CD1	22	7472033CB1
7472034	2	7472034CD1	23	7472034CB1
7472035	3	7472035CD1	24	7472035CB1
7472036	4	7472036CD1	25	7472036CB1
7472037	5	7472037CD1	26	7472037CB1
7472039	6	7472039CD1	27	7472039CB1
7472040	7	7472040CD1	28	7472040CB1
4250893	8	4250893CD1	29	4250893CB1
6726656	9	6726656CD1	30	6726656CB1
7472062	10	7472062CD1	31	7472062CB1
7472067	11	7472067CD1	32	7472067CB1
7472072	12	7472072CD1	33	7472072CB1
7472074	13	7472074CD1	34	7472074CB1
7472077	14	7472077CD1	35	7472077CB1
7472082	15	7472082CD1	36	7472082CB1
7472128	16	7472128CD1	37	7472128CB1
7472134	17	7472134CD1	38	7472134CB1
7472136	18	7472136CD1	39	7472136CB1
7472142	19	7472142CD1	40	7472142CB1
7472171	20	7472171CD1	41	7472171CB1
7472172	21	7472172CD1	42	7472172CB1

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability Score	GenBank Homolog
1	7472033CD1	94062997	4.3e-38	Neuropeptide Y receptor type 4 [Sus scrofa]
2	7472034CD1	96532001	3.6e-89	Odorant receptor S19 [Mus musculus]
3	7472035CD1	94680260	2.5e-72	Odorant receptor S18 [Mus musculus]
4	7472036CD1	94680260	2.9e-87	Odorant receptor S18 [Mus musculus]
5	7472037CD1	932093	2.5e-81	Olfactory receptor HGMP07J [Homo sapiens]
6	7472039CD1	93983374	9.3e-75	Olfactory receptor C6 [Mus musculus]
7	7472040CD1	97707801	1.0e-177	G protein-coupled receptor C5L2 [Homo sapiens]
8	4250893CD1	93341996	5.0e-65	Angiotensin/vasopressin receptor AII/AVP [Homo sapiens] (Mao, M. et al. (1998) Proc. Natl. Acad. Sci. USA 95(14):8175-8180)
9	6726656CD1	93983408	7.4e-82	Olfactory receptor H7 [Mus musculus] (Krautwurst, D. et al. (1998) Cell 95(7):917-926)
10	7472062CD1	93746443	7.6e-80	Olfactory receptor OR93Ch [Pan troglodytes] (Rouquier, S. et al. (1998) Hum. Mol. Genet. 7(9):1337-1345)
11	7472067CD1	92358267	6.3e-23	Galanin receptor [Mus musculus] (Jacoby, A.S. et al. (1997) Genomics 45(3):496-508)
12	7472072CD1	91336043	3.4e-68	HSOLF3 [Homo sapiens]
13	7472074CD1	g10732802	1.0e-47	Vomeronasal receptor 1 [Homo sapiens]
14	7472077CD1	g8118040	1.0e-168	Orphan G-protein coupled receptor [Homo sapiens]
15	7472082CD1	g23117704	2.2e-114	Olfactory receptor [Rattus norvegicus] (McClintock, T.S. et al. (1997) Brain Res. Mol. Brain Res. 2:59-68)
16	7472128CD1	g1246534	3.5e-82	Olfactory receptor 4 [Gallus gallus] (Leibovici, M. et al. (1996) Dev. Biol. 175(1):118-131)
17	7472134CD1	g4680254	1.4e-78	Odorant receptor S1 [Mus musculus] (Malnic, B. et al. (1999) Cell 96(5):713-723)
18	7472136CD1	g206810	1.3e-43	G-protein coupled receptor [Rattus norvegicus] (Ross, P.C. et al. (1990) Proc. Natl. Acad. Sci. USA 87:3052-3056)
19	7472142CD1	g5869918	1.0e-93	Olfactory receptor [Mus musculus] (Strotmann, J. et al. (1999) Gene 236(2):281-291)
20	7472171CD1	g5869925	1.6e-134	Olfactory receptor [Mus musculus] (Strotmann, J. et al. (1999) Gene 236(2):281-291)
21	7472172CD1	g3983374	3.9e-76	Olfactory receptor C6 [Mus musculus] (Krautwurst, D. et al. (1998) Cell 95(7):917-926)

Table 3

SEQ ID NO:	Incute Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
1	7472033CD1	470	S131 T153 S24 S73 Y82	N2 N46 N51 N56	G-protein coupled receptor motif: V184-I200 Transmembrane domains: P80-Y105, L145-Y164, V214-Y234, Y271-Y291 7 transmembrane receptor (rhodopsin family) signature: L140-Y379 G-protein coupled receptor signatures: Y164-P203, Y280-Y291, R316-F342, S371-R387 G-protein coupled receptor signature: A175-A224 Neuropeptide Y receptor signatures: T153-G165, Q178-A193, R314-I326, M366-N375, L377-I390 Rhodopsin-like GPCR superfamily signatures: M84-S108, Q178-I200, G212-V233, F269-A290, S272-Y295, T321-Y345, Y361-R387 Probable G protein-coupled receptor signatures: I174-A191, G380-L393 T22D1.12 protein (similar to G-protein coupled receptors): PD061410: Y271-A415 G-protein coupled receptor: PD000009: L140-Y234	MOTIFS HMMER HMMER-PFAM BLIMPS-BLOCKS PROFILESCAN BLIMPS-PRINTS BLIMPS-PRINTS BLIMPS-PRINTS BLAST-PRODOM BLAST-PRODOM

Table 3 (cont.)

SEQ ID NO:	Incite Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
1					G-protein coupled receptor DM00013 P49683 54-350: L140-L394 DM00013 P50391 35-337: S141-L394 DM00013 P49146 44-341: M84-K388 DM00013 P25929 34-335: S141-Q391	BLAST-DOMO
2	7472034CD1	326	T276 T323 S123 T323	N57	G-protein coupled receptor motif: M125-I141 Transmembrane domains: W61-D67, M161-C184, T208-G230 7 transmembrane receptor (rhodopsin family) signature: G56-Y307	MOTIFS HMMER HMMER-PFAM

Table 3 (cont.)

SEQ ID NO:	Incite Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases	
3	7472035CD1	315	T49 T103 S172 S48 T144 S224		G-protein coupled receptor motif: V105-I121 Signal Peptide: M1-A28 Transmembrane domain: Y30-S48 7 transmembrane receptor (rhodopsin family) signature: G336-Y288 G-protein coupled receptor signatures: S85-P124, T227-S253, P280-R296 G-protein coupled receptor signature: F97-R146 Olfactory receptor signatures: M54-K75, S172-D186, L233-L248 Angiotensin II receptor signature: I209-V220 EDG1 orphan receptor signature: A43-F57 Olfactory receptor PD000921: L161-V240 G-protein coupled receptor: DM00013 P23274 18-306: I12-I299 DM00013 G45774 18-309: P13-E297 DM00013 S29708 18-306: H19-I299 DM00013 P23269 15-304: Q16-I299	BLIMPS-BLOCKS PROFILESCAN BLIMPS-PRINTS BLIMPS-PRINTS BLIMPS-PRINTS BLIMPS-PRINTS BLAST-PRODOM BLAST-PRODOM	MOTIFS HMMER HMMER HMMER-PFAM MOTIFS HMMER HMMER-PFAM
4	7472036CD1	314	S110	N5 N44	G-protein coupled receptor motif: M112-I128 Transmembrane domains: I27-L42, I199-L218 7 transmembrane receptor (rhodopsin family) signature: G43-Y294	MOTIFS HMMER HMMER-PFAM	

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
4					G-protein coupled receptor signatures: R92-P131, E234-S260, P286-R302 G-protein coupled receptor signature: F104-A152	BLIMPS-BLOCKS PROFILESCAN
					Olfactory receptor signatures: M61-K82, C179-D193, F240-T255, L278-V289	BLIMPS-PRINTS
					Melanocortin receptor signature: A53-L65	BLIMPS-PRINTS
					Rhodopsin-like GPCR superfamily signatures: W28-Q52, M61-K82, L106-I128, I143-L164, G201-L224, A203-V227, I276-R302	BLIMPS-PRINTS
					Olfactory receptor PD000921: Y170-I247	BLAST-PRODOM
					Putative G-protein coupled receptor RA1C PD170483: I247-F309	BLAST-PRODOM
					G-protein coupled receptor: DM00013 P23275 17-306: H24-I305 DM00013 G45774 18-309: P20-I305 DM00013 S29708 18-306: E23-V308 DM00013 P23269 15-304: E23-V308	BLAST-DOMO
5	7472037CD1	321	S75 S196 S201 S240 T299	N12 N50	Transmembrane domains: P33-G49, V148-I171, L205-I229 7 transmembrane receptor (rhodopsin family) signature: G49-Y298	HMMER HMmer - PFAM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
5					G-protein coupled receptor signatures: Q98-P137, F208-F219, R243-R269, T290-R306	BLIMPS-BLOCKS
					G-protein coupled receptor signature: F110-S159	PROFILESCAN
					Olfactory receptor signatures: M67-N88, F185-E199, F246-G261, V282-L293, T299-L313	BLIMPS-PRINTS
					Melanocortin receptor signature: V59-L71, I134-R145	BLIMPS-PRINTS
					Olfactory receptor PD000921: F176-L253	BLAST-PRODOM
					Olfactory receptor PD149621: T254-R315	BLAST-PRODOM
					G-protein coupled receptor: DM00013 P30954 29-316: S26-L309	BLAST-DOMO
					DM00013 P23270 18-311: L31-L313	
					DM00013 P30955 18-305: P29-K311	
					DM00013 S29709 11-299: P29-L313	
6	7472039CD1	331	S69 S24 T195 S235 S326	N6 N40 N67	G-protein coupled receptor motif: S112-I128	MOTIFS
					Signal Peptide: M1-A53	SPSCAN
					Transmembrane domains: M61-L84, A98-M120, S207-I229, F241-V263	HMMER
					7 transmembrane receptor (rhodopsin family) signature: G43-Y293	HMMER-PFAM
					G-protein coupled receptor signatures: H92-P131, Q238-R264, T285-K301	BLIMPS-BLOCKS

Table 3 (cont.)

SEQ NO:	Incite Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
6					G-protein coupled receptor signature: Y104-A149	PROFILESCAN
					Olfactory receptor signatures: M61-K82, F180-N194, F241-G256, V277-L288, A294-F308	BLIMPS- PRINTS
					Melanocortin receptor signature: A53-L65, I128-S139	BLIMPS- PRINTS
					Olfactory receptor FD000921: L168-I249	BLAST- PRODOM
					Olfactory receptor FD149621: V250-K310	BLAST- PRODOM
					G-protein coupled receptor: DM00013 P23267 20-309: P20-K305 DM00013 P23270 18-311: R26-K305 DM00013 P23274 18-306: F30-L304 DM00013 P30955 18-305: F30-K305	BLAST- DOMO
7	7472040CD1	337	S17 S323 S326 S194 T327 S333	N3	7 transmembrane receptor (rhodopsin family) signature: G52-D131, V153-F291	HMMER - PFAM
					G-protein coupled receptor signatures: W100-P139, F209-H220, W226-L252, H283-L299	BLIMPS- BLOCKS
					CSA-anaphylatoxin receptor signatures: V59-W72, C83-P93, L110-S121 P111-L123	BLIMPS- PRINTS
					Rhodopsin-like GPCR superfamily signatures: A37-G61, G69-L90, I114-A136, G150-I171, T201-L224, C231-V255, E273-L299	BLIMPS- PRINTS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Prostanoid EP1 receptor signature: W58-L73	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
7					G-protein coupled receptor: PD000009: W72-Y172	BLIMPS-PRINTS; BLAST-PRODOM	
8	4250893CD1	1473	S990 S37 S49 S99 S162 S258 S299 S368 S379 S400 S485 S509 S587 T747 T850 T866 T868 S923 T962 T993 S1047 S1064 T1075 S1313 S1371 T1394 S132 S144 S227 T457 S484 T543 T670 T831 T841 S893 S985 S1009 S1017 S1107 S1258 S1464 Y1311 Y1445	N727 N864 N1005	Transmembrane domain: G1216-L1237	HMMER	
9	6726656CD1	328	S17 T309	N23	Leucine Rich Repeats: N809-R833; L838-R862; T866-R890; K895-P922; S923-R947 RECEPTOR ANGIOTENSIN/VASOPRESSIN AI1/AVP VASOPRESSIN PD156095: M534-V704 ATP/GTP binding site (P-loop): G334-S341	HMMER-PFAM; BLAST-PRODOM; MOTIFS	
					Transmembrane domains: V43-I63; Y211-M231 7 transmembrane receptors (rhodopsin family) domain: G59-Y308 G-protein coupled receptors signature: S108-P147; S300-K316	HMMER; HMMER-PFAM; BLIMPS-BLOCKS	

Table 3 (cont.)

SEQ NO:	Incycyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
9					G-protein coupled receptors signature: Y120-V166	PROFILESCAN
					Olfactory receptor signature: M77-K98; F195-S209; F256-T271; A292-L303; T309-F323	BLIMPS- PRINTS
10	7472062CD1	384	T298 S34 S36 T69 T256 S10 T146 T205 T231 S258 T338 T359 Y378	N49 N73 N133 N223	RECEPTOR OLFACTORY PROTEIN RECEPTORLIKE GPROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN MULTIGENE FAMILY PD000921: L184-L263 G-PROTEIN COUPLED RECEPTORS DM00013 P23266 17-306: S36-L322 G-protein coupled receptors motif: S128-I144	BLAST- PRODOM BLAST-DOMO BLIMPS- BLOCKS HMMER HMMER- PFAM HMMER-PFAM PROFILESCAN

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
10					OLFACTORE RECEPTOR PROTEIN RECEPTORLIKE GPROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN MULTIGENE FAMILY PD149621: I316-V373	BLAST-PRODOM
11	7472067CD1	419	T234 S81 S102 T331 S358 S398 T177 T326 S370 T375	N10 N15 N79 N151	G-PROTEIN COUPLED RECEPTORS DM00013 S51356 18-307; L85-A368 G-protein coupled receptors motif: V178-V194	BLAST-DOMO
12	7472072CD1	314	S67 S188 S227 S291	N5 N155	Transmembrane domain: A41-L61 7 transmembrane receptor (rhodopsin family) domain: G53-A133; W155-F306 G-protein coupled receptors signature: W104-P143; I243-A269; I298-R314 Rhodopsin-like GPCR superfamily signature: I38-L62; I73-I94; T153-F174; V248-W272; I288-R314 G-PROTEIN COUPLED RECEPTORS DM00013 P47211 27-319; V49-K322	BLIMPS-BLOCKS BLIMPS-PRINTS BLAST-DOMO

Table 3 (cont.)

SEQ ID NO:	Incyte polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
12					G-protein coupled receptors signature: F102-S147	PROFILESCAN
					Rhodopsin-like GPCR superfamily signature: L26-R50; M59-K80; L104-V126; L199-L222; A237-V261; N272-W298	BLIMPS-PRINTS
					Olfactory receptor signature: M59-K80; F177-D191; V238-G253; V274-L285; S291-L305	BLIMPS-PRINTS
					RECEPTOR OLFACTORY PROTEIN RECEPTORLIKE GPROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN MULTIGENE FAMILY PD000921: Y168-I245	BLAST~PRODOM
					G-PROTEIN COUPLED RECEPTORS DM00013 P23275 17-306: L26-L305	BLAST~DOMO
					G-protein coupled receptors motif: A110-V126	MOTIFS
13	7472074CD1	254	T159 S185 S110 S111 T150 T178 S222	N154 N157	Signal peptide: M1-G61 Transmembrane domain: V127-F145; M182-S199; I235-V254 5-hydroxytryptamine 2A receptor signature: H48-A68	SPSCAN MOTIFS
					G-protein coupled receptors signature: Y73-R112; S226-F252	BLIMPS-BLOCKS
					PHEROMONE RECEPTOR VN1 VN2 VN3 VN7 VN5 VN4 VN6 PD009900: R38-Y246	BLAST~PRODOM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
14	7472077CD1	362	S8 S268		Transmembrane domains: S28-M48; F66-N85; V91-A109; C164-M181; L205-L224; W251-N278 7 transmembrane receptor (metabotropic glutamate family) domain: W22-Q271 (Score: -137.1; E-value: 0.35) B1 bradykinin receptor signature: T37-Q56	HMMER-PFAM
15	7472082CD1	370	S334 S42 S68 S127 S153 S326 T138 T147 S351	N65	Transmembrane domains: F88-L108; W203-L228; L260-A283 7 transmembrane receptor (rhodopsin family) domain: 'G101-Y350 G-protein coupled receptors signature: N150-P189; V342-K358 Olfactory receptor signature: M119-K140; Y237-S251; F298-G313; S334-L345; S351-L365 RECEPTOR OLFACTORY PROTEIN RECEPTORLIKE GPROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN MULTIGENE FAMILY PD000921: L226-L306 G-PROTEIN COUPLED RECEPTORS DM00013 S51356 18-307: L77-V361	HMMER-PFAM BLIMPS-PRINTS BLAST-PRODOM BLAST-BLOCKS BLIMPS-PRINTS BLAST-PRODOM BLAST-DOMO

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Domains and Motifs	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
1.6	7472128CD1	319	T2 S74 T85 S95 T201 S298	N274	Transmembrane domain: V204-C226 7 transmembrane receptor (rhodopsin family) domain: G48-Y297	HMMER HMMER-PFAM	
					G-protein coupled receptors signature: K97-P136; T214-Y225; I289-K305	BLIMPS-BLOCKS G-protein coupled receptors signature: F110-A157	PROFILESCAN
1.7	7472134CD1	312	S67 S87 S204 S291	N5	Olfactory receptor signature: M66-K87; Y184-N198 L245-G260; V281-L292; S298-L312	BLIMPS-PRINTS	

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
17					G-protein coupled receptors signature: Y102-I146 Rhodopsin-like GPCR superfamily signature: Y26-C50; M59-K80; F104-I126; D199-I222; Q272-K298 Olfactory receptor signature: M59-K80; V177-D191; I238-G253; L274-L285; S291-L305 RECEPTOR OLFACTORY PROTEIN RECEPTORLIKE GPROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN MULTIGENE FAMILY P0000921: L166-H244	BLIMPS- PRINTS BLIMPS- PRINTS BLAST- PRODOM BLAST- DOMO BLAST- DOMO
18	7472136CD1	321	S209 T94 T121 S281 S284	N2 N6 N16 N92	Transmembrane domain: Y109-F129; V229-Y245 7 transmembrane receptor (rhodopsin family) domain: G44-S78; L104-Y276 G-protein coupled receptors signature: V91-P130; R214-Y240; S268-S284 G-protein coupled receptors signature: L104-L149	HMMER HMMER-PFAM BLIMPS- BLOCKS PROFILESCAN

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
18					Rhodopsin-like GPCR superfamily signature: V29-G53; F61-T82; M105-V127; L219-V243; F258-S284	BLIMPS-PRINTS
19	7472142CD1	316	T49 S67 T228 S88 S290	N5 N42 N65	Transmembrane domains: F28-I48; Y102-D121; L199-I227 7 transmembrane receptor (rhodopsin family) domain: G41-Y289	HMMER

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
19					RECEPTOR OLFACTORY PROTEIN RECEPTORLIKE GPROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN MULTIGENE FAMILY PD000921: L166-L244	BLAST-PRODOM
20	7472171CD1	325	S49 S67 T118 S156 S193 S87 S88 S137 S163 T178 S291	N5. N65 N191	Transmembrane domain: L143-S163; S203-V228 7 transmembrane receptor (rhodopsin family) domain: G41-Y290 G-protein coupled receptors signature: K90-P129; T282-K298 G-protein coupled receptors signature: L103-A147 Olfactory receptor signature: V59-L80; F177-N191; F238-G253; F274-L285; S291-W305	HHMER HHMER-PFAM BLIMPS-BLOCKS PROFILESCAN BLIMPS-PRINTS BLAST-PRODOM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
21	7472172CD1	313	T6 S65 S263 T76 S288	N3 N40 N63 N262	<p>Signal peptide: M1-T36 Transmembrane domains: I10-T32; M96-M116; L191-L208</p> <p>7 transmembrane receptor (rhodopsin family) domain: G39-Y287</p> <p>G-protein coupled receptors signature: K88-P127; T279-Q295</p> <p>G-protein coupled receptors signature: Y100-L144</p> <p>Rhodopsin-like GPCR superfamily signature: S24-W48; M57-K78; Y102-I124; A138-I159; N196-I219; K269-Q295</p> <p>Olfactory receptor signature: M57-K78; F174-N188; F235-G250; A271-L282; S288-V302</p> <p>RECEPTOR OLFACTORY PROTEIN RECEPTORLIKE GPROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN MULTIGENE FAMILY P0000921: L164-I242</p> <p>G-PROTEIN COUPLED RECEPTORS DM00013 P23267 20-309: F15-V302</p> <p>G-protein coupled receptors motif: V108-I124</p>	<p>SPSCAN</p> <p>HHMER</p> <p>HHMER - PFAM</p> <p>BLOCKS-BLIMPS</p> <p>PROFILESCAN</p> <p>BLIMPS-PRINTS</p> <p>BLIMPS-PRINTS</p> <p>BLAST-PRODOM</p> <p>BLAST-DOMO</p> <p>MOTIFS</p>

Table 4

Polynucleotide SEQ ID NO:	Incute Polynucleotide ID	Sequence Length	Selected Fragments	Sequence Fragments	5' Position	3' Position
22	7472033CB1	1413	1-1413	GNN.95902227_030_edit	1	1413
23	7472034CB1	1076	212-1076	GNN.96087993_008_edit	1	1076
24	7472035CB1	948	1-87, 908-948, 377-798	GNN.96088009_006	1	948
25	7472036CB1	945	1-36	GNN.g6088009_016	1	945
26	7472037CB1	966	1-46, 931-966	GNN.g6094563_010	1	966
27	7472039CB1	996	1-94, 583-996, 454-524	GNN.g6094604_016	1	996
28	7472040CB1	1014	1-843	GNN.g6165152_010	1	1014
29	4250893CB1	5122	3275-3357, 1-1445, 4869-5122, 2954-3232, 4873-4944, 4411-4479, 1740-2862, 3840-4064	SB5A02572V1 5080262H1 (LNODNOT11) 4882636F6 (LUNLTMT01) 639691X12F1 (BRSTNOT03) 2654889F6 (THYMMNOT04) 94589483_CD 2831336F6 (TLXMMNOT03) SAFB00488F1 1559811H1 (SPLNNNOT04) 3345781H1 (SPLNNNOT09) 4220888H1 (PANCNOT07) 5090301F6 (UTRSTMHR01) 504356R6 (TMLR3DT02) SB5A00168V1 SAFC01343F1 4882636T6 (LUNLTMT01)	4180 2345 508 2904 2372 339 1 3464 3448 1626 1884 3883 1659 4586 5122 4155 3022 621	4818 2606 909 3418 2912 4294 513 4111 3642 1884 4171 2322 5122 4681 3565 1150

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incye Polynucleotide ID	Sequence Length	Selected Fragments	Sequence Fragments	5' Position	3' Position
30	6726656CB1	1241	1-311	GNN.g6524208_008 6726656H1 (COLITUT02)	312	1241
31	7472062CB1	1155	1-211, 649-921, 1104-1155	GNN.g6009916_000010_002	1	580
32	7472067CB1	1260	1-1260	GNN.g6013566_000014_004	1	1260
33	7472072CB1	945	920-945	GNN.g96165017_000177_002	1	945
34	7472074CB1	765	538-765	GNN.g96165058_000059_002	1	765
35	7472077CB1	1089	897-944	GNN.g95815499_006	1	1089
36	7472082CB1	1334	1-181	GNN.g96521401_012	1	1113
37	7472128CB1	960	1-22, 477-642, 940-960	95754986 GNN.g96451812_008.edit	883	1334
38	7472134CB1	939	1-223, 756-804, 587-627	GNN.g96479069_014	1	960
39	7472136CB1	968	1-968	GNN.g96498052_008.edit	1	968
40	7472142CB1	1000	1-82, 975-1000, 563-684	GNN.g96524207_010.edit	1	1000
41	7472171CB1	1008	1-33, 931-1008	GNN.g96562243_020.edit	1	1008
42	7472172CB1	972	1-29, 605-972	GNN.g96525268_002.edit	1	972

Table 5

Polynucleotide SEQ ID NO.:	Incyte Project ID	Representative Library
29	4250893CB1	SYNORAT05
30	6726656CB1	COLITUT02

Table 6

Library	Vector	Library Description
COLITUT02	PINCY	Library was constructed using RNA isolated from colon tumor tissue of the ileocecal valve removed from a 29-year-old female. Pathology indicated malignant lymphoma, small cell, non-cleaved (Burkitt's lymphoma, B-cell phenotype), forming a polypoid mass in the region of the ileocecal valve, associated with intussusception and obstruction clinically. The liver and multiple (3 of 12) ileocecal region lymph nodes were also involved by lymphoma.
SYNORAT05	PSPORT1	Library was constructed using RNA isolated from the knee synovial tissue of a 62-year-old female with rheumatoïd arthritis.

Table 7

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
ABI/PARACEI FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25:3389-3402.	<i>ESTs</i> : Probability value= 1.0E-8 or less <i>Full Length sequences</i> : Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and search.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad Sci. USA 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183:63-98; and Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489.	<i>ESTs</i> : fasta E value=1.06E-6 <i>Assembled ESTs</i> : fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less <i>Full Length sequences</i> : fastx score=100 or greater
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff (1991) Nucleic Acids Res. 19:6365-6372; Henikoff, J.G. and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Atwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37:417-424.	Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) J. Mol. Biol. 235:1501-1531; Sonhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322; Durbin, R. et al. (1998) Our World View, in a Nutshell, Cambridge Univ. Press, pp. 1-350.	<i>PFAM hits</i> : Probability value= 1.0E-3 or less <i>Signal peptide hits</i> : Score= 0 or greater

Table 7 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, M. et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.	Normalized quality score \geq GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phred Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M.S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies.	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12:431-439.	Score=3.5 or greater
TMAP	A program that uses weight matrices to delineate transmembrane segments on protein sequences and determine orientation.	Persson, B. and P. Argos (1994) J. Mol. Biol. 237:182-192; Persson, B. and P. Argos (1996) Protein Sci. 5:363-371.	
TMHMMER	A program that uses a hidden Markov model (HMM) to delineate transmembrane segments on protein sequences and determine orientation.	Sonnhammer, E.L. et al. (1998) Proc. Sixth Int. Conf. on Intelligent Systems for Mol. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence Press, Menlo Park, CA, pp. 175-182.	
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - 5 a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-21,
 - b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-21,
 - c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21, and
 - 10 d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-21.
2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1-21.
- 15 3. An isolated polynucleotide encoding a polypeptide of claim 1.
4. An isolated polynucleotide encoding a polypeptide of claim 2.
- 20 5. An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID NO:22-42.
6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.
- 25 7. A cell transformed with a recombinant polynucleotide of claim 6.
8. A transgenic organism comprising a recombinant polynucleotide of claim 6.
- 30 9. A method for producing a polypeptide of claim 1, the method comprising:
 - a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and
 - 35 b) recovering the polypeptide so expressed.

10. An isolated antibody which specifically binds to a polypeptide of claim 1.

11. An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:

- 5 a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:22-42,
- b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:22-42,
- c) a polynucleotide sequence complementary to a),
- d) a polynucleotide sequence complementary to b), and
- 10 e) an RNA equivalent of a)-d).

12. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 11.

15 13. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:

- a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and
- 20 b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

14. A method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides.

25

15. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:

- a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
- 30 b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

16. A composition comprising an effective amount of a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

35

17. A composition of claim 16, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-21.

18. A method for treating a disease or condition associated with decreased expression of 5 functional GCREC, comprising administering to a patient in need of such treatment the composition of claim 16.

19. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

10 a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
b) detecting agonist activity in the sample.

20. A composition comprising an agonist compound identified by a method of claim 19 and a pharmaceutically acceptable excipient.

15 21. A method for treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment a composition of claim 20.

20 22. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
b) detecting antagonist activity in the sample.

25 23. A composition comprising an antagonist compound identified by a method of claim 22 and a pharmaceutically acceptable excipient.

24. A method for treating a disease or condition associated with overexpression of functional GCREC, comprising administering to a patient in need of such treatment a composition of claim 23.

30 35 25. A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:
a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a

compound that specifically binds to the polypeptide of claim 1.

26. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:

- 5 a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,
- b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and
- c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in 10 the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

27. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method 15 comprising:

- a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,
- b) detecting altered expression of the target polynucleotide, and
- c) comparing the expression of the target polynucleotide in the presence of varying amounts of 20 the compound and in the absence of the compound.

28. A method for assessing toxicity of a test compound, said method comprising:

- a) treating a biological sample containing nucleic acids with the test compound;
- b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at 25 least 20 contiguous nucleotides of a polynucleotide of claim 11 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 11 or fragment thereof;
- c) quantifying the amount of hybridization complex; and
- d) comparing the amount of hybridization complex in the treated biological sample with the 30 amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

<110> INCYTE GENOMICS, INC.
BAUGHN, Mariah R.
AU-YOUNG, Janice
YUE, Henry

<120> G-PROTEIN COUPLED RECEPTORS

<130> PI-0032 PCT

<140> To Be Assigned
<141> Herewith

<150> 60/180,093; 60/182,045
<151> 2000-02-02; 2000-02-11

<160> 42
<170> PERL Program

<210> 1
<211> 470
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7472033CD1

<220>
<221> unsure
<222> 59, 128, 309
<223> unknown or other

<400> 1
Met Asn Gln Thr Glu Pro Ala Gln Leu Ala Asp Gly Glu His Leu
1 5 10 15
Ser Gly Tyr Ala Ser Ser Ser Asn Ser Val Arg Tyr Leu Asp Asp
20 25 30
Arg His Pro Leu Asp Tyr Leu Asp Leu Gly Thr Val His Ala Leu
35 40 45
Asn Thr Thr Ala Ile Asn Thr Ser Asp Leu Asn Glu Thr Xaa Ser
50 55 60
Arg Pro Leu Asp Pro Val Leu Ile Asp Arg Phe Leu Ser Asn Arg
65 70 75
Ala Val Asp Ser Pro Trp Tyr His Met Leu Ile Ser Met Tyr Gly
80 85 90
Val Leu Ile Val Phe Gly Ala Leu Gly Asn Thr Leu Gly Cys Tyr
95 100 105
Ser Pro Ser Ser Gly Ser Pro Ser Cys Ala Leu Leu Ala Ile Trp
110 115 120
Phe Ile Leu Asn Leu Ala Ile Xaa Gly Gln Ser Lys Cys Glu Ser
125 130 135
His Pro Ser Gly Leu Ser Asp Leu Leu Cys Leu Val Thr Met
140 145 150
Pro Leu Thr Leu Met Glu Ile Leu Ser Lys Tyr Trp Pro Tyr Gly
155 160 165
Ser Cys Ser Ile Leu Cys Lys Thr Ile Ala Met Leu Gln Ala Leu
170 175 180
Cys Ile Phe Val Ser Thr Ile Ser Ile Thr Ala Ile Ala Phe Asp
185 190 195
Arg Tyr Gln Val Ile Val Tyr Pro Thr Arg Asp Ser Leu Gln Phe
200 205 210
Val Gly Ala Val Thr Ile Leu Ala Gly Ile Trp Ala Leu Ala Leu
215 220 225
Leu Leu Ala Ser Pro Leu Phe Val Tyr Lys Glu Leu Ile Asn Thr
230 235 240
Asp Thr Pro Ala Leu Leu Gln Gln Ile Gly Leu Gln Asp Thr Ile

245	250	255
Pro Tyr Cys Ile Glu Asp Trp Pro Ser	Arg Asn Gly Arg Phe	Tyr
260	265	270
Tyr Ser Ile Phe Ser Leu Cys Val Gln	Tyr Leu Val Pro Ile	Leu
275	280	285
Ile Val Ser Val Ala Tyr Phe Gly Ile	Tyr Asn Lys Leu Lys	Ser
290	295	300
Arg Ile Thr Val Val Ala Val Gln Xaa	Arg Lys Val Glu Arg	Gly
305	310	315
Arg Arg Met Lys Arg Thr Asn Cys Leu	Leu Ile Ser Ile Ala	Ile
320	325	330
Ile Phe Gly Val Ser Trp Leu Pro Leu	Asp Phe Phe Asn Leu	Tyr
335	340	345
Ala Asp Met Glu Arg Ser Pro Val Thr	Gln Ser Met Leu Val	Arg
350	355	360
Tyr Ala Ile Cys His Met Ile Gly Met	Ser Ser Ala Cys Ser	Asn
365	370	375
Pro Leu Leu Tyr Gly Trp Leu Asn Asp	Asn Phe Arg Lys Glu	Ile
380	385	390
Gln Glu Leu Leu Cys Arg Cys Ser Asp	Thr Asn Val Ala Leu	Asn
395	400	405
Gly His Thr Thr Gly Cys Asn Val Gln	Ala Ala Ala Arg Arg	Arg
410	415	420
Arg Lys Tyr Gly Arg Arg Ile Leu Gln	Arg Arg Thr Gln Ala	Ala
425	430	435
Gly Ala Gly Gly Ala Arg Ala Val Pro	Arg Arg Gly Arg Arg	Ser
440	445	450
Gly Gly His Arg Leu His Asp Arg His	His Glu Gly Gly Leu	Ala
455	460	465
Asn Ile Val His His		
470		

<210> 2
<211> 326
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7472034CD1

<400> 2			
Met Asp Pro Asn Gln Asp Glu Ile Ser Glu	Leu Pro Glu Lys Glu		
1	5	10	15
Phe Arg Arg Ser Ile Ile Lys Leu Ile Lys	Glu Ala Pro Glu Lys		
20		25	30
Gly Ile Pro Gly Leu Glu Glu Ser Gln His	Trp Ile Ala Leu Pro		
35		40	45
Leu Gly Ile Leu Tyr Leu Leu Ala Leu Val	Gly Asn Val Thr Ile		
50		55	60
Leu Phe Ile Ile Trp Met Asp Pro Ser Leu	His Gln Ser Met Tyr		
65		70	75
Leu Phe Leu Ser Met Leu Ala Ala Ile Asp	Leu Val Leu Ala Ser		
80		85	90
Ser Thr Ala Pro Lys Ala Leu Ala Val	Leu Leu Val His Ala His		
95		100	105
Glu Ile Gly Tyr Ile Val Cys Leu Ile Gln	Met Phe Phe Ile His		
110		115	120
Ala Phe Ser Ser Met Glu Ser Gly Val	Leu Val Ala Met Ala Leu		
125		130	135
Asp Arg Tyr Val Ala Ile Cys His Pro	Leu His His Ser Thr Ile		
140		145	150
Leu His Pro Gly Val Ile Gly Arg Ile	Gly Met Val Val Leu Val		
155		160	165
Arg Gly Leu Leu Leu Leu Ile Pro Phe	Pro Ile Leu Leu Gly Thr		
170		175	180
Leu Ile Phe Cys Gln Ala Thr Ile Gly His	Ala Tyr Cys Glu		

185	190	195
His Met Ala Val Val Lys Leu Ala Cys	Ser Glu Thr Thr Val	Asn
200	205	210
Arg Ala Tyr Gly Leu Thr Met Ala Leu	Leu Val Ile Gly Leu	Asp
215	220	225
Val Leu Ala Ile Gly Val Ser Tyr Ala	His Ile Leu Gln Ala Val	
230	235	240
Leu Lys Val Pro Gly Ser Glu Ala Arg	Leu Lys Ala Phe Ser	Thr
245	250	255
Cys Gly Ser His Ile Cys Val Ile Leu	Val Phe Tyr Val Pro	Gly
260	265	270
Ile Phe Ser Phe Leu Thr His Arg Phe	Gly His His Val Pro	His
275	280	285
His Val His Val Leu Leu Ala Thr Arg	Tyr Leu Leu Met Pro	Pro
290	295	300
Ala Leu Asn Pro Leu Val Tyr Gly Val	Lys Thr Gln Gln Ile	Arg
305	310	315
Gln Arg Val Leu Arg Val Phe Thr Gln	Lys Asp	
320	325	

<210> 3

<211> 315

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472035CD1

<400> 3

Met Glu Thr Pro Ala Ser Phe Leu Leu Val	Gly Ile Pro Gly Leu		
1	5	10	15
Gln Ser Ser His Leu Trp Leu Ala Ile Ser	Leu Ser Ala Met Tyr		
20	25	30	
Ile Ile Ala Leu Leu Gly Asn Thr Ile Ile	Val Thr Ala Ile Trp		
35	40	45	
Met Asp Ser Thr Arg His Glu Pro Met Tyr	Cys Phe Leu Cys Val		
50	55	60	
Leu Ala Ala Val Asp Ile Val Met Ala Ser	Ser Val Val Pro Lys		
65	70	75	
Met Val Ser Ile Phe Cys Ser Gly Asp Ser	Ser Ile Ser Phe Ser		
80	85	90	
Ala Cys Phe Thr Gln Met Phe Phe Val His	Leu Ala Thr Ala Val		
95	100	105	
Glu Thr Gly Leu Leu Leu Thr Met Ala Phe	Asp Arg Tyr Val Ala		
110	115	120	
Ile Cys Lys Pro Leu His Tyr Lys Arg Ile	Leu Thr Pro Gln Val		
125	130	135	
Met Leu Gly Met Ser Met Ala Ile Thr Ile	Arg Ala Ile Ile Ala		
140	145	150	
Ile Thr Pro Leu Ser Trp Met Val Ser His	Leu Pro Phe Cys Gly		
155	160	165	
Ser Asn Val Val His Ser Tyr Cys Glu His	Ile Ala Leu Ala		
170	175	180	
Arg Leu Ala Cys Ala Asp Pro Val Pro Ser	Ser Leu Tyr Ser Leu		
185	190	195	
Ile Gly Ser Ser Leu Met Val Gly Ser Asp	Val Ala Phe Ile Ala		
200	205	210	
Ala Ser Tyr Ile Leu Ile Leu Lys Ala Val	Phe Gly Leu Ser Ser		
215	220	225	
Lys Thr Ala Gln Leu Lys Ala Leu Ser Thr	Cys Gly Ser His Val		
230	235	240	
Gly Val Met Ala Leu Tyr Tyr Leu Pro Gly	Met Ala Ser Ile Tyr		
245	250	255	
Ala Ala Trp Leu Gly Gln Asp Val Val Pro	Leu His Thr Gln Val		
260	265	270	
Leu Leu Ala Asp Leu Tyr Val Ile Ile Pro	Ala Thr Leu Asn Pro		

275	280	285
Ile Ile Tyr Gly Met Arg Thr Lys Gln	Leu Arg Glu Arg Ile Trp	
290	295	300
Ser Tyr Leu Met His Val Leu Phe Asp	His Ser Asn Leu Gly Ser	
305	310	315

<210> 4
 <211> 314
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472036CD1

<400> 4

Met Ser Ala Ser Asn Ile Thr Leu Thr His Pro Thr Ala Phe Leu		
1 5	10	15
Leu Val Gly Ile Pro Gly Leu Glu His Leu His Ile Trp Ile Ser		
20 25		30
Ile Pro Phe Cys Leu Ala Tyr Thr Leu Ala Leu Leu Gly Asn Cys		
35 40		45
Thr Leu Leu Leu Ile Ile Gln Ala Asp Ala Ala Leu His Glu Pro		
50 55		60
Met Tyr Leu Phe Leu Ala Met Leu Ala Ala Ile Asp Leu Val Leu		
65 70		75
Ser Ser Ser Ala Leu Pro Lys Met Leu Ala Ile Phe Trp Phe Arg		
80 85		90
Asp Arg Glu Ile Asn Phe Phe Ala Cys Leu Ala Gln Met Phe Phe		
95 100		105
Leu His Ser Phe Ser Ile Met Glu Ser Ala Val Leu Leu Ala Met		
110 115		120
Ala Phe Asp Arg Tyr Val Ala Ile Cys Lys Pro Leu His Tyr Thr		
125 130		135
Lys Val Leu Thr Gly Ser Leu Ile Thr Lys Ile Gly Met Ala Ala		
140 145		150
Val Ala Arg Ala Val Thr Leu Met Thr Pro Leu Pro Phe Leu Leu		
155 160		165
Arg Cys Phe His Tyr Cys Arg Gly Pro Val Ile Ala His Cys Tyr		
170 175		180
Cys Glu His Met Ala Val Val Arg Leu Ala Cys Gly Asp Thr Ser		
185 190		195
Phe Asn Asn Ile Tyr Gly Ile Ala Val Ala Met Phe Ile Val Val		
200 205		210
Leu Asp Leu Leu Leu Val Ile Leu Ser Tyr Ile Phe Ile Leu Gln		
215 220		225
Ala Val Leu Leu Leu Ala Ser Gln Glu Ala Arg Tyr Lys Ala Phe		
230 235		240
Gly Thr Cys Val Ser His Ile Gly Ala Ile Leu Ala Phe Tyr Thr		
245 250		255
Thr Val Val Ile Ser Ser Val Met His Arg Val Ala Arg His Ala		
260 265		270
Ala Pro His Val His Ile Leu Leu Ala Asn Phe Tyr Leu Leu Phe		
275 280		285
Pro Pro Met Val Asn Pro Ile Ile Tyr Gly Val Lys Thr Lys Gln		
290 295		300
Ile Arg Glu Ser Ile Leu Gly Val Phe Pro Arg Lys Asp Met		
305		

<210> 5
 <211> 321
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature

<223> Incyte ID No: 7472037CD1

<400> 5

Met	Ala	His	Gln	Ala	Pro	Glu	Lys	Gln	Gln	Asp	Asn	Gly	Thr	Trp
1	5					10							15	
Leu	Val	Thr	Glu	Phe	Leu	Leu	Val	Gly	Phe	Ser	Asn	Leu	Pro	Glu
		20				25							30	
Leu	Arg	Pro	Thr	Leu	Phe	Ile	Leu	Phe	Leu	Leu	Thr	Tyr	Leu	Val
		35				40						45		
Thr	Leu	Ser	Gly	Asn	Ala	Thr	Ile	Ile	Thr	Ile	Ile	Gln	Val	Asp
		50				55						60		
Arg	Thr	Leu	His	Thr	Pro	Met	Tyr	Arg	Phe	Leu	Ala	Val	Leu	Ser
		65				70						75		
Leu	Ser	Glu	Thr	Cys	Tyr	Thr	Leu	Val	Thr	Ile	Pro	Asn	Met	Leu
		80				85						90		
Ala	His	Leu	Leu	Met	Glu	Ser	Gln	Ala	Ile	Ser	Ile	Ala	Gly	Cys
		95				100						105		
Arg	Ala	Gln	Met	Phe	Phe	Phe	Leu	Gly	Leu	Gly	Cys	Ser	His	Cys
		110				115						120		
Phe	Leu	Leu	Thr	Leu	Met	Gly	Tyr	Asp	Arg	Tyr	Val	Ala	Ile	Cys
		125				130						135		
His	Pro	Leu	Arg	Tyr	Ser	Val	Ile	Met	Arg	Pro	Thr	Val	Cys	Leu
		140				145						150		
Cys	Leu	Gly	Ala	Leu	Val	Phe	Cys	Ser	Gly	Phe	Ser	Val	Ala	Leu
		155				160						165		
Ile	Glu	Thr	Cys	Met	Ile	Phe	Ser	Ser	Pro	Phe	Cys	Gly	Ala	Gly
		170				175						180		
His	Val	Glu	His	Phe	Phe	Cys	Asp	Ile	Ala	Pro	Val	Leu	Lys	Leu
		185				190						195		
Ser	Cys	Asp	Glu	Ser	Ser	Leu	Lys	Gly	Leu	Gly	Ile	Phe	Phe	Leu
		200				205						210		
Ser	Ile	Leu	Val	Val	Leu	Val	Ser	Phe	Leu	Phe	Ile	Leu	Leu	Ser
		215				220						225		
Tyr	Ala	Phe	Ile	Val	Ala	Ala	Ile	Val	Arg	Ile	Pro	Ser	Ala	Ser
		230				235						240		
Gly	Arg	Arg	Lys	Ala	Phe	Ser	Thr	Cys	Ala	Ala	His	Leu	Thr	Val
		245				250						255		
Val	Ile	Val	His	Phe	Gly	Cys	Ala	Ser	Ile	Ile	Tyr	Leu	Arg	Pro
		260				265						270		
Asp	Ser	Gly	Ala	Asn	Pro	Ser	Gln	Asp	Arg	Leu	Val	Ala	Val	Phe
		275				280						285		
Tyr	Thr	Val	Val	Thr	Pro	Leu	Leu	Asn	Pro	Val	Val	Tyr	Thr	Leu
		290				295						300		
Arg	Asn	Lys	Glu	Val	Arg	Val	Ala	Leu	Arg	Lys	Asn	Leu	Ala	Arg
		305				310						315		
Gly	Cys	Gly	Ala	Phe	Lys									
		320												

<210> 6

<211> 331

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472039CD1

<400> 6

Met	Ser	Pro	Asp	Gly	Asn	His	Ser	Ser	Asp	Pro	Thr	Glu	Phe	Val
1	5				10							15		
Leu	Ala	Gly	Leu	Pro	Asn	Leu	Asn	Ser	Ala	Arg	Val	Glu	Leu	Phe
		20				25						30		
Ser	Val	Phe	Leu	Leu	Val	Tyr	Leu	Leu	Asn	Leu	Thr	Gly	Asn	Val
		35				40						45		
Leu	Ile	Val	Gly	Val	Val	Arg	Ala	Asp	Thr	Arg	Leu	Gln	Thr	Pro
		50				55						60		
Met	Tyr	Phe	Phe	Leu	Gly	Asn	Leu	Ser	Cys	Leu	Glu	Ile	Leu	Leu

65	70	75
Thr Ser Val Ile Ile Pro Lys Met Leu Ser	Asn Phe Leu Ser	Arg
80	85	90
Gln His Thr Ile Ser Phe Ala Ala Cys Ile	Thr Gln Phe Tyr	Phe
95	100	105
Tyr Phe Phe Leu Gly Ala Ser Glu Phe Leu	Leu Leu Ala Val	Met
110	115	120
Ser Ala Asp Arg Tyr Leu Ala Ile Cys His	Pro Leu Arg Tyr	Pro
125	130	135
Leu Leu Met Ser Gly Ala Val Cys Phe Arg	Val Ala Leu Ala	Cys
140	145	150
Trp Val Gly Gly Leu Val Pro Val Leu Gly	Pro Thr Val Ala	Val
155	160	165
Ala Leu Leu Pro Phe Cys Lys Gln Gly Ala	Val Val Gln His	Phe
170	175	180
Phe Cys Asp Ser Gly Pro Leu Leu Arg Leu	Ala Cys Thr Asn	Thr
185	190	195
Lys Lys Leu Glu Glu Thr Asp Phe Val Leu	Ala Ser Leu Val	Ile
200	205	210
Val Ser Ser Leu Leu Ile Thr Ala Val Ser	Tyr Gly Leu Ile	Val
215	220	225
Leu Ala Val Leu Ser Ile Pro Ser Ala Ser	Gly Arg Gln Lys	Ala
230	235	240
Phe Ser Thr Cys Thr Ser His Leu Ile Val	Val Val Thr Leu Phe	Tyr
245	250	255
Gly Ser Ala Ile Phe Leu Tyr Val Arg Pro	Ser Gln Ser Gly	Ser
260	265	270
Val Asp Thr Asn Trp Ala Val Thr Val Ile	Thr Thr Phe Val	Thr
275	280	285
Pro Leu Leu Asn Pro Phe Ile Tyr Ala Leu	Arg Asn Glu Gln	Val
290	295	300
Lys Glu Ala Leu Lys Asp Met Phe Arg Lys	Val Val Ala Gly	Val
305	310	315
Leu Gly Asn Leu Leu Leu Asp Lys Cys Leu	Ser Glu Lys Ala	Val
320	325	330
Lys		

<210> 7

<211> 337

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472040CD1

<400> 7

Met Gly Asn Asp Ser Val Ser Tyr Glu Tyr	Gly Asp Tyr Ser Asp	
1 5	10	15
Leu Ser Asp Arg Pro Val Asp Cys Leu Asp	Gly Ala Cys Leu Ala	
20	25	30
Ile Asp Pro Leu Arg Val Ala Pro Leu Pro	Leu Tyr Ala Ala	Ile
35	40	45
Phe Leu Val Gly Val Pro Gly Asn Ala Met	Val Ala Trp Val Ala	
50	55	60
Gly Lys Val Ala Arg Arg Arg Val Gly Ala	Thr Trp Leu Leu His	
65	70	75
Leu Ala Val Ala Asp Leu Leu Cys Cys Leu	Ser Leu Pro Ile Leu	
80	85	90
Ala Val Pro Ile Ala Arg Gly Gly His Trp	Pro Tyr Gly Ala Val	
95	100	105
Gly Cys Arg Ala Leu Pro Ser Ile Ile Leu	Leu Thr Met Tyr Ala	
110	115	120
Ser Val Leu Leu Leu Ala Ala Leu Ser Ala	Asp Leu Cys Phe Leu	
125	130	135
Ala Leu Gly Pro Ala Trp Trp Ser Thr Val	Gln Arg Ala Cys Gly	

140	145	150
Val Gln Val Ala Cys Gly Ala Ala Trp	Thr Leu Ala Leu Leu	Leu
155	160	165
Thr Val Pro Ser Ala Ile Tyr Arg Arg	Leu His Gln Glu His	Phe
170	175	180
Pro Ala Arg Leu Gln Cys Val Val Asp	Tyr Gly Gly Ser Ser	Ser
185	190	195
Thr Glu Asn Ala Val Thr Ala Ile Arg	Phe Leu Phe Gly Phe	Leu
200	205	210
Gly Pro Leu Val Ala Val Ala Ser Cys	His Ser Ala Leu Leu	Cys
215	220	225
Trp Ala Ala Arg Arg Cys Arg Pro Leu	Gly Thr Ala Ile Val	Val
230	235	240
Gly Phe Phe Val Cys Trp Ala Pro Tyr	His Leu Leu Gly Leu	Val
245	250	255
Leu Thr Val Ala Ala Pro Asn Ser Ala	Leu Leu Ala Arg Ala	Leu
260	265	270
Arg Ala Glu Pro Leu Ile Val Gly Leu	Ala Leu Ala His Ser	Cys
275	280	285
Leu Asn Pro Met Leu Phe Leu Tyr Phe	Gly Arg Ala Gln Leu	Arg
290	295	300
Arg Ser Leu Pro Ala Ala Cys His Trp	Ala Leu Arg Glu Ser	Gln
305	310	315
Gly Gln Asp Glu Ser Val Asp Ser Lys	Lys Ser Thr Ser His	Asp
320	325	330
Leu Val Ser Glu Met Glu Val		
335		

<210> 8
<211> 1473
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 4250893CD1

<400> 8		
Met Ala Gly Gly Ala Trp Gly Arg Leu Ala Cys Tyr Leu Glu Phe		
1 5 10 15		
Leu Lys Lys Glu Glu Leu Lys Glu Phe Gln Leu Leu Leu Ala Asn		
20 25 30		
Lys Ala His Ser Arg Ser Ser Ser Gly Glu Thr Pro Ala Gln Pro		
35 40 45		
Glu Lys Thr Ser Gly Met Glu Val Ala Ser Tyr Leu Val Ala Gln		
50 55 60		
Tyr Gly Glu Gln Arg Ala Trp Asp Leu Ala Leu His Thr Trp Glu		
65 70 75		
Gln Met Gly Leu Arg Ser Leu Cys Ala Gln Ala Gln Glu Gly Ala		
80 85 90		
Gly His Ser Pro Ser Phe Pro Tyr Ser Pro Ser Glu Pro His Leu		
95 100 105		
Gly Ser Pro Ser Gln Pro Thr Ser Thr Ala Val Leu Met Pro Trp		
110 115 120		
Ile His Glu Leu Pro Ala Gly Cys Thr Gln Gly Ser Glu Arg Arg		
125 130 135		
Val Leu Arg Gln Leu Pro Asp Thr Ser Gly Arg Arg Trp Arg Glu		
140 145 150		
Ile Ser Ala Ser His Val Tyr Gln Ala Leu Pro Ser Ser Pro Asp		
155 160 165		
His Glu Ser Pro Ser Gln Glu Ser Pro Asn Ala Pro Thr Ser Thr		
170 175 180		
Ala Val Leu Gly Ser Trp Gly Ser Pro Pro Gln Pro Ser Leu Ala		
185 190 195		
Pro Arg Glu Gln Glu Ala Pro Gly Thr Gln Trp Pro Leu Asp Glu		
200 205 210		
Thr Ser Gly Ile Tyr Tyr Thr Glu Ile Arg Glu Arg Glu Arg Glu		

215	220	225
Lys Ser Glu Lys Gly Arg Pro Pro Trp Ala Ala Val Val Gly Thr		
230	235	240
Pro Pro Gln Ala His Thr Ser Leu Gln Pro His His His Pro Trp		
245	250	255
Glu Pro Ser Val Arg Glu Ser Leu Cys Ser Thr Trp Pro Trp Lys		
260	265	270
Asn Glu Asp Phe Asn Gln Lys Phe Thr Gln Leu Leu Leu Leu Gln		
275	280	285
Arg Pro His Pro Arg Ser Gln Asp Pro Leu Val Lys Arg Ser Trp		
290	295	300
Pro Asp Tyr Val Glu Glu Asn Arg Gly His Leu Ile Glu Ile Arg		
305	310	315
Asp Leu Phe Gly Pro Gly Leu Asp Thr Gln Glu Pro Arg Ile Val		
320	325	330
Ile Leu Gln Gly Ala Ala Gly Ile Gly Lys Ser Thr Leu Ala Arg		
335	340	345
Gln Val Lys Glu Ala Trp Gly Arg Gly Gln Leu Tyr Gly Asp Arg		
350	355	360
Phe Gln His Val Phe Tyr Phe Ser Cys Arg Glu Leu Ala Gln Ser		
365	370	375
Lys Val Val Ser Leu Ala Glu Leu Ile Gly Lys Asp Gly Thr Ala		
380	385	390
Thr Pro Ala Pro Ile Arg Gln Ile Leu Ser Arg Pro Glu Arg Leu		
395	400	405
Leu Phe Ile Leu Asp Gly Val Asp Glu Pro Gly Trp Val Leu Gln		
410	415	420
Glu Pro Ser Ser Glu Leu Cys Leu His Trp Ser Gln Pro Gln Pro		
425	430	435
Ala Asp Ala Leu Leu Gly Ser Leu Leu Gly Lys Thr Ile Leu Pro		
440	445	450
Glu Ala Ser Phe Leu Ile Thr Ala Arg Thr Thr Ala Leu Gln Asn		
455	460	465
Leu Ile Pro Ser Leu Glu Gln Ala Arg Trp Val Glu Val Leu Gly		
470	475	480
Phe Ser Glu Ser Ser Arg Lys Glu Tyr Phe Tyr Arg Tyr Phe Thr		
485	490	495
Asp Glu Arg Gln Ala Ile Arg Ala Phe Arg Leu Val Lys Ser Asn		
500	505	510
Lys Glu Leu Trp Ala Leu Cys Leu Val Pro Trp Val Ser Trp Leu		
515	520	525
Ala Cys Thr Cys Leu Met Gln Gln Met Lys Arg Lys Glu Lys Leu		
530	535	540
Thr Leu Thr Ser Lys Thr Thr Thr Leu Cys Leu His Tyr Leu		
545	550	555
Ala Gln Ala Leu Gln Ala Gln Pro Leu Gly Pro Gln Leu Arg Asp		
560	565	570
Leu Cys Ser Leu Ala Ala Glu Gly Ile Trp Gln Lys Lys Thr Leu		
575	580	585
Phe Ser Pro Asp Asp Leu Arg Lys His Gly Leu Asp Gly Ala Ile		
590	595	600
Ile Ser Thr Phe Leu Lys Met Gly Ile Leu Gln Glu His Pro Ile		
605	610	615
Pro Leu Ser Tyr Ser Phe Ile His Leu Cys Phe Gln Glu Phe Phe		
620	625	630
Ala Ala Met Ser Tyr Val Leu Glu Asp Glu Lys Gly Arg Gly Lys		
635	640	645
His Ser Asn Cys Ile Ile Asp Leu Glu Lys Thr Leu Glu Ala Tyr		
650	655	660
Gly Ile His Gly Leu Phe Gly Ala Ser Thr Thr Arg Phe Leu Leu		
665	670	675
Gly Leu Leu Ser Asp Glu Gly Glu Arg Glu Met Glu Asn Ile Phe		
680	685	690
His Cys Arg Leu Ser Gln Gly Arg Asn Leu Met Gln Trp Val Pro		
695	700	705
Ser Leu Gln Leu Leu Leu Gln Pro His Ser Leu Glu Ser Leu His		
710	715	720

Cys Leu Tyr Glu Thr Arg Asn Lys Thr Phe Leu Thr Gln Val Met
 725 730 735
 Ala His Phe Glu Glu Met Gly Met Cys Val Glu Thr Asp Met Glu
 740 745 750
 Leu Leu Val Cys Thr Phe Cys Ile Lys Phe Ser Arg His Val Lys
 755 760 765
 Lys Leu Gln Leu Ile Glu Gly Arg Gln His Arg Ser Thr Trp Ser
 770 775 780
 Pro Thr Met Val Val Leu Phe Arg Trp Val Pro Val Thr Asp Ala
 785 790 795
 Tyr Trp Gln Ile Leu Phe Ser Val Leu Lys Val Thr Arg Asn Leu
 800 805 810
 Lys Glu Leu Asp Leu Ser Gly Asn Ser Leu Ser His Ser Ala Val
 815 820 825
 Lys Ser Leu Cys Lys Thr Leu Arg Arg Pro Arg Cys Leu Leu Glu
 830 835 840
 Thr Leu Arg Leu Ala Gly Cys Gly Leu Thr Ala Glu Asp Cys Lys
 845 850 855
 Asp Leu Ala Phe Gly Leu Arg Ala Asn Gln Thr Leu Thr Glu Leu
 860 865 870
 Asp Leu Ser Phe Asn Val Leu Thr Asp Ala Gly Ala Lys His Leu
 875 880 885
 Cys Gln Arg Leu Arg Gln Pro Ser Cys Lys Leu Gln Arg Leu Gln
 890 895 900
 Leu Val Ser Cys Gly Leu Thr Ser Asp Cys Cys Gln Asp Leu Ala
 905 910 915
 Ser Val Leu Ser Ala Ser Pro Ser Leu Lys Glu Leu Asp Leu Gln
 920 925 930
 Gln Asn Asn Leu Asp Asp Val Gly Val Arg Leu Leu Cys Glu Gly
 935 940 945
 Leu Arg His Pro Ala Cys Lys Leu Ile Arg Leu Gly Leu Asp Gln
 950 955 960
 Thr Thr Leu Ser Asp Glu Met Arg Gln Glu Leu Arg Ala Leu Glu
 965 970 975
 Gln Glu Lys Pro Gln Leu Leu Ile Phe Ser Arg Arg Lys Pro Ser
 980 985 990
 Val Met Thr Pro Thr Glu Gly Leu Asp Thr Gly Glu Met Ser Asn
 995 1000 1005
 Ser Thr Ser Ser Leu Lys Arg Gln Arg Leu Gly Ser Glu Arg Ala
 1010 1015 1020
 Ala Ser His Val Ala Gln Ala Asn Leu Lys Leu Leu Asp Val Ser
 1025 1030 1035
 Lys Ile Phe Pro Ile Ala Glu Ile Ala Glu Glu Ser Ser Pro Glu
 1040 1045 1050
 Val Val Pro Val Glu Leu Leu Cys Val Pro Ser Pro Ala Ser Gln
 1055 1060 1065
 Gly Asp Leu His Thr Lys Pro Leu Gly Thr Asp Asp Asp Phe Trp
 1070 1075 1080
 Gly Pro Thr Gly Pro Val Ala Thr Glu Val Val Asp Lys Glu Lys
 1085 1090 1095
 Asn Leu Tyr Arg Val His Phe Pro Val Ala Gly Ser Tyr Arg Trp
 1100 1105 1110
 Pro Asn Thr Gly Leu Cys Phe Val Met Arg Glu Ala Val Thr Val
 1115 1120 1125
 Glu Ile Glu Phe Cys Val Trp Asp Gln Phe Leu Gly Glu Ile Asn
 1130 1135 1140
 Pro Gln His Ser Trp Met Val Ala Gly Pro Leu Leu Asp Ile Lys
 1145 1150 1155
 Ala Glu Pro Gly Ala Val Glu Ala Val His Leu Pro His Phe Val
 1160 1165 1170
 Ala Leu Gln Gly Gly His Val Asp Thr Ser Leu Phe Gln Met Ala
 1175 1180 1185
 His Phe Lys Glu Glu Gly Met Leu Leu Glu Lys Pro Ala Arg Val
 1190 1195 1200
 Glu Leu His His Ile Val Leu Glu Asn Pro Ser Phe Ser Pro Leu
 1205 1210 1215
 Gly Val Leu Leu Lys Met Ile His Asn Ala Leu Arg Phe Ile Pro

1220	1225	1230
Val Thr Ser Val Val	Leu Leu Tyr His Arg	Val His Pro Glu Glu
1235	1240	1245
Val Thr Phe His Leu	Tyr Leu Ile Pro Ser	Asp Cys Ser Ile Arg
1250	1255	1260
Lys Ala Ile Asp Asp	Leu Glu Met Lys	Phe Gln Phe Val Arg Ile
1265	1270	1275
His Lys Pro Pro Pro	Leu Thr Pro Leu Tyr	Met Gly Cys Arg Tyr
1280	1285	1290
Thr Val Ser Gly Ser	Gly Met Leu Glu Ile	Leu Pro Lys
1295	1300	1305
Glu Leu Glu Leu Cys	Tyr Arg Ser Pro Gly	Glu Asp Gln Leu Phe
1310	1315	1320
Ser Glu Ser Tyr Val	Gly His Leu Gly	Ser Gly Ile Arg Leu Gln
1325	1330	1335
Val Lys Asp Lys Asp	Glu Thr Leu Val	Trp Glu Ala Leu Val
1340	1345	1350
Lys Pro Gly Asp Leu	Met Pro Ala Thr	Leu Ile Pro Pro Ala
1355	1360	1365
Arg Ile Ala Val Pro	Ser Pro Leu Asp	Ala Pro Gln Leu Leu His
1370	1375	1380
Phe Val Asp Gln Tyr	Arg Glu Gln Leu	Ile Ala Arg Val Thr Ser
1385	1390	1395
Val Glu Val Val Leu	Asp Lys Leu His	Gly Gln Val Leu Ser Gln
1400	1405	1410
Glu Gln Tyr Glu Arg	Val Leu Ala Glu	Asn Thr Arg Pro Ser Gln
1415	1420	1425
Met Arg Lys Leu Phe	Ser Leu Ser Gln	Ser Trp Asp Arg Lys Cys
1430	1435	1440
Lys Asp Gly Leu Tyr	Gln Ala Leu Lys	Glu Thr His Pro His Leu
1445	1450	1455
Ile Met Glu Leu Trp	Glu Lys Gly Ser	Lys Lys Gly Leu Leu Pro
1460	1465	1470
Leu Ser Ser		

<210> 9
 <211> 328
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 6726656CD1

<400> 9
 Met Lys Leu Trp Met Glu Ser His Leu Ile Val Pro Glu Thr Arg
 1 5 10 15
 Pro Ser Pro Arg Met Met Ser Asn Gln Thr Leu Val Thr Glu Phe
 20 25 30
 Ile Leu Gln Gly Phe Ser Glu His Pro Glu Tyr Arg Val Phe Leu
 35 40 45
 Phe Ser Cys Phe Leu Phe Leu Tyr Ser Gly Ala Leu Thr Gly Asn
 50 55 60
 Val Leu Ile Thr Leu Ala Ile Thr Phe Asn Pro Gly Leu His Ala
 65 70 75
 Pro Met Tyr Phe Phe Leu Leu Asn Leu Ala Thr Met Asp Ile Ile
 80 85 90
 Cys Thr Ser Ser Ile Met Pro Lys Ala Leu Ala Ser Leu Val Ser
 95 100 105
 Glu Glu Ser Ser Ile Ser Tyr Gly Gly Cys Met Ala Gln Leu Tyr
 110 115 120
 Phe Leu Thr Trp Ala Ala Ser Ser Glu Leu Leu Leu Thr Val
 125 130 135
 Met Ala Tyr Asp Arg Tyr Ala Ala Ile Cys His Pro Leu His Tyr
 140 145 150
 Ser Ser Met Met Ser Lys Val Phe Cys Ser Gly Leu Ala Thr Ala

155	160	165
Val Trp Leu Leu Cys Ala Val Asn Thr	Ala Ile His Thr Gly	Leu
170	175	180
Met Leu Arg Leu Asp Phe Cys Gly Pro	Asn Val Ile Ile His	Phe
185	190	195
Phe Cys Glu Val Pro Pro Leu Leu Leu	Leu Ser Cys Ser Ser	Thr
200	205	210
Tyr Val Asn Gly Val Met Ile Val Leu	Ala Asp Ala Phe Tyr	Gly
215	220	225
Ile Val Asn Phe Leu Met Thr Ile Ala	Ser Tyr Gly Phe Ile	Val
230	235	240
Ser Ser Ile Leu Lys Val Lys Thr Ala	Trp Gly Arg Gln Lys	Ala
245	250	255
Phe Ser Thr Cys Ser Ser His Leu Thr	Val Val Cys Met Tyr	Tyr
260	265	270
Thr Ala Val Phe Tyr Ala Tyr Ile Ser	Pro Val Ser Gly Tyr	Ser
275	280	285
Ala Gly Lys Ser Lys Leu Ala Gly Leu	Leu Tyr Thr Val Leu	Ser
290	295	300
Pro Thr Leu Asn Pro Leu Ile Tyr Thr	Leu Arg Asn Lys Glu	Val
305	310	315
Lys Ala Ala Leu Arg Lys Leu Phe Pro	Phe Phe Arg Asn	
320	325	

<210> 10
<211> 384
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7472062CD1

<400> 10
Met Asn Val Leu Leu Ala Asp Ser Asn Ser Asn Lys Lys Ile Val
1 5 10 15
His Lys His Ile Cys Ser Leu Gln Ser Ala Pro Lys Thr Thr Asn
20 25 30
Leu Gln Pro Ser Ile Ser Asp Ile Leu Leu Ser Val Glu Ser Asn
35 40 45
Asp Arg Lys Asn Val Ser Lys Ile Lys Gly Asp Cys Phe Asn Thr
50 55 60
Arg Val Ser Cys Asp Ser Lys Ile Thr Ser Met Glu Asn Asn Thr
65 70 75
Glu Val Ser Glu Phe Ile Leu Leu Gly Leu Thr Asn Ala Pro Glu
80 85 90
Leu Gln Val Pro Leu Phe Ile Met Phe Thr Leu Ile Tyr Leu Ile
95 100 105
Thr Leu Thr Gly Asn Leu Gly Met Ile Ile Leu Ile Leu Leu Asp
110 115 120
Ser His Leu His Thr Pro Met Tyr Phe Phe Leu Ser Asn Leu Ser
125 130 135
Leu Ala Gly Ile Gly Tyr Ser Ser Ala Val Thr Pro Lys Val Leu
140 145 150
Thr Gly Leu Leu Ile Glu Asp Lys Ala Ile Ser Tyr Ser Ala Cys
155 160 165
Ala Ala Gln Met Phe Phe Cys Ala Val Phe Ala Thr Val Glu Asn
170 175 180
Tyr Leu Leu Ser Ser Met Ala Tyr Asp Arg Tyr Ala Ala Val Cys
185 190 195
Asn Pro Leu His Tyr Thr Thr Met Thr Thr Arg Val Cys Ala
200 205 210
Cys Leu Ala Ile Gly Cys Tyr Val Ile Gly Phe Leu Asn Ala Ser
215 220 225
Ile Gln Ile Gly Asp Thr Phe Arg Leu Ser Phe Cys Met Ser Asn
230 235 240
Val Ile His His Phe Phe Cys Asp Lys Pro Ala Val Ile Thr Leu

245	250	255
Thr Cys Ser Glu Lys His Ile Ser Glu	Leu Ile Leu Val Leu	Ile
260	265	270
Ser Ser Phe Asn Val Phe Phe Ala Leu	Leu Val Thr Leu Ile	Ser
275	280	285
Tyr Leu Phe Ile Leu Ile Thr Ile Leu	Lys Arg His Thr Gly	Lys
290	295	300
Gly Tyr Gln Lys Pro Leu Ser Thr Cys	Gly Ser His Leu Ile	Ala
305	310	315
Ile Phe Leu Phe Tyr Ile Thr Val Ile	Ile Met Tyr Ile Arg	Pro
320	325	330
Ser Ser Ser His Ser Met Asp Thr Asp	Lys Ile Ala Ser Val	Phe
335	340	345
Tyr Thr Met Ile Ile Pro Met Leu Ser	Pro Ile Val Tyr Thr	Leu
350	355	360
Arg Asn Lys Asp Val Lys Asn Ala Phe	Met Lys Val Val Glu	Lys
365	370	375
Ala Lys Tyr Ser Leu Asp Ser Val Phe		
380		

<210> 11

<211> 419

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472067CD1

<400> 11

Met Leu Ala Ala Ala Phe Ala Asp Ser Asn Ser Ser Ser Met Asn			
1	5	10	15
Val Ser Phe Ala His Leu His Phe Ala Gly	Gly	Tyr Leu Pro Ser	
20	25		30
Asp Ser Gln Asp Trp Arg Thr Ile Ile Pro Ala Leu Leu Val Ala			
35	40		45
Val Cys Leu Val Gly Phe Val Gly Asn Leu Cys Val Ile Gly Ile			
50	55		60
Leu Leu His Asn Ala Trp Lys Gly Lys Pro Ser Met Ile His Ser			
65	70		75
Leu Ile Leu Asn Leu Ser Leu Ala Asp Leu Ser Leu Leu Leu Phe			
80	85		90
Ser Ala Pro Ile Arg Ala Thr Ala Tyr Ser Lys Ser Val Trp Asp			
95	100		105
Leu Gly Trp Phe Val Cys Lys Ser Ser Asp Trp Phe Ile His Thr			
110	115		120
Cys Met Ala Ala Lys Ser Leu Thr Ile Val Val Val Ala Lys Val			
125	130		135
Cys Phe Met Tyr Ala Ser Asp Pro Ala Lys Gln Val Ser Ile His			
140	145		150
Asn Tyr Thr Ile Trp Ser Val Leu Val Ala Ile Trp Thr Val Ala			
155	160		165
Ser Leu Leu Pro Leu Pro Glu Trp Phe Phe Ser Thr Ile Arg His			
170	175		180
His Glu Gly Val Glu Met Cys Leu Val Asp Val Pro Ala Val Ala			
185	190		195
Glu Glu Phe Met Ser Met Phe Gly Lys Leu Tyr Pro Leu Leu Ala			
200	205		210
Phe Gly Leu Pro Leu Phe Phe Ala Ser Phe Tyr Phe Trp Arg Ala			
215	220		225
Tyr Asp Gln Cys Lys Lys Arg Gly Thr Lys Thr Gln Asn Leu Arg			
230	235		240
Asn Gln Ile Arg Ser Lys Gln Val Thr Val Met Leu Leu Ser Ile			
245	250		255
Ala Ile Ile Ser Ala Leu Leu Trp Leu Pro Glu Trp Val Ala Trp			
260	265		270
Leu Trp Val Trp His Leu Lys Ala Ala Gly Pro Ala Pro Pro Gln			

275	280	285
Gly Phe Ile Ala Leu Ser Gln Val Leu Met	Phe Ser Ile Ser Ser	
290	295	300
Ala Asn Pro Leu Ile Phe Leu Val Met Ser	Glu Glu Phe Arg Glu	
305	310	315
Gly Leu Lys Gly Val Trp Lys Trp Met Ile	Thr Lys Lys Pro Pro	
320	325	330
Thr Val Ser Glu Ser Gln Glu Thr Pro Ala	Gly Asn Ser Glu Gly	
335	340	345
Leu Pro Asp Lys Val Pro Ser Pro Glu Ser	Pro Ala Ser Ile Pro	
350	355	360
Glu Lys Glu Lys Pro Ser Ser Pro Ser Ser	Gly Lys Gly Lys Thr	
365	370	375
Glu Lys Ala Glu Ile Pro Ile Leu Pro Asp	Val Glu Gln Phe Trp	
380	385	390
His Glu Arg Asp Thr Val Pro Ser Val Gln	Asp Asn Asp Pro Ile	
395	400	405
Pro Trp Glu His Glu Asp Gln Glu Thr Gly	Glu Gly Val Lys	
410	415	

<210> 12
<211> 314
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7472072CD1

<400> 12		
Met Gly Asp Val Asn Gln Ser Val Ala Ser Asp Phe Ile Leu Val		
1 5 10 15		
Gly Leu Phe Ser His Ser Gly Ser Arg Gln Leu Leu Phe Ser Leu		
20 25 30		
Val Ala Val Met Phe Val Ile Gly Leu Leu Gly Asn Thr Val Leu		
35 40 45		
Leu Phe Leu Ile Arg Val Asp Ser Arg Leu His Thr Pro Met Tyr		
50 55 60		
Phe Leu Leu Ser Gln Leu Ser Leu Phe Asp Ile Gly Cys Pro Met		
65 70 75		
Val Thr Ile Pro Lys Met Ala Ser Asp Phe Leu Arg Gly Glu Gly		
80 85 90		
Ala Thr Ser Tyr Gly Gly Gly Ala Ala Gln Ile Phe Phe Leu Thr		
95 100 105		
Leu Met Gly Val Ala Glu Gly Val Leu Leu Val Leu Met Ser Tyr		
110 115 120		
Asp Arg Tyr Val Ala Val Cys Gln Pro Leu Gln Tyr Pro Val Leu		
125 130 135		
Met Arg Arg Gln Val Cys Leu Leu Met Met Gly Ser Ser Trp Val		
140 145 150		
Val Gly Val Leu Asn Ala Ser Ile Gln Thr Ser Ile Thr Leu His		
155 160 165		
Phe Pro Tyr Cys Ala Ser Arg Ile Val Asp His Phe Phe Cys Glu		
170 175 180		
Val Pro Ala Leu Leu Lys Leu Ser Cys Ala Asp Thr Cys Ala Tyr		
185 190 195		
Glu Met Ala Leu Ser Thr Ser Gly Val Leu Ile Leu Met Leu Pro		
200 205 210		
Leu Ser Leu Ile Ala Thr Ser Tyr Gly His Val Leu Gln Ala Val		
215 220 225		
Leu Ser Met Arg Ser Glu Glu Ala Arg His Lys Ala Val Thr Thr		
230 235 240		
Cys Ser Ser His Ile Thr Val Val Gly Leu Phe Tyr Gly Ala Ala		
245 250 255		
Val Phe Met Tyr Met Val Pro Cys Ala Tyr His Ser Pro Gln Gln		
260 265 270		
Asp Asn Val Val Ser Leu Phe Tyr Ser Leu Val Thr Pro Thr Leu		

275	280	285
Asn Pro Leu Ile Tyr Ser Leu Arg Asn Pro Glu Val Trp Met Ala		
290	295	300
Leu Val Lys Val Leu Ser Arg Ala Gly Leu Arg Gln Met Cys		
305	310	

<210> 13
 <211> 254
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472074CD1

<400> 13

Met Ala Ser Arg Tyr Val Ala Val Gly Met Ile Leu Ser Gln Thr		
1 5	10	15
Val Val Gly Val Leu Gly Ser Phe Ser Val Leu Leu His Tyr Leu		
20 25	30	
Ser Phe Tyr Cys Thr Gly Cys Arg Leu Arg Ser Thr Asp Leu Ile		
35 40	45	
Val Lys His Leu Ile Val Ala Asn Phe Leu Ala Leu Arg Cys Lys		
50 55	60	
Gly Val Pro Gln Thr Met Ala Ala Phe Gly Val Arg Tyr Phe Leu		
65 70	75	
Asn Ala Leu Gly Cys Lys Leu Val Phe Tyr Leu His Arg Val Gly		
80 85	90	
Arg Gly Val Ser Ile Gly Thr Thr Cys Leu Leu Ser Val Phe Gln		
95 100	105	
Val Ile Thr Val Ser Ser Arg Lys Ser Arg Trp Ala Lys Leu Lys		
110 115	120	
Glu Lys Ala Pro Lys His Val Gly Phe Ser Val Leu Leu Cys Trp		
125 130	135	
Ile Val Cys Met Leu Val Asn Ile Ile Phe Pro Met Tyr Val Thr		
140 145	150	
Gly Lys Trp Asn Tyr Thr Asn Ile Thr Val Asn Glu Asp Leu Gly		
155 160	165	
Tyr Cys Ser Gly Gly Gly Asn Asn Lys Ile Ala Gln Thr Leu Arg		
170 175	180	
Ala Met Leu Leu Ser Phe Pro Asp Val Leu Cys Leu Gly Leu Met		
185 190	195	
Leu Trp Val Ser Ser Ser Met Val Cys Ile Leu His Arg His Lys		
200 205	210	
Gln Arg Val Gln His Ile Asp Arg Ser Asp Leu Ser Pro Arg Ala		
215 220	225	
Ser Pro Glu Asn Arg Ala Thr Gln Ser Ile Leu Ile Leu Val Ser		
230 235	240	
Thr Phe Val Ser Ser Tyr Thr Leu Ser Cys Leu Phe Gln Val		
245 250		

<210> 14
 <211> 362
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472077CD1

<400> 14

Met Tyr Lys Asp Cys Ile Glu Ser Thr Gly Asp Tyr Phe Leu Leu		
1 5	10	15
Cys Asp Ala Glu Gly Pro Trp Gly Ile Ile Leu Glu Ser Leu Ala		
20 25	30	
Ile Leu Gly Ile Val Val Thr Ile Leu Leu Leu Leu Ala Phe Leu		
35 40	45	

Phe Leu Met Arg Lys Ile Gln Asp Cys Ser Gln Trp Asn Val Leu
 50 55 60
 Pro Thr Gln Leu Leu Phe Leu Leu Ser Val Leu Gly Leu Phe Gly
 65 70 75
 Leu Ala Phe Ala Phe Ile Ile Glu Leu Asn Gln Gln Thr Ala Pro
 80 85 90
 Val Arg Tyr Phe Leu Phe Gly Val Leu Phe Ala Leu Cys Phe Ser
 95 100 105
 Cys Leu Leu Ala His Ala Ser Asn Leu Val Lys Leu Val Arg Gly
 110 115 120
 Cys Val Ser Phe Ser Trp Thr Thr Ile Leu Cys Ile Ala Ile Gly
 125 130 135
 Cys Ser Leu Leu Gln Ile Ile Ile Ala Thr Glu Tyr Val Thr Leu
 140 145 150
 Ile Met Thr Arg Gly Met Met Phe Val Asn Met Thr Pro Cys Gln
 155 160 165
 Leu Asn Val Asp Phe Val Val Leu Leu Val Tyr Val Leu Phe Leu
 170 175 180
 Met Ala Leu Thr Phe Phe Val Ser Lys Ala Thr Phe Cys Gly Pro
 185 190 195
 Cys Glu Asn Trp Lys Gln His Gly Arg Leu Ile Phe Ile Thr Val
 200 205 210
 Leu Phe Ser Ile Ile Ile Trp Val Val Trp Ile Ser Met Leu Leu
 215 220 225
 Arg Gly Asn Pro Gln Phe Gln Arg Gln Pro Gln Trp Asp Asp Pro
 230 235 240
 Val Val Cys Ile Ala Leu Val Thr Asn Ala Trp Val Phe Leu Leu
 245 250 255
 Leu Tyr Ile Val Pro Glu Leu Cys Ile Leu Tyr Arg Ser Cys Arg
 260 265 270
 Gln Glu Cys Pro Leu Gln Gly Asn Ala Cys Pro Val Thr Ala Tyr
 275 280 285
 Gln His Ser Phe Gln Val Glu Asn Gln Glu Leu Ser Arg Asp Lys
 290 295 300
 Trp Lys Val Leu Leu Asn Ser Asp Phe Leu Ser His Ser Gly Ala
 305 310 315
 Ala Arg Asp Ser Asp Gly Ala Glu Glu Asp Val Ala Leu Thr Ser
 320 325 330
 Tyr Gly Thr Pro Ile Gln Pro Gln Thr Val Asp Pro Thr Gln Glu
 335 340 345
 Cys Phe Ile Pro Gln Ala Lys Leu Ser Pro Gln Gln Asp Ala Gly
 350 355 360
 Gly Val

<210> 15
 <211> 370
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472082CD1

<400> 15
 Met Cys Lys Cys Phe Arg Ser Gly Asn Ser Thr Pro Val Leu Cys
 1 5 10 15
 His Arg Asn Ser Glu Ala Trp Gln Pro Arg Lys Ala Pro Arg Thr
 20 25 30
 Gln Gln Thr Asp Met Gly Tyr Thr Asn Leu Asn Ser Lys Lys Glu
 35 40 45
 Cys Met Tyr Ile Lys Glu Asn Phe Lys Lys Thr Val Asp Lys Ile
 50 55 60
 Val Asp Pro Gly Asn His Ser Ser Val Thr Glu Ser Ile Leu Ala
 65 70 75
 Gly Leu Ser Glu Gln Pro Glu Leu Gln Leu Arg Leu Phe Leu Leu
 80 85 90

Phe Leu Gly Ile Cys Val Val Thr Val Val Gly Asn Leu Gly Met
 95 100 105
 Ile Thr Leu Ile Gly Leu Ser Ser His Leu His Thr Pro Met Tyr
 110 115 120
 Tyr Phe Leu Ser Ser Leu Ser Phe Ile Asp Phe Cys His Ser Thr
 125 130 135
 Val Ile Thr Pro Lys Met Leu Val Asn Phe Ala Thr Glu Lys Asn
 140 145 150
 Ile Ile Ser Tyr Pro Glu Cys Met Ala Gln Leu Tyr Leu Phe Ser
 155 160 165
 Ile Phe Ala Ile Ala Glu Cys His Met Leu Ala Ala Met Ala Tyr
 170 175 180
 Asp Cys Tyr Val Ala Ile Cys Ser Pro Leu Leu Tyr Asn Val Ile
 185 190 195
 Met Ser Tyr His His Cys Phe Trp Leu Thr Val Gly Val Tyr Ile
 200 205 210
 Leu Gly Ile Leu Gly Ser Thr Ile His Thr Ser Phe Met Leu Arg
 215 220 225
 Leu Phe Leu Cys Lys Thr Asn Val Ile Asn His Tyr Phe Cys Asp
 230 235 240
 Leu Phe Pro Leu Leu Gly Leu Ser Cys Ser Ser Thr Tyr Ile Asn
 245 250 255
 Glu Leu Leu Val Leu Val Leu Ser Ala Phe Asn Ile Leu Met Pro
 260 265 270
 Ala Leu Thr Ile Leu Ala Ser Tyr Ile Phe Ile Ile Ala Ser Ile
 275 280 285
 Leu Arg Ile His Ser Thr Glu Gly Arg Ser Lys Ala Phe Ser Thr
 290 295 300
 Cys Ser Ser His Ile Leu Ala Val Ala Val Phe Phe Gly Ser Ala
 305 310 315
 Ala Phe Met Tyr Leu Gln Pro Ser Ser Val Ser Ser Met Asp Gln
 320 325 330
 Arg Lys Val Ser Ser Val Phe Tyr Thr Thr Ile Val Pro Met Leu
 335 340 345
 Asn Pro Leu Ile Tyr Ser Leu Arg Asn Lys Asp Val Lys Leu Ala
 350 355 360
 Val Lys Lys Ile Leu His Gln Thr Ala Cys
 365 370

<210> 16
 <211> 319
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472128CD1

<400> 16

Met	Thr	Pro	Gly	Glu	Leu	Ala	Leu	Ala	Ser	Gly	Asn	His	Thr	Pro
1				5						10			15	
Val	Thr	Lys	Phe	Ile	Leu	Gln	Gly	Phe	Ser	Asn	Tyr	Pro	Asp	Leu
		20						25			30			
Gln	Glu	Leu	Leu	Phe	Gly	Ala	Ile	Leu	Ile	Tyr	Ala	Ile	Thr	
				35				40			45			
Val	Val	Gly	Asn	Leu	Gly	Met	Met	Ala	Leu	Ile	Phe	Thr	Asp	Ser
				50				55			60			
His	Leu	Gln	Ser	Pro	Met	Tyr	Phe	Phe	Leu	Asn	Val	Leu	Ser	Phe
				65				70			75			
Leu	Asp	Ile	Cys	Tyr	Ser	Ser	Val	Val	Thr	Pro	Lys	Leu	Leu	Val
				80				85			90			
Asn	Phe	Leu	Val	Ser	Asp	Lys	Ser	Ile	Ser	Phe	Glu	Gly	Cys	Val
				95				100			105			
Val	Gln	Leu	Ala	Phe	Phe	Val	Val	His	Val	Thr	Ala	Glu	Ser	Phe
				110				115			120			
Leu	Leu	Ala	Ser	Met	Ala	Tyr	Asp	Arg	Phe	Leu	Ala	Ile	Cys	Gln
				125				130			135			

Pro Leu His Tyr Gly Ser Ile Met Thr Arg Gly Thr Cys Leu Gln
 140 145 150
 Leu Val Ala Val Ser Tyr Ala Phe Gly Gly Ala Asn Ser Ala Ile
 155 160 165
 Gln Thr Gly Asn Val Phe Ala Leu Pro Phe Cys Gly Pro Asn Gln
 170 175 180
 Leu Thr His Tyr Tyr Cys Asp Ile Pro Pro Leu Leu His Leu Ala
 185 190 195
 Cys Ala Asn Thr Ala Thr Ala Arg Val Val Leu Tyr Val Phe Ser
 200 205 210
 Ala Leu Val Thr Leu Leu Pro Ala Ala Val Ile Leu Thr Ser Tyr
 215 220 225
 Cys Leu Val Leu Val Ala Ile Gly Arg Met Arg Ser Val Ala Gly
 230 235 240
 Arg Glu Lys Asp Leu Ser Thr Cys Ala Ser His Phe Leu Ala Ile
 245 250 255
 Ala Ile Phe Tyr Gly Thr Val Val Phe Thr Tyr Val Gln Pro His
 260 265 270
 Gly Ser Thr Asn Asn Thr Asn Gly Gln Val Val Ser Val Phe Tyr
 275 280 285
 Thr Ile Ile Ile Pro Met Leu Asn Pro Phe Ile Tyr Ser Leu Arg
 290 295 300
 Asn Lys Glu Val Lys Gly Ala Leu Gln Arg Lys Leu Gln Val Asn
 305 310 315
 Ile Phe Pro Gly

<210> 17
 <211> 312
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472134CD1

<400> 17
 Met Asp Thr Gly Asn Trp Ser Gln Val Ala Glu Phe Ile Ile Leu
 1 5 10 15
 Gly Phe Pro His Leu Gln Gly Val Gln Ile Tyr Leu Phe Leu Leu
 20 25 30
 Leu Leu Leu Ile Tyr Leu Met Thr Val Leu Gly Asn Leu Ile
 35 40 45
 Phe Leu Val Val Cys Leu Asp Ser Arg Leu His Thr Pro Met Tyr
 50 55 60
 His Phe Val Ser Ile Leu Ser Phe Ser Glu Leu Gly Tyr Thr Ala
 65 70 75
 Ala Thr Ile Pro Lys Met Leu Ala Asn Leu Leu Ser Glu Lys Lys
 80 85 90
 Thr Ile Ser Phe Ser Gly Cys Leu Leu Gln Ile Tyr Phe Phe His
 95 100 105
 Ser Leu Gly Ala Thr Glu Cys Tyr Leu Leu Thr Ala Met Ala Tyr
 110 115 120
 Asp Arg Tyr Leu Ala Ile Cys Arg Pro Leu His Tyr Pro Thr Leu
 125 130 135
 Met Thr Pro Thr Leu Cys Ala Glu Ile Ala Ile Gly Cys Trp Leu
 140 145 150
 Gly Gly Leu Ala Gly Pro Val Val Glu Ile Ser Leu Ile Ser Arg
 155 160 165
 Leu Pro Phe Cys Gly Pro Asn Arg Ile Gln His Val Phe Cys Asp
 170 175 180
 Phe Pro Pro Val Leu Ser Leu Ala Cys Thr Asp Thr Ser Ile Asn
 185 190 195
 Val Leu Val Asp Phe Val Ile Asn Ser Cys Lys Ile Leu Ala Thr
 200 205 210
 Phe Leu Leu Ile Leu Cys Ser Tyr Val Gln Ile Ile Cys Thr Val
 215 220 225

Leu Arg Ile Pro Ser Ala Ala Gly Lys Arg Lys Ala Ile Ser Thr
 230 235 240
 Cys Ala Ser His Phe Thr Val Val Leu Ile Phe Tyr Gly Ser Ile
 245 250 255
 Leu Ser Met Tyr Val Gln Leu Lys Lys Ser Tyr Ser Leu Asp Tyr
 260 265 270
 Asp Gln Ala Leu Ala Val Val Tyr Ser Val Leu Thr Pro Phe Leu
 275 280 285
 Asn Pro Phe Ile Tyr Ser Leu Arg Asn Lys Glu Ile Lys Glu Ala
 290 295 300
 Val Arg Arg Gln Leu Lys Arg Ile Gly Ile Leu Ala
 305 310

<210> 18
 <211> 321
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472136CD1

<400> 18
 Met Asn Gln Thr Leu Asn Ser Ser Gly Thr Val Glu Ser Ala Leu
 1 5 10 15
 Asn Tyr Ser Arg Gly Ser Thr Val His Thr Ala Tyr Leu Val Leu
 20 25 30
 Ser Ser Leu Ala Met Phe Thr Cys Leu Cys Gly Met Ala Gly Asn
 35 40 45
 Ser Met Val Ile Trp Leu Leu Gly Phe Arg Met His Arg Asn Pro
 50 55 60
 Phe Cys Ile Tyr Ile Leu Asn Leu Ala Ala Ala Asp Leu Leu Phe
 65 70 75
 Leu Phe Ser Met Ala Ser Thr Leu Ser Leu Glu Thr Gln Pro Leu
 80 85 90
 Val Asn Thr Thr Asp Lys Val His Glu Leu Met Lys Arg Leu Met
 95 100 105
 Tyr Phe Ala Tyr Thr Val Gly Leu Ser Leu Leu Thr Ala Ile Ser
 110 115 120
 Thr Gln Arg Cys Leu Ser Val Leu Phe Pro Ile Trp Phe Lys Cys
 125 130 135
 His Arg Pro Arg His Leu Ser Ala Trp Val Cys Gly Leu Leu Trp
 140 145 150
 Thr Leu Cys Leu Leu Met Asn Gly Leu Thr Ser Ser Phe Cys Ser
 155 160 165
 Lys Phe Leu Lys Phe Asn Glu Asp Arg Cys Phe Arg Val Asp Met
 170 175 180
 Val Gln Ala Ala Leu Ile Met Gly Val Leu Thr Pro Val Met Thr
 185 190 195
 Leu Ser Ser Leu Thr Leu Phe Val Trp Val Arg Arg Ser Ser Gln
 200 205 210
 Gln Trp Arg Arg Gln Pro Thr Arg Leu Phe Val Val Val Leu Ala
 215 220 225
 Ser Val Leu Val Phe Leu Ile Cys Ser Leu Pro Leu Ser Ile Tyr
 230 235 240
 Trp Phe Val Leu Tyr Trp Leu Ser Leu Pro Pro Glu Met Gln Val
 245 250 255
 Leu Cys Phe Ser Leu Ser Arg Leu Ser Ser Ser Val Ser Ser Ser
 260 265 270
 Ala Asn Pro Val Ile Tyr Phe Leu Val Gly Ser Arg Arg Ser His
 275 280 285
 Arg Leu Pro Thr Arg Ser Leu Gly Thr Val Leu Gln Gln Ala Leu
 290 295 300
 Arg Glu Glu Pro Glu Leu Glu Gly Gly Glu Thr Pro Thr Val Gly
 305 310 315
 Thr Asn Glu Met Gly Ala
 320

<210> 19
 <211> 316
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472142CD1

<400> 19
 Met Gln Gly Asn Phe Thr Ile Trp Ser Ile Phe Phe Leu Glu
 1 5 10 15
 Gly Phe Ser Gln Tyr Pro Gly Leu Glu Val Val Leu Phe Val Phe
 20 25 30
 Ser Leu Val Met Tyr Leu Thr Thr Leu Leu Gly Asn Ser Thr Leu
 35 40 45
 Ile Leu Ile Thr Ile Leu Asp Ser Arg Leu Lys Thr Pro Met Tyr
 50 55 60
 Leu Phe Leu Gly Asn Leu Ser Phe Met Asp Ile Cys Tyr Thr Ser
 65 70 75
 Ala Ser Val Pro Thr Leu Leu Val Asn Leu Leu Ser Ser Gln Lys
 80 85 90
 Thr Ile Ile Phe Ser Gly Cys Ala Val Gln Met Tyr Leu Ser Leu
 95 100 105
 Ala Met Gly Ser Thr Glu Cys Val Leu Leu Ala Val Met Ala Tyr
 110 115 120
 Asp Arg Tyr Val Ala Ile Cys Asn Pro Leu Arg Tyr Ser Ile Ile
 125 130 135
 Met Asn Arg Cys Val Cys Ala Arg Met Ala Thr Val Ser Trp Val
 140 145 150
 Thr Gly Cys Leu Thr Ala Leu Leu Glu Thr Ser Phe Ala Leu Gln
 155 160 165
 Ile Pro Leu Cys Gly Asn Leu Ile Asp His Phe Thr Cys Glu Ile
 170 175 180
 Leu Ala Val Leu Lys Leu Ala Cys Thr Ser Ser Leu Leu Met Asn
 185 190 195
 Thr Ile Met Leu Val Val Ser Ile Leu Leu Leu Pro Ile Pro Met
 200 205 210
 Leu Leu Val Cys Ile Ser Tyr Ile Phe Ile Leu Ser Thr Ile Leu
 215 220 225
 Arg Ile Thr Ser Ala Glu Gly Arg Asn Lys Ala Phe Ser Thr Cys
 230 235 240
 Gly Ala His Leu Thr Val Val Ile Leu Tyr Tyr Gly Ala Ala Leu
 245 250 255
 Ser Met Tyr Leu Lys Pro Ser Ser Ser Asn Ala Gln Lys Ile Asp
 260 265 270
 Lys Ile Ile Ser Leu Leu Tyr Gly Val Leu Thr Pro Met Leu Asn
 275 280 285
 Pro Ile Ile Tyr Ser Leu Arg Asn Lys Glu Val Lys Asp Ala Met
 290 295 300
 Lys Lys Leu Leu Gly Lys Ile Thr Leu His Gln Thr His Glu His
 305 310 315
 Leu

<210> 20
 <211> 325
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472171CD1

<400> 20
 Met Glu Pro Leu Asn Arg Thr Glu Val Ser Glu Phe Phe Leu Lys
 1 5 10 15

Gly	Phe	Ser	Gly	Tyr	Pro	Ala	Leu	Glu	His	Leu	Leu	Phe	Pro	Leu
				20					25					30
Cys	Ser	Ala	Met	Tyr	Leu	Val	Thr	Leu	Leu	Gly	Asn	Thr	Ala	Ile
				35					40					45
Met	Ala	Val	Ser	Val	Leu	Asp	Ile	His	Leu	His	Thr	Pro	Val	Tyr
				50					55					60
Phe	Phe	Leu	Gly	Asn	Leu	Ser	Thr	Leu	Asp	Ile	Cys	Tyr	Thr	Pro
				65					70					75
Thr	Phe	Val	Pro	Leu	Met	Leu	Val	His	Leu	Leu	Ser	Ser	Arg	Lys
				80					85					90
Thr	Ile	Ser	Phe	Ala	Val	Cys	Ala	Ile	Gln	Met	Cys	Leu	Ser	Leu
				95					100					105
Ser	Thr	Gly	Ser	Thr	Glu	Cys	Leu	Leu	Leu	Ala	Ile	Thr	Ala	Tyr
				110					115					120
Asp	Arg	Tyr	Leu	Ala	Ile	Cys	Gln	Pro	Leu	Arg	Tyr	His	Val	Leu
				125					130					135
Met	Ser	His	Arg	Leu	Cys	Val	Leu	Leu	Met	Gly	Ala	Ala	Trp	Val
				140					145					150
Leu	Cys	Leu	Leu	Lys	Ser	Val	Thr	Glu	Met	Val	Ile	Ser	Met	Arg
				155					160					165
Leu	Pro	Phe	Cys	Gly	His	His	Val	Val	Ser	His	Phe	Thr	Cys	Lys
				170					175					180
Ile	Leu	Ala	Val	Leu	Lys	Leu	Ala	Cys	Gly	Asn	Thr	Ser	Val	Ser
				185					190					195
Glu	Asp	Phe	Leu	Leu	Ala	Gly	Ser	Ile	Leu	Leu	Leu	Pro	Val	Pro
				200					205					210
Leu	Ala	Phe	Ile	Cys	Leu	Ser	Tyr	Leu	Leu	Ile	Leu	Ala	Thr	Ile
				215					220					225
Leu	Arg	Val	Pro	Ser	Ala	Ala	Arg	Cys	Cys	Lys	Ala	Phe	Ser	Thr
				230					235					240
Cys	Leu	Ala	His	Leu	Ala	Val	Val	Leu	Leu	Phe	Tyr	Gly	Thr	Ile
				245					250					255
Ile	Phe	Met	Tyr	Leu	Lys	Pro	Lys	Ser	Lys	Glu	Ala	His	Ile	Ser
				260					265					270
Asp	Glu	Val	Phe	Thr	Val	Leu	Tyr	Ala	Met	Val	Thr	Thr	Met	Leu
				275					280					285
Asn	Pro	Thr	Ile	Tyr	Ser	Leu	Arg	Asn	Lys	Glu	Val	Lys	Glu	Ala
				290					295					300
Ala	Arg	Lys	Val	Trp	Gly	Arg	Ser	Arg	Ala	Ser	Ser	Glu	Gly	Gly
				305					310					315
Arg	Gly	Ser	Val	Gln	Thr	Gln	Val	Ser	Gly					
				320					325					

<210> 21
<211> 313
<212> PRT
<213> *Homo sapien*

<220>
<221> misc_feature
<223> Incyte ID No: 7472172CD1

<400> 21														
Met	Gly	Asn	Trp	Ser	Thr	Val	Thr	Glu	Ile	Thr	Leu	Ile	Ala	Phe
1				5					10					15
Pro	Ala	Leu	Leu	Glu	Ile	Arg	Ile	Ser	Leu	Phe	Val	Val	Leu	Val
					20				25					30
Val	Thr	Tyr	Thr	Leu	Thr	Ala	Thr	Gly	Asn	Ile	Thr	Ile	Ile	Ser
					35				40					45
Leu	Ile	Trp	Ile	Asp	His	Arg	Leu	Gln	Thr	Pro	Met	Tyr	Phe	Phe
					50				55					60
Leu	Ser	Asn	Leu	Ser	Phe	Leu	Asp	Ile	Leu	Tyr	Thr	Thr	Val	Ile
					65				70					75
Thr	Pro	Lys	Leu	Leu	Ala	Cys	Leu	Leu	Gly	Glu	Glu	Lys	Thr	Ile
					80				85					90
Ser	Phe	Ala	Gly	Cys	Met	Ile	Gln	Thr	Tyr	Phe	Tyr	Phe	Phe	Leu
					95				100					105

Gly Thr Val Glu Phe Ile Leu Leu Ala Val Met Ser Phe Asp Arg
 110 115 120
 Tyr Met Ala Ile Cys Asp Pro Leu His Tyr Thr Val Ile Met Asn
 125 130 135
 Ser Arg Ala Cys Leu Leu Leu Val Leu Gly Cys Trp Val Gly Ala
 140 145 150
 Phe Leu Ser Val Leu Phe Pro Thr Ile Val Val Thr Arg Leu Pro
 155 160 165
 Tyr Cys Arg Lys Glu Ile Asn His Phe Phe Cys Asp Ile Ala Pro
 170 175 180
 Leu Leu Gln Val Ala Cys Ile Asn Thr His Leu Ile Glu Lys Ile
 185 190 195
 Asn Phe Leu Leu Ser Ala Leu Val Ile Leu Ser Ser Leu Ala Phe
 200 205 210
 Thr Thr Gly Ser Tyr Val Tyr Ile Ile Ser Thr Ile Leu Arg Ile
 215 220 225
 Pro Ser Thr Gln Gly Arg Gln Lys Ala Phe Ser Thr Cys Ala Ser
 230 235 240
 His Ile Thr Val Val Ser Ile Ala His Gly Ser Asn Ile Phe Val
 245 250 255
 Tyr Val Arg Pro Asn Gln Asn Ser Ser Leu Asp Tyr Asp Lys Val
 260 265 270
 Ala Ala Val Leu Ile Thr Val Val Thr Pro Leu Leu Asn Pro Phe
 275 280 285
 Ile Tyr Ser Leu Arg Asn Glu Lys Val Gln Glu Val Leu Arg Glu
 290 295 300
 Thr Val Asn Arg Ile Met Thr Leu Ile Gln Arg Lys Thr
 305 310

<210> 22
 <211> 1413
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472033CB1

<220>
 <221> unsure
 <222> 176, 383, 927
 <223> a, t, c, g, or other

<400> 22
 atgaatcaga cggagccccgc ccagctggca gatggggagc atctgagtgg atacgccagc 60
 agcagcaaca gcgtgcgcta tctggacac cggcatccgc tggactacct tgacctggc 120
 acgggtgcacg ccctcaacac cactgcccac aacacctcg atctgaatga gactngagc 180
 aggcccctgg acccggtgct tatcgatagg ttccctgagca acagggcggt ggacagcccc 240
 tggtaccaca tgcctcatcag catgtacggc gtgctaatcg ttttcggcgc cctaggcaac 300
 accctgggtt gtatagccc gtcatccgga agcccatcat ggcgcactgct cgcaatctgg 360
 ttcatctca acctggccat atncggccaa agcaagtgtg agtctcatcc gagcggactt 420
 tcagacccat ttttatgcct agtcacccat cgcgtacccat tgatggagat cctgtccaaag 480
 tactggccct acggctcctg ctccatcctg tgcaaaaacga ttgcccgtgc gcaggcaactt 540
 tggatattcg tggcacaat atccataacg gccattgcct tcgacagatata tcaggtgtc 600
 gtgtacccca cgcgggacag cctgcagttc gtggcgcgg tgacgatcc ggcggggatc 660
 tgggcactgg cactgctgct ggcctccgc ctgttcgtct acaaggagct gatcaacaca 720
 gacaccccg cactctcgca gcagatccgc ctgcaggaca cgatccgcgt ctgcatttag 780
 gactggccaa gtcgcacgg ggcgttctac tactcgatct tctcgctgt cgtacaatac 840
 ctggtgccta tctcgatcgt ctcgggtggca tacttcggga ttctacaacaa gctgaagagc 900
 cgcacatcccg tggcggctgt gcaggcncgg aagggtggagc gggggcggcgc gatgaagcgc 960
 accaactgcc tactgatcag catcgccatc atcttggcg tttttggct gcccgttgac 1020
 tttttcaacc tggcggcggca catggcggcgc tcgcggcgtca ctgcaggatc gctagtcgc 1080
 tacggccatct gccacatgtat cggcatgagc tccgcctgtc ccaaccgtt gctctacggc 1140
 tggctcaacg acaacttcccg taaagaaatt caagaactgc tctgcgggtt ctcagacact 1200
 aatgtggctc ttaacggcgtca cacgacacgc tgcaacgtcc aggccggcggc ggcgcaggcgt 1260
 cgcaagatag ggcggcgaat tctccaaagg cgaactcaag ctgcgtggggc aggccggcgc 1320
 agagcggtac cgcggcgggg gaggcggctc ggcggccacc gacttcatgc ccggcaccac 1380

gaggggggac tcgccaacat agttcatcat tga 1413
<210> 23
<211> 1076
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7472034CB1

<400> 23
tctacccaaa tgagaaggaa cagagaaaca attctggtaa tattacaaaa caaggttctt 60
taaacacctt gaaggatcaa accagctcac cagcaatgga tccaaaccaa gatgaaatct 120
ctgaattacc agaaaaagaa ttccagaagat caattattaa gctgatcaa gaggcaccag 180
aaaaaggat tccaggtta gaggaaagcc agcaactggat tgcaactgccc ctgggcatcc 240
tttacctct tgcgttagtg gccaatgtta ccattctt catcatctgg atggacccat 300
ccttgcacca atctatgtac ctcttcctgt ccattgtac tgccatcgac ctggttctgg 360
cctccctccac tgccatccaaa gccttgcag tgcttcctgt tcatgcccac gagatgggt 420
acatcgctcg cctgtatccag atgttcttca tccatgcatt ctccctccatg gagtccagg 480
tacttgttgc catggctcg gatcgctatg tagccatgtt tcaccccttg caccattcca 540
caatcctgca tccagggttc ataggcgca tcggaatgtt ggtgttggt aggggattac 600
tactcttat cccctcccc attttgttgg gaacacttat ctctgccaa gccaccatca 660
taggccatgc ctattgtgaa catatggctg ttgtgaaact tgcctgctca gaaaccacag 720
tcaatcgagc ttatggctg actatggcct tgcttgcgtat tgggttggat gttctggcca 780
tttgttgcctt ctatgcccac accttcagg cagtgtca ggtaccagg agtgaggccc 840
gacttaaggc ttgttgcaca tttggcttc atatttgcgtat catctggtc tctatgttc 900
ttggaaattt ctcttcctc actcaccgtt ttggcatca tgtaaccatc catgtccatg 960
ttcttctggc cacacgtat ctctcatgc cacctgcgtt caattctt gtctatggag 1020
tgaagactca gcagatccgc cagcgagtgc tcagagtgtt tacacaaaag gattga 1076

<210> 24
<211> 948
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7472035CB1

<400> 24
atggaaatcc ctgccttcctt cctccttgg ggtatccag gactgcaatc ttcacatctt 60
tggctggcta tctcaactgag tgccatgtac atcatggcc ttttagaaaa caccatcatc 120
gtgactgcaa tctggatgga ttccactcg catgagccca tttttgttctt tctgtgttt 180
ctggctgtcg tggacattgtt tatggccctt tcgggtgtac ccaagatgtt gagcatctt 240
tgctcaggag acagctcaat cagcttttagt gcttgcattca ctcagatgtt ttttgcac 300
tttagccacag ctgtggagac ggggtgtctg ctgaccatgg ctgttgcaccg ctatgttagcc 360
atctgcaagc ctctactaca caagagaatt ctcacgcctc aagtgtatgtt gggaaatgagt 420
atggccatca ctatcgagc tatcatgccc ataactccac tggttggat ggtgtatgtt 480
ctaccccttc gtggctccaa ttgttgcata cactcctact gtgagcacat agcttggcc 540
aggttagcat gtgttgcaccc cttgtccca gtttgcatac agtcttaca gtcttgcattt 600
atggtgggtt ctgtatgtgc ctccattgtt gcctcctata tcttaattctt caaggcagta 660
tttgttctt cctcaaaagac tgctcgttttgg aaagcattaa gcacatgtgg ctccatgtt 720
gggggtttagg ctttgcatac ttccatgttgc atggcatcca tctatgcggc ctgggttgggg 780
caggatgttag tggccatgtca caccggatc ctgttgcatac acctgttgcgtt gatcatccca 840
ggccacccatccatccatcat ctatggcatg aggaccaac aactgcggga gagaatatgg 900
aggatcatgttgc tgcattgttgc ctggaccat tccaaacctgg gttcatgtt 948

<210> 25
<211> 945
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7472036CB1

<210> 26
<211> 966
<212> DNA
<213> *Homo sapiens*

<220>
<221> misc_feature
<223> Incvte ID No: 7472037CB1

```

<400> 26
atggctcatc aggccctga gaagcagcag gacaatggga cctggctgg gacagagtcc 60
ctgtggtgg gatttccaa cctccccagaa ctgaggccca ctctttcat cttgttcctc 120
ctcacctacc tggtacact cagtggcaat gccaccatca tcaccatcat ccaggtggat 180
cgcactctcc acacacccat gtaccgcttc ctggccgtc tctcccttc tgagacctgc 240
tacacactgg tcaccatccc caatatgtgc gtcatctgc tgatggagag ccaggccatc 300
tccatcgccg gctgtcgccg cceagatgttc ttcttccctag gcttgggttgc cagccattgt 360
ttccatcttcc cctgtatggg ctatgacagg tatgtggcca tctggccatctc ttgtgcctac 420
tctgtatca tgagacccac cgtctgcctg tggttggag ccttgggttt ctgtctgtt 480
ttctcagtgg ccttgattga gacctgcattt atcttctctt cacccttc tggtggcc 540
catgtggagc actttttctg tgacattgcg cctgtgtga agctcagctg tgatggagac 600
tcactcaagg gacttggcat ttcttccctg agcatccctg tgggtgttgc ttcccttcctc 660
ttcattctcc tctccatcgc ttcttgcattt gctgcattt tgaggatccc ttccgttctt 720
ggccggcgca aagccctctc tacctgcgcg gccaccatca cgggtgtcat cgtacatttt 780
gggtgtgcct ccatcatctt cctggaggccg gactctgggg ctaatccctc ccaggaccgc 840
ctggggccgg tggttctacac cgtggtgaca ccgctgttgc accctgttgc ttacaccctg 900
aggaacaagg aggtgagggt agcgctgagg aaaaacctgg cacggggctg tggagcattt 960
aagtaa

```

<210> 27
<211> 996
<212> DNA
<213> *Homo sapiens*

<220>
<221> misc_feature
<223> Incyte ID No: 7472039CB1

```

<400> 27
atgagtctgtatgggaacca cagtagtgat ccaacagagt tcgtcctggc agggctccca 60
aatctcaaca gcgcagaagt ggaattattttctgttttc ttcttgctatctctgaat 120
ctgacaggca atgtttgtat tgggggggtgtaaaggctgataactcgact acagaccct 180
atgtacttcttctggtaaccgtgcctagagatactgctcaacttc tgcatcatt 240
ccaaagatgc tgagcaatttctcaaggcaacacactatttctttgc tgcatgtatc 300
acccaaatcttatttctacttcttcggggctcttgcggacttactgttggctgtcatg 360
tctgcggatc gctacctggccatctgtcatcctctgcgtacccttgcgtatgagtgg 420
gctgtgtgttctgtgtggccttggctgc tgggtgggggactctgtccc tggcttggt 480
cccacagtgg ctgtggcctt gcttccttc tgtaaggcagg gtgtgtggatagacttc 540
ttctgcgaca gtggccact gctccggctgtttgcaccaagaa gctggaggag 600
actgactttgccttcctcgatcttgcattgtatcttccttgctgtatc tggctgttgc 660

```

tacggcctca	ttgtgtggc	agtccctgagc	atcccccttg	cttcaggccg	tcagaaggcc	720
ttctctacct	gtacccctcca	cttgatagtg	gtgaccctct	tctatggaaag	tgccattttt	780
ctctatgtgc	ggccatcgca	gagtggttct	gtggacacta	actggcagt	gacagtaata	840
acgacatttg	tgacaccact	gttgaatcca	ttcatctatg	cttacgtaa	tgagcaagtc	900
aaggaaagt	tgaaggacat	gtttagaaag	gtatgtggcag	gcgttttagg	gaatctttta	960
cttgataaat	gtctca	gttgatgtga	gaaaagcgtta	aaagttaa		996

<210> 28
<211> 1014
<212> DNA
<213> *Homo sapiens*

<220>
<221> misc_feature
<223> Incyte ID No: 7472040CB1

```

<400> 28
atggggaaacg attctgtcag ctacgagtat ggggattaca gcgacctctc ggaccgccc 60
gtggactgcc tggatggcgc ctgcctggcc atcgaccgc tcgcgtggc cccgctccca 120
ctgtatggcg ccatcttctt ggtgggggtg cggggcaatg ccatggtgcc ctgggtggct 180
gggaagggtgg cccggccggag ggtgggtgcc acctgggtgc tccacctggc cgtggcggat 240
ttgctgtgtt gtttgcgtt cccatcttgc gcaagtgcaca ttggccgtgg aggccactgg 300
ccgtatggtg cagtggctg tggggcgtg cccctccatca tcctgtgtac catgtatgc 360
agcttcttc tctggcagc ttcagtgcct gacctctgtc tcctgtgtt cggggctggc 420
tggtgtctca cggttcagcg ggcgtgcggg gtgcagggtt cctgtggggc agccctggaca 480
ctggcccttc tgctcaccgt gcctccggc atctaccgc ggctgcacca ggagcacttc 540
ccagccccgc tgcaagtgtt ggtggactac ggccggctct ccagcaccga gaatgcgggt 600
actgcctatcc gttttttttt tggttcttc gggccctgg tggccgtggc cagctgccac 660
agtgccttcc tgggtgtggc agcccgacgc tgccggccgc tgggcacagc cattgtgggt 720
gggttttttg tctgtgtggc acccttaccac ctgtgtggc tgggtgttcac tggggccggc 780
ccgaaactccg cactcttggc caggggccctg cgggctgaaac cccttcatgtt gggcccttgc 840
ctcgctcaca gttgttccaa tccatgttc ttctgttatt ttggggaggcc tcaactccgc 900
cggtaactgc cagctgttgc tcaatggggcc ctgaggggagt cccaggccca ggacgaaagt 960
gtggacacgca aqaaatccac caaggatgtac ctggatcttgg agatggaggt ttag 1014

```

<210> 29
<211> 5122
<212> DNA
<213> *Homo sapiens*

<220>
<221> misc_feature
<223> Incyte ID No: 4250893CB1

```

<400> 29
gaggccagcg cccggggctc cactctgggt tctgaaagcc catccctgc tctgcggctc 60
ctcccacccc acctttctc agccttcagag ctcagggtt gatctcagga gtccaggacc 120
caggagaggg aagaatctga ggaacacaga acagtgcgcg ttgcccacac cccatctccc 180
gtcaccacat ctccccctgt taacacccctc cctgccttcg cctgacccccc atcccaggac 240
ctccctatca gctgacttt tccagtgtt tgccggcccc tctggcttc tccctccccc 300
ggctttctc accactcccc ctttatccgc gtctatctgt aggtgcctgg ggtattataa 360
aactgggttc cgaatgtcga ataagagacg gtaagagccca aggccaaagga cagcactgtt 420
ctctgcctgc ctgataccct caccacctgg gaacatcccc cagacacccct cttaaactccg 480
ggacagagat ggctggcgga gctggggcc gcctggctg ttacttggag ttccctgaaga 540
aggaggagct gaaggagttc cagcttctgc tcgccaataa agcgcactcc aggagcttctt 600
cgggtgagac acccgcttcg ccagagaaga cgagtggcat ggaggtggcc tcgtactctgg 660
tggctcgtatg tggggagcc cggccttggg accttagccct ccatactctgg gacgatgg 720
ggctggggctc actgtggccc caagccccagg aaggggccagg ccactctcccc tattttccct 780
acagccccaa g tgaacccccc ctgggtctc ccagccaaacc cacctccacc gcagtgtctaa 840
tgccttggat ccatgaattt cccgggggggt gcacccaggg ctcagagaga agggttttga 900
gacagctgcc tgacacatct ggacggccgt ggagagaaaat ctctgcctca cacgtctacc 960
aagctttcc aagctccccca gaccatgagt ctccaaggccca ggagtccaccc aacgccccca 1020
catccacacgc agtgtctgggg agctggggat cccacccctca gcccagccctaa gcaccccgaa 1080
agcaggagggc tccttggggcc caatggccctc tggatggaaac gtcaggaaatt tactacacag 1140
aaatcagaga aagagagaga gagaatctcg agaaaaggcag gccccatgg gcagcggttg 1200
taggaacgccc cccacccggc cacaccagcc tacagccccca ccacccacca tggggccctt 1260
ctgtgagaga gaggctctgt tccacatggc ccttggaaaaaa tgaggatttt aacccaaaaat 1320

```

tccacacagct	gctactttctca	caaagacacctc	accccagaag	ccaagatccc	ctggtaaaga	1380
gaagctggcc	tgatttatgtg	gaggagaatc	gaggacattt	aatttagagatc	agagacttat	1440
ttggcccaagg	cctggatacc	caagaacctc	gcatagtcat	actgcagggg	gctgctggaa	1500
ttgggaagtc	aacactggcc	aggcaggtga	aggaagctg	ggggagagggc	cagctgtatg	1560
gggaccgctt	ccagcatgtc	ttctacttca	gctgcagaga	gctggccag	tccaagggtgg	1620
tgagtcctcg	tgagctcata	ggaaaagatg	ggacagccac	tccgcttcc	attagacaga	1680
tcttgtctcg	ggcagagcgg	ctgtcttca	tcctcgatg	ttgatgatg	ccaggatggg	1740
tcttcaggg	gcccagttt	gagctctgtc	tgcactggag	ccagccacag	ccggcgtatg	1800
cactgcggg	cagttgtctg	ggaaaaacta	tacttccca	ggcatccctc	ctgtacacgg	1860
ctcgaccac	agctctgcag	aacctcattc	cttcttgg	gcagggcacgt	tggtagaggg	1920
tcctggggtt	ctctgagtcc	acagaggaagg	aatatttcta	cagatatttc	acagatgaaa	1980
ggcaagcaat	tagagccctt	agttgtgtca	aatcaaaca	agagctctgg	gcctgtgtc	2040
tttgtccctg	ggtgtcttgg	ctggcgttca	cttgcgtat	gcagcagatg	aaaggaaagg	2100
aaaaaaacca	actgacttcc	aaagaccacca	caaccctctg	tctacattac	cttgcggcagg	2160
ctctccaagc	tcagccattt	ggaccccccagc	tcagagacct	ctgcctctg	gctgctgagg	2220
gcatctggca	aaaaaaagacc	cttttcaagtc	cagatgacct	caggaagcat	gggttagatg	2280
gggcatcat	ctccacccctt	ttgaagatgg	gtattctca	agagacaccc	atccctctga	2340
gctacagtt	cattcaccc	tgtttccaaag	agttcttgc	agcaatgtcc	tatgtcttgg	2400
aggatgagaa	ggggagaggt	aaacattcta	attgcatacat	agatggaa	aaagacgctag	2460
aagcatgtgg	aatacatggc	ctgtttgggg	catcaaccac	acgtttccata	tggggctgt	2520
taatgtatga	ggggggagaga	gagatggaga	acattttca	ctgcccgtt	tctcagggg	2580
ggaaacctgt	gcagtgggtc	ccgttccctgc	agctgctgt	gcaggccacac	tcttggagt	2640
ccctccactg	cttgcatacg	actcggaaaca	aaacgttctt	gacacaagt	atggccatt	2700
tcgaagaaaat	gggcatgtgt	gtagaaaacag	acatggagct	cttagtgtc	actttctgca	2760
ttaaatttcag	ccgcccacgt	aagaagcttc	agctgattga	gggcaggcag	cacagatcaa	2820
catggagcccc	caccaatgtt	gtctctgttca	gggtgggtccc	agtccacatg	gcctattggc	2880
agattctctt	ctccgttctc	aaggtcacca	gaaacctgaa	ggagctggac	ctaagtggaa	2940
actcgtctgg	ccactgtca	gttgcggatc	tttgcataag	cctggagacgc	cttgcgttgc	3000
tcctggagac	cctgcgggtt	gtctggctgt	gcctcacagc	tgaggactgc	aggacccctt	3060
ccttgggct	gagagccaa	cagacccctg	ccgagcttga	cctgagcttc	aatgtgctca	3120
cgatgtctgg	agccaaacac	cttgcggaga	gactgagaca	gccgagctgc	aagctacagc	3180
gactgcagtt	ggtcagctgt	ggcctcacgt	ctgactgtt	ccaggacctg	gcctctgtc	3240
tttagtgcac	ccccagccgt	aaggagctag	acgtgcagca	gaacaaac	gtacgttgc	3300
cgctgtcgac	gctctgtgt	gggtctcaggc	atctctgcgt	caaactcata	cgccctgggg	3360
tggccaggac	aactctgtat	gtatgatgt	ggcggacaa	gaggccctt	gagcaggaga	3420
aaacctcagtt	gctcatctt	acgagacggc	aaccaagtgt	gatgacccct	actgaggggc	3480
tggatacggg	agagatgagt	aatagcacat	cctcactcaa	gcggcagaga	ctcgatcag	3540
agagggcgcc	tcccacatgtt	gttcaggctt	atctcaact	cctggacgt	agcaagatct	3600
tcccaatttc	tgagatttgc	gagggaaagct	ccccagaggt	agtacccgt	gaactcttgc	3660
gctgtccctt	tcctgcctt	caaggggacc	tgcatacgaa	gccttgggg	actgacatg	3720
acttttgggg	ccccacgggg	cctgtggctt	ctgaggtagt	tgacaaaagaa	aagaacttgt	3780
accggatttc	cttccctgtt	gtctggctct	accgtgttgc	caacacgggt	cttgcgttttgc	3840
tgatgagaga	agccgttgacc	gttgagattt	aattctgtgt	gtgggaccag	ttcttgggttgc	3900
agatcaaccc	acagcacage	tggatgggtt	cagggccctt	gtctggacatc	aaggctgagc	3960
ctggagctgt	ggaagctgtt	caccccttcc	acttttgcgtt	tctccaagg	ggccatgtgg	4020
acacatcccc	gttccaaatgt	gcccacattt	aaggaggagg	gtatgttgc	gagaagccag	4080
ccagggttgg	gtcgtatcac	atagttctgg	aaaaccccg	cttccccc	tggggatgtcc	4140
tcttgaaaat	gtccataat	gcctctgcgt	tcattccctgt	cacctgttgc	gttgcgtttt	4200
accacccgggt	ccatccctgt	gaatgtccat	tccaccttca	cctgatccc	agtgtactgt	4260
ccattcggaa	ggccatagat	gtatctgaaa	tgaaatttca	gtttgtgc	atccacaagc	4320
caccccccgt	gaccccaattt	tatatgggt	gtcgatcac	tgtgtcttgc	tctgggttca	4380
ggatgtctgg	aatactcccc	aaggaaacttgg	agctctgttca	tcgaacccct	ggagaagacc	4440
agctgtttcc	ggagttctac	gttggccact	tgggatcagg	gtatccgt	caagtgtaaag	4500
acaagaaaga	tgagactctg	gttggggagg	ccttgggttca	accaggat	ctcatgttgc	4560
caactactt	gatcccttca	gcccgtat	cgatcttcc	actcttggat	gcccccgagt	4620
tgctgttgc	tgtggaccag	tatctggatc	agctgatag	ccgagtgaca	tcgggttgggg	4680
ttgtcttgg	caaacttgc	ggacagggtc	tgagccatgg	gcagttacg	agggtgttgc	4740
ctgagaacac	gaggcccage	cagatgcgg	agctgttcc	cttgcaccc	tccttgggacc	4800
ggaagtgtca	agatggactc	taccaagccc	tgaaggagac	ccatcttcac	cttattatgg	4860
aactctggga	gaagggcage	aaaaaggggc	tcctgcact	cagcagctga	agtatcaaca	4920
ccagcccttgc	acccttggat	cttggcttgc	gctgaccctt	ctttgggtct	cagttttttt	4980
ctctgcacac	aagtgtccat	cttggccat	ttccagact	aaagtaatgg	aactttagat	5040
gatgccttgc	tggccat	gttgcaccc	agggtatgcac	agggggccca	gtcagggtggg	5100
ctacagcatc	tcaggatgtt	cc				5122

<210> 30
<211> 1241

<212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 6726656CB1

<400> 30
 atttatggag gcaaccaaca aattacacag caatgaattc tggactgttag tcccacagcc 60
 ttgaggctag atactagctg tgtcaactaat actctgtgtg accaggaagc ttgagtgccc 120
 aagggttta taaatgttga aaataaccgc tggtcaataa tcctgttggc ctgctgtat 180
 gtgaggtgtg gaagaaacac gggagcagcc ttccctcagga caccctttgtt ttatctct 240
 agctctgaaa tcacatgaag ctgtggatgg agagtcaccc gatagtccca gaaaccgc 300
 ccagcccaag gatgtatggat aaccagacgt tggttaaccga gttcatcctg cagggcttt 360
 cggagcaccc agaatacccg gtgttcttat tcacgtgtt cctcttcctc tactctggg 420
 ccctcacagg taatgttcc tcacacctgg ccatcacgtt aacccttggg ctccacgctc 480
 ctatgtactt ttcttactc aacttggcta ctatggacat tatctgcacc tcttccatca 540
 tgcccaaggc gctggccagt ctgggtgtgg aagagagctc catctcctac gggggctgca 600
 tggcccaagct ctatttctc acgtgggctg catctcaga gctgtgtc ctcacggtca 660
 tggccatgta ccggtaacgca gccatctgca acccgctgca ttacagcagc atgatgagca 720
 aggtgttctg cagcgggctg gccacaggcc tgggtgtgtc ctgcggcgtc aacacggcca 780
 tccacacggg gttgtatgtc cgcttggatt tctgtggccc caatgttattt atccatttct 840
 tctggaggtt ccttccctc ctgtttctc cttgcagctc cacatgtc aacgggtgtca 900
 tgattgtctt ggcggatgtct ttctacgca tagtgaactt cctgtatgacc atcgcgttct 960
 atggcttcat cgtctccagc atcctgaagg tgaagactgc ctgggggagg cagaaaggct 1020
 tctccacctg ctcttccac ctcaccgtgg tggcatgtt ttacaccgtc gtcttctacg 1080
 cctacataag cccggctctc ggctacagcg cagggaaagag caagttggctt ggcctgctgt 1140
 aactgtgtctt gaggcttacc ctcaacccca tcatctatac ttgagaaac aaggagggtca 1200
 aagcagccctt caggaagctt ttcccttctc tcagaaattt a 1241

<210> 31
 <211> 1155
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472062CB1

<400> 31
 atgaatgtcc ttctggcaga ttcaaattca aataaaaaga ttgtgcataa acacatctgc 60
 agcctacatg cagcccccaa gactacgaac ctccaaacctt caatatctga tattctgtca 120
 agtgttggata gtaatgacag gaagaatgtg tctaagataa aaggggattt tttcaacaca 180
 agatgtatctt gtgattctaa aataacatcc atggagaata atacagaggt gagtgttattc 240
 atccgttgc ttctaaaccctt tgccccagaa ctacagggtt ccctctttat catgtttacc 300
 ctcatctacc tcatactactt gactggaaac ctggggatga tcatattat cctgtctggac 360
 tctcatctcc acactcccat gtactttttt ctcaatgttacc tttctcttgc aggcatgtt 420
 tactcttcag ctgttactcc aaagggttta actgggttgc ttatagaaga caaaggccatc 480
 tcctacatgtt ctgttgcgc tcagatgtt ttttgcag tttttccac tttttttttt 540
 tacctttgtt ctctaatggc ctatgaccgc tacgcagcag tttttttttt cttttttttt 600
 accaccacca tggatgttgc tttttttttt tttttttttt tttttttttt tttttttttt 660
 tttctgtatgtt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 720
 gtgatttcattt acctttttttt tttttttttt tttttttttt tttttttttt tttttttttt 780
 cacatgttgc agtttgcattt tttttttttt tttttttttt tttttttttt tttttttttt 840
 gttacatgtt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 900
 ggatgttgc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 960
 ataactgtca tcatacatgtt tttttttttt tttttttttt tttttttttt tttttttttt 1020
 attgtatgtt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1080
 aggaacaaatggatgttgc tttttttttt tttttttttt tttttttttt tttttttttt 1140
 gatttgcattt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1155

<210> 32
 <211> 1260
 <212> DNA
 <213> Homo sapiens

<220>

aaacttgttt tctatctcca tagagtggc aggggagtgt ccattggcac cacctgcctc 300
 ttgagtgct tcagggtgat cacggtcage tcaggaaat ccaggtggc aaaactaaa 360
 gagaaagccc ccaagcatgt tggctttct gttctcctgt gctggatcggt gtgcatgtt 420
 gtaaacatca tcttccatca gtatgtact ggcaaatgga actacacaaa catcacagt 480
 aacggaggatt tgggatactg ttctgggga ggcaacaaca aaatcgacaca gacactgcgt 540
 gcaatgttgc tatcatccc tgatgtttg tgctgggc tcatgctctg ggtcagcagc 600
 tccatggttt gcatcctgc caggcacaag caggggtcc agcacattga taggagcgat 660
 ctctccccca gagectccccca agagaacaga gctacgcaga gcattcctcat cctggtgagc 720
 accttgttgc ttcttacac tctctcctgc ctttccaag ttgtt 765

<210> 35
 <211> 1089
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472077CB1

<400> 35
 atgtacaagg actgcacatcgaa gtccactggaa gactattttc ttctctgtga cgccgagggg 60
 ccatggggca tcattctggaa gtccctggcc atacttggca tcgtggtcac aattctgtca 120
 ctcttagcat ttctcttcct catgcgaaag atccaagact gcagccagtg gaatgtcctc 180
 cccaccggc tccctttccct cctgagtgtc ctggggctct tcggactcgc ttttgcttc 240
 atcatcgac tcaatcaaca aactgcccccc gtacgctact ttctctttgg gtttctttt 300
 gctctctgtt ttcatgcctt cttagctcat gccttcaatc tagtggaaat gtttcggggt 360
 tgggttctctt ttcctggac gacaatttgc ttgattgtca ttgggtggcgt tctgttgca 420
 atcattatttgc ccaactgagta tggactctc atcatgacca gaggtatgtatgtt 480
 atgacaccctt gccagctcaa tggactttt gtttactcc tggcttatgtt cctcttcctg 540
 atggccctca cattttctgtt ctccaaagcc accttctgtg gcccgtgtga gaactggaag 600
 cagcatggaa ggctcatctt tatcaactgtt ctcttctcca tcacatcttgc ggtgggttgg 660
 atctccatgc tccctggagg caaaccggcag ttccagcgc acggccatgtt ggacgaccgg 720
 gtctgttgc ttgttctgtt cacaacgc tgggtttcc ttgtgtgtatgtt catgttccct 780
 gagctctgc ttctcttacag atcgttgcata caggagtgcctt ctttacaagg caatgcctgc 840
 cccgtcacag ctttaccaaca cagttccaa gtggagaacc agggactctc cagagataaa 900
 tggaaaggctt tactcaactt ggacttcttca tcacacatgtt gtgcagcccg agacagtgtt 960
 ggagctgagg aggatgttagt attaacttca tatgttactt ccattcagcc gcagactgtt 1020
 gatccacac aagagtgtttt catccacac gctaaactaa gccccagca agatgcagga 1080
 ggagtataa 1089

<210> 36
 <211> 1334
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472082CB1

<400> 36
 atgtgttaat gcttcagaag tggcaatagc actccagttcc tgggttcacccg aaactcagaa 60
 gcatggcage ccaggaaggc cccaaagaca cagcaaactg acatgggtta caccatata 120
 aattccaaaga aagagtgcac gtacattaa gaaaattca aaaagactgt tgacaagatc 180
 gtggaccctt gaaaccatcc ttcactgtact gatccatcc tggctgggtt ctcagaacag 240
 ccagagctcc agctgcgcctt ttctctctgtt ttcttaggaa tctgtgtgtt cacagtgggt 300
 ggcaacttgg gcatgatcac actgatttttgc ttctgttcc acctgcacac acctatgtac 360
 tatttctca gcaatgttgc ttcttgcattt ccactgtcat tacccttaag 420
 atgctgttgc acatttgcac agagaagaac atcatcttcc accctgtatgtt catggctcg 480
 ctcttattt tcaatgttgc tggatgttgc gatgttgcata ttgggtgtt aatggcgat 540
 gactgttgc ttggccatgtt cagggcccttgc ttgttgcataatg tcacatgtt ctttaccc 600
 tgcttcttgc tcaatgttgc agtttacatt ttggatgttgc ttggatgttcat aatttataacc 660
 agttttatgt tgagacttgc ttgttgcacacta ataaatgttgc ttaaccatata ttggatgtt 720
 cttttccctt tcttgggtt ctcctgttcc agcaccttaca tcaatgttcat ttttgcgtt 780
 gtcttgcgtt catttacat ctttgcgttcc gcttacca ttttgcgttcc ttacatctttt 840
 atcatgttgc gcatcctcccg catttacatcc actgaggggca ggtccaaagc ctttgcgtt 900
 tgcaatgttgc acatgttgc tggatgttgc ttggatgttgc ttggatgttcat ttttgcgtt 960
 cagccatcat ctgtcagctc catggaccac agggaaatgtt ctttgcgtt ttttgcgtt 1020

attgtgccc tgctgaaccc cctgatctac agcctgagga ataaagatgt caaacttgcc 1080
 gtgaagaaaa ttctgcata gacagcatgt taatgaatag aatcaatgtt atgttggat 1140
 atcaagatag gtctttgggt tgattagata tctaacttat tggatttatt gttgagat 1200
 atgaaaattt agtgatgctc ttttatgtaa cacctctcca aaatattccct ccggctgtct 1260
 tccatcgaaat ttatattcca atgagcatat gtaaagaaat acaaagaata aaatcaaaag 1320
 acttttgagg ttta 1334

<210> 37
 <211> 960
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472128CB1

<400> 37
 atgacacctg gagaacttagc ctttgccagt ggcaaccaca ccccaagtac caagttcatc 60
 ttgcaggat ttcctcaatta tccagaccc caggagttc tcttcggagc catcctgtct 120
 atctatgcca taacagtgggt gggcaacttg ggaatgtgg cactcatctt cacagactcc 180
 catctccaaa gcccaatgtt tttcttcctc aatgtccctt cgtttcttga tatttggat 240
 tcttcgtgg tcaacaccaa gctctgttc aacttccctt gttctgtacaa gtccatctt 300
 ttggagggt gtgtggtcca gctcgcctt ttttagtgc atgtgacagc tgagagttc 360
 ctgctggcctt ccattggctt tgaccgcctt ctggccatctt gtcaaccctt ccattatgg 420
 tctatcatgtt ccaggggggac ctgtctccag ctggtagctg tttcttgc atttgggtgg 480
 gccaactccg ctatccagac tggaaatgtt tttcccttc ctttctgtgg gcccaaccag 540
 ctaacacact actactgttca cataccaccc ctttccacc tggcttgc caacacagcc 600
 acagcaagag tggcttctt tttcttgc tttcttgc ccatttgc tgctgcgtc 660
 attctcacctt cttactgtttt ggtcttgc gttttttttt ggtttttttt ggtttttttt 720
 agggagaagg acctctccac ttgtgcctcc cactttctgg ccatttgc tttctatggc 780
 actgtggttt tcaacatgtt tcaacatgtt tcaacatgtt tcaacatgtt tcaacatgtt 840
 gtgtccgtct tctacaccat cataatttttccat atgtcaatc ctttcatctt tttcttgc 900
 aacaaggagg tgaaggggcgc tctgcagagg aagtttcagg tcaacatctt tcccggtga 960

<210> 38
 <211> 939
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472134CB1

<400> 38
 atggacacag ggaactggag ccaggttagca gaattcatca tcttgggctt ccccatctc 60
 cagggtgtcc agatattatctt cttcccttgc ttgtttctca tttacatcat gactgtgttg 120
 gggaaacctgc tgatatttctt ggtggcttc ctggactccc ggcttcacac acccatgtac 180
 cactttgtca gcatcttc tttcttcctt cttcttcctt cttcttcctt cttcttcctt 240
 atgctggcaa acttgcgttca tgagaaaaatg accatttcat tttttttttt tttttttttt 300
 atctattttt ttcactccctt tggagcgact gagggttcatc tttttttttt tttttttttt 360
 gataggtatt tagccatctt ccggcccttc cactaccaccc ctttcatgtac cccaaacctt 420
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 480
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 540
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 600
 gttataattt cttgtcaagat cttgtcaagat cttgtcaagat cttgtcaagat cttgtcaagat 660
 atcatctgtca cttgtcaagat aattccctca gttttttttt tttttttttt tttttttttt 720
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 780
 cttgtcaagat aattccctca gttttttttt tttttttttt tttttttttt tttttttttt 840
 cttgtcaagat aattccctca gttttttttt tttttttttt tttttttttt tttttttttt 900
 gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 939

<210> 39
 <211> 968
 <212> DNA
 <213> Homo sapiens

<220>

<221> misc_feature
 <223> Incyte ID No: 7472136CB1

<400> 39
 ggatgaacca gactttgaat agcagtggga ccgtggagtc agccctaaac tattccagag 60
 ggagcacagt gcacacggcc tacctggtgc tgagtcctt ggccatgttc acctgcctgt 120
 gcgggatggc aggcaacagc atggtgatct ggctgctggg ctttgcataatg cacaggaacc 180
 ccttcgtcat ctataatctc aacctggcg cagccgaccc ctttgccttc ttcatggatgg 240
 ctccacgtc cagccgtggaa accccagcccc tggtaatac cactgacaag gtccacgagc 300
 tggatgaagag actgtatgtac ttgcctaca cagttggcctt gggctgtc acggccatca 360
 gcaccacgcg ctgtctctct gtcccttcctt ctatctgtt caagtgtcac cggcccaggc 420
 acctgtcagc ctgggtgtgt ggccctgtgtt ggacactctg tctctgtatg aacgggttga 480
 ccttcctt ctgcagcaag ttcttgaat tcaatgaaga tgggtgtctt agggtgacca 540
 tggtcacggc cggccatcata atgggggtct taacccatgt gatgactctg tccagccatgt 600
 cccttttgc ctgggtcggtt aggagcttcc acgagtggcg gggcagccc acacggctgt 660
 tgggtgtgtt ctggcctctt gtccctgtgtt ttccctgtctt ctgacatct 720
 actgggttgtt gtctactgtt ttgagccgtc cggccgagat ggacgttctg tggatgtt 780
 tggatgtatgtt ctccatgtcc gtaaggcaga gggccaaaccc cgtcatctac ttccctgtgtt 840
 gcaaggccggag gagccacagg ctgcccacca ggtccctggg gactgtgtc caacaggcgc 900
 ttgcgagga gcccggatgtt ggacgttgggg agacggccac cgtggccacc aatgagatgg 960
 gggctgtt 968

<210> 40
 <211> 1000
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472142CB1

<400> 40
 attaaatgaa gggaaatagta ctggaaagaaa tataatgaa agaaagaaaa tgcaaggaga 60
 aaacttcacc atttggagca tttttttctt ggagggtttt tccctgttcc cagggtttaga 120
 agtgggttctc ttctgttctca gccttgcataat gtatgtaca acgtctttgg gcaacacgc 180
 tcttatttttgc atccatatcc tagatttacgc ctttttttttgc cccatgtact tatttccttgg 240
 aaatctctctt ttcatggata ttgttacac atctgcctctt gttcttactt tgctgggttga 300
 ctgtgtca tcccaaaaaa ccattatctt ttctgggtgt gctgtacaga tttatctgtc 360
 ctttgcatttgc ggctccacag agtgtgtctt cttggccgtt atggcatatg accgttatgt 420
 ggcattttgtt aacccgcgtt gataactccat catcatgaac aggtgcgtt gtgcacggat 480
 ggcacgggtt tccctgggttgc cgggttgcgtt gacccgttgcgtt ctggaaacca gttttggccct 540
 gcaatccatcc ctgtgtggaa atctcatgttca ttttttttttgc ttttttttttgc ttttttttttgc 600
 aaagtttagct tgcacaatgtt cactgttccat gaaatccatcc atgtgtgttgc ttttttttttgc 660
 ctttgcatttgc atttccatgtt ctttttttttgc catcttttgc atcttcatcc ttttttttttgc 720
 tctgagaatc acctcagcag agggaaagaaa caaggtttt ttttttttttgc ttttttttttgc 780
 gactgtgggtt attttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 840
 aaatgcacaa aaaaatagaca aaatcatctc gttgttttac ggagtgttta cccctatgtt 900
 gaaatccatcc atttacatgtt taagaaacaa ggaatgttta gatgttatgtt agaaatgtt 960
 gggcaaaa acatgttccatcc aaacacacgc acatctctgtt 1000

<210> 41
 <211> 1008
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472171CB1

<400> 41
 ctgtggacca tcttttcaga actctgcacgc atggagccgc tcaacagaaac agagggtgtcc 60
 gagtttttc tgaaggattt ttctggatcc ccagccctgg agcatctgtt ctttttttttgc 120
 tgctcagccca tgatctgtgtt gacccctcttgg gggaaacacag ccatcatgtt ggtgagcgtt 180
 ctatgtatcc acctgcacac gcccgtgtac ttcttcctgg gcaacatcttc ttttttttttgc 240
 atctgtatcc cggccacccctt ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 300
 accatctctt ttctgtgttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 360
 gagggtgttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 420

aggtaccacg tgctcatgag ccaccggctc tgctgtgc tgatgggagc tgctgggtc 480
 ctctgcctcc tcaagtccgt gactgagatg gtcattcca tgaggctgcc cttctgtggc 540
 caccacgtgg tcagtcaatt caccgtcaag atccctggcag tgctgaagct ggcattgcggc 600
 aacacgtcgg tcagcgaaga ctctctgtg gccccctcca tcctgtgtc gctgtaccc 660
 ctggcattca tctgcctgtc ctacttgtc atccctggcca ccattctgtg ggtgcctcg 720
 gcccgggt gctgcaaaagc ctctccacc tgcttggcac acctggctgt agtgctgtt 780
 ttctacggca ccatcatctt catgtacttg aagcccaaga gtaaggaagc ccacatctt 840
 gatgagggtct tcacagtctt ctatgccatg gtcacgacca tgctgaaccc caccatctac 900
 agcctgagga acaaggaggt gaaggaggccc gccaggaagg tggggccag gatgcggcc 960
 tccagtgagg gaggggggggg ctctgtacag acgcagggtct caggttag 1008

<210> 42
 <211> 972
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472172CB1

<400> 42
 gaaaccctg cccaccatat agtagttgtc atggaaact ggagcactgt gactgaaatc 60
 acccttaatttgcctcccccgtctccctggag attcgaatat ctctttcgat gttcttgc 120
 gtaacttaca cattaacagc aacaggaaac atcaccatca tctccctgtat atggatgtat 180
 catgcctgc aaactccat gtacttctt ctcagtaatt tgcctttctt ggatatctta 240
 tacaccactg tcatttacccc aaagttgttgcctcc tggagaaga gaaaaccata 300
 tctttgctg gttgcatgtat ccaaaccatat ttctacttctt ttctggggac ggtggagttt 360
 atcccttgg cggtgatgtc ctttgaccgc tacatggcta tctgcgaccctt actgcactac 420
 acggcatca tgaacacgcggcctt ctgctgggtc tggatgtctt ggtggagcc 480
 ttccctgtctg tttttttcc aaccattgttgcataacggc taccttactgt taggaagaa 540
 attaaatccatttcttctgtgtat ctttcccttccatggccttgcgtat aaataactcac 600
 ctcatttgcata agataaaactt tctcccttccatggccttgcgtat cctggcattt 660
 actactgggtt ctttccatggcataatttttccatggccttgcgtatcccttccatggcattt 720
 cgtcagaaag ctttttcttccatggccttgcgtatccatggcatttgcgtatcccttccatggcattt 780
 agcaacatctt ttgtgtatgtt gagacccat cagaacttccatgggatata tgacaaggtg 840
 gcccgtgtcc tcatcacatgtt ggtgaccctt ctccttgcataatttttccatggcattt 900
 aatgagaagg tacaggaagg gttgagagatc acgtgaaca gaatcatgac cttgatataaa 960
 aggaaaaactt ga 972